
<html lang="en"     class="pb-page"  data-request-id="12a7c681-4918-4f74-ab6e-80be77a9727e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-21;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b00841;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT" /></meta><meta name="dc.Creator" content="Helena  Kaitsiotou" /></meta><meta name="dc.Creator" content="Marina  Keul" /></meta><meta name="dc.Creator" content="Julia  Hardick" /></meta><meta name="dc.Creator" content="Thomas  Mühlenberg" /></meta><meta name="dc.Creator" content="Julia  Ketzer" /></meta><meta name="dc.Creator" content="Christiane  Ehrt" /></meta><meta name="dc.Creator" content="Jasmin  Krüll" /></meta><meta name="dc.Creator" content="Federico  Medda" /></meta><meta name="dc.Creator" content="Oliver  Koch" /></meta><meta name="dc.Creator" content="Fabrizio  Giordanetto" /></meta><meta name="dc.Creator" content="Sebastian  Bauer" /></meta><meta name="dc.Creator" content="Daniel  Rauh" /></meta><meta name="dc.Description" content="In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated sig..." /></meta><meta name="Description" content="In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated sig..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 24, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00841" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00841" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00841" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00841" /></link>
        
    
    

<title>Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00841" /></meta><meta property="og:title" content="Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0009.jpeg" /></meta><meta property="og:description" content="In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies. The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clinically relevant RTK. KIT is targeted for cancer therapy in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML). However, acquired resistance mutations within the catalytic domain decrease the efficacy of this strategy and are the most common cause of failed therapy. Here, we present the structure-based design and synthesis of novel type II kinase inhibitors to overcome these mutations in KIT. Biochemical and cellular studies revealed promising molecules for the inhibition of mutated KIT." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00841"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00841">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00841&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00841&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00841&amp;href=/doi/10.1021/acs.jmedchem.7b00841" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 8801-8815</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00811" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00876" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helena++Kaitsiotou">Helena Kaitsiotou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marina++Keul">Marina Keul</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julia++Hardick">Julia Hardick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++M%C3%BChlenberg">Thomas Mühlenberg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julia++Ketzer">Julia Ketzer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christiane++Ehrt">Christiane Ehrt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jasmin++Kr%C3%BCll">Jasmin Krüll</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Federico++Medda">Federico Medda</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Oliver++Koch">Oliver Koch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fabrizio++Giordanetto">Fabrizio Giordanetto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sebastian++Bauer">Sebastian Bauer</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Rauh">Daniel Rauh</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Medical Oncology, Sarcoma Centre West German Cancer Centre University Duisburg−Essen, Medical School, Hufelandstraße 55, D-45122 Essen, Germany</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Germany and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Taros Chemicals GmbH & Co. KG, Emil-Figge-Straße 76a, D-44227 Dortmund, Germany</span></div><div class="corresp-info"><strong>*</strong>For D.R.: phone, +49 (0)231-755-7080; fax, +49 (0)231-755-7082; E-mail, <a href="/cdn-cgi/l/email-protection#d3b7b2bdbab6bffda1b2a6bb93a7a6b7bca1a7bea6bdb7fdb7b6"><span class="__cf_email__" data-cfemail="660207080f030a481407130e261213020914120b130802480203">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For S.B.: phone, +49 (0) 201-723-2112; fax, +49 (0) 201-201-5996; E-mail, <a href="/cdn-cgi/l/email-protection#1b687e797a686f727a7535797a6e7e695b6e70367e68687e75357f7e"><span class="__cf_email__" data-cfemail="ff8c9a9d9e8c8b969e91d19d9e8a9a8dbf8a94d29a8c8c9a91d19b9a">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00841&amp;href=/doi/10.1021%2Facs.jmedchem.7b00841" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 8801–8815</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 9, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 June 2017</li><li><span class="item_label"><b>Published</b> online</span>24 October 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 November 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00841" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00841</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8801%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHelena%2BKaitsiotou%252C%2BMarina%2BKeul%252C%2BJulia%2BHardick%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D21%26contentID%3Dacs.jmedchem.7b00841%26title%3DInhibitors%2Bto%2BOvercome%2BSecondary%2BMutations%2Bin%2Bthe%2BStem%2BCell%2BFactor%2BReceptor%2BKIT%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8815%26publicationDate%3DNovember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00841"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1771</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00841" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Helena&quot;,&quot;last_name&quot;:&quot;Kaitsiotou&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;Keul&quot;},{&quot;first_name&quot;:&quot;Julia&quot;,&quot;last_name&quot;:&quot;Hardick&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Mühlenberg&quot;},{&quot;first_name&quot;:&quot;Julia&quot;,&quot;last_name&quot;:&quot;Ketzer&quot;},{&quot;first_name&quot;:&quot;Christiane&quot;,&quot;last_name&quot;:&quot;Ehrt&quot;},{&quot;first_name&quot;:&quot;Jasmin&quot;,&quot;last_name&quot;:&quot;Krüll&quot;},{&quot;first_name&quot;:&quot;Federico&quot;,&quot;last_name&quot;:&quot;Medda&quot;},{&quot;first_name&quot;:&quot;Oliver&quot;,&quot;last_name&quot;:&quot;Koch&quot;},{&quot;first_name&quot;:&quot;Fabrizio&quot;,&quot;last_name&quot;:&quot;Giordanetto&quot;},{&quot;first_name&quot;:&quot;Sebastian&quot;,&quot;last_name&quot;:&quot;Bauer&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Rauh&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;8801-8815&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00841&quot;},&quot;abstract&quot;:&quot;In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies. The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clinically relevant RTK. KIT is targeted for cancer therapy in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML). However, acquired resistance mutations within the catalytic domain decrease the efficacy of this strategy and are the most common cause of failed therapy. Here, we present the structure-based design and synthesis of novel type II kinase inhibitors to overcome these mutations in KIT. Biochemical and cellular studies revealed promising molecules for the inhibition of mutated KIT.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00841&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00841" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00841&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00841" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00841&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00841" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00841&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00841&amp;href=/doi/10.1021/acs.jmedchem.7b00841" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00841" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00841" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00841%26sid%3Dliteratum%253Aachs%26pmid%3D28991465%26genre%3Darticle%26aulast%3DKaitsiotou%26date%3D2017%26atitle%3DInhibitors%2Bto%2BOvercome%2BSecondary%2BMutations%2Bin%2Bthe%2BStem%2BCell%2BFactor%2BReceptor%2BKIT%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D21%26spage%3D8801%26epage%3D8815%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290692" title="Elements">Elements</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/jmcmar.2017.60.issue-21/20171109/jmcmar.2017.60.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies. The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clinically relevant RTK. KIT is targeted for cancer therapy in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML). However, acquired resistance mutations within the catalytic domain decrease the efficacy of this strategy and are the most common cause of failed therapy. Here, we present the structure-based design and synthesis of novel type II kinase inhibitors to overcome these mutations in KIT. Biochemical and cellular studies revealed promising molecules for the inhibition of mutated KIT.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">KIT is a type III receptor tyrosine kinase that is an important signaling protein for the development of melanocytes, erythrocytes, germ cells, mast cells, and interstitial cells of cajal (gastrointestinal pacemaker cells).<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Upon binding of its ligand, stem cell factor (SCF), KIT activates downstream signaling pathways that promote cell survival and cell proliferation and inhibit apoptosis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Constitutive activation of KIT as an oncogenic driver has first been described in feline sarcomas (“kitten”-KIT) but was later also found in a variety of human cancers including melanomas,<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> seminomas, acute myeloid leukemias, systemic mastocytosis, sinonasal lymphoma, and gastrointestinal stromal tumors (GIST).<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Particularly, GISTs have since then become a paradigm of successful targeted treatment for cancer.</div><div class="NLM_p">GIST represents the most common mesenchymal tumor of the gastrointestinal tract,<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> and approximately 85% of GISTs harbor oncogenic gain-of-function mutations of KIT or the platelet-derived growth factor receptor (PDGFR).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> Activating mutations of KIT represent an early oncogenic event, but KIT also remains the central oncogenic driver in patients with highly advanced GIST disease.<a onclick="showRef(event, 'ref7 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref7 ref14 ref15">(7, 14, 15)</a> Primary, activating mutations of KIT in GIST most commonly occur within the juxtamembrane (exon 11) and the extracellular regions (exon 9) and only very rarely in other exons (8, 13, 17).<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16-19)</a> Three inhibitors of KIT have until now been approved for the treatment of GIST. Of note, these three inhibitors had been primarily developed as inhibitors of kinases other than KIT such as BCR-ABL (<b>1</b> (imatinib)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a>) and VEGFR (<b>2</b> (sunitinib),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and <b>3</b> (regorafenib)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23-26)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structural alignment of kinase inhibitors, approved by the FDA for the treatment of GIST, bound to wild-type KIT (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>) (<b>1</b> (green, pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4bkj">4bkj</a>), <b>2</b> (yellow, pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3g0e">3g0e</a>), <b>3</b> (blue, modeled), and <b>4</b> (red, pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>)). Unique substitution patterns and hinge binding elements of the inhibitors highlighted (right). (B) X-ray crystal structure of <b>4</b> in complex with wild-type KIT (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>) with modeled secondary mutations (sticks and surfaces). Hydrogen bonds are depicted by blue dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The possibility of inhibiting dysregulated tyrosine kinases in kinase mutation-driven cancer has led to the development of tyrosine kinase inhibitor (TKI) therapies. In many cases, TKIs have been shown to be more beneficial than traditional cancer treatments in terms of side effects and the overall clinical outcomes for patients with GIST.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a><b>1</b>, a 2-phenylaminopyrimidine derivative, is a rapidly absorbed oral kinase inhibitor that effectively inhibits exon 9 and exon 11 KIT mutants and whose response rates, as well as duration of clinical benefit, correlate with genotype.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> Long lasting disease control (median progression-free survival [PFS] exon 11:2.3 years; exon 9:1.6 years)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> paired with a favorable side effect profile have made <b>1</b> the standard first-line treatment. Nonetheless, the majority of patients eventually progress and secondary mutations within the ATP-binding pocket (exon 13, V654A; exon 14, T670I) and the activation loop (affecting codons 816–829) represent the major mechanisms of resistance.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> Both <b>2</b> and <b>3</b> show better activity against KIT mutants with secondary resistance mutations, and approval was granted based on an improved median PFS of 4–5 months over placebo in second-<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and third-line treatment.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> However, response rates for both drugs are low (<8%). Most patients progressing on <b>1</b> exhibit multiple, polyclonal resistance mutations (genomic heterogeneity) and neither drug inhibits the full spectrum of resistant mutants, which may explain the moderate clinical activity.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Peculiarly, inhibitors had not yet been developed for the needs of patients with GIST but had rather been byproducts of drug development for other diseases. <b>2</b> and <b>3</b> were optimized as potent inhibitors of VEGFR, but very little evidence suggests an added therapeutic value of inhibiting VEGFR in KIT mutant GIST. A randomized phase III trial that compared <b>1</b> with <b>1</b> plus bevacizumab, a VEGF antibody, was prematurely terminated for futility and lack of evidence for clinical activity.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In addition, both drugs inhibit a vastly broader spectrum of kinases compared to <b>1</b>, particularly angiogenic kinases such as VEGFR 1–3 and TIE2, which adds substantial skin and gastrointestinal toxicity as well as hypertension-related side effects. Compared to the substantial benefits obtained with <b>1</b> as first-line treatment, the clinical benefits of <b>2</b> and <b>3</b> are moderate, and the side effect profiles of both inhibitors are much less favorable than those of <b>1</b>.<a onclick="showRef(event, 'ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38">(35-38)</a> Currently, (<i>S</i>)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrrolo[2,1-<i>f</i>][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> ((BLU-285) (NCT02508532)), a potent inhibitor of PDGFRA-D842 and KIT exon 17 mutations and 1-<i>N</i>′-[2,5-difluoro-4-[2-(1-methylpyrazol-4-yl)pyridine-4-yl]oxyphenyl]-1-<i>N</i>-phenylcyclopropane-1,1-dicarboxamide<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> ((DCC-2618) (NCT02571036)), a type III inhibitor of KIT and PDGFRA, and PLX9486/PLX3397<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (NCT02401815) represent the first wave of novel compounds that were designed especially for KIT to exhibit strong activity against exon 13/14 and 17, which is not only important for GIST but also for KIT-driven leukemias and melanomas.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a><b>4</b> (ponatinib) is a next-generation, highly potent ATP-competitive inhibitor of BCR-ABL, which was rationally designed to inhibit the notoriously resistant T315I mutation.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> Approval was granted for the treatment of T315I-positive BCR-ABL leukemias (chronic myelogenous and acute lymphoblastic) based on significant antileukemic activity across categories of disease stage and mutation status within the PACE trial.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Notably, <b>4</b> also inhibits a broad spectrum of imatinib-resistant KIT mutants, including those affecting codon Asp816 of exon 17, which confers resistance to all approved drugs in GIST but is less potent to secondary mutant V654A.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p last">In patients with GIST, <b>4</b> has already shown encouraging activity with clinical benefit rates of up to 55% in a small cohort of heavily pretreated patients with primary exon 11 mutation. A current trial (POETIG, NCT03171389) investigates the clinical benefit of <b>4</b> in second-line and last-line patients. <b>4</b> is also a multikinase inhibitor that targets protein kinases of the VEGFR, PDGFR, and SRC families. Most common side effects include skin rash, fatigue, myalgia, dry skin, headache, and mucositis, which is usually perceived less intense than with <b>2</b> or <b>3</b>. A more severe side effect observed in 11.8% of patients with BCR-ABL-driven leukemia are arterial thrombotic events, which appear to be dose-dependent and less frequent at lower dose intensity.<a onclick="showRef(event, 'ref35 ref46'); return false;" href="javascript:void(0);" class="ref ref35 ref46">(35, 46)</a> The role of inhibition of angiogenesis-related kinases (VEGFR1–3 and TIE2) by <b>4</b> as related to the observed thrombotic events has yet to be explored.<a onclick="showRef(event, 'ref34 ref47'); return false;" href="javascript:void(0);" class="ref ref34 ref47">(34, 47)</a> Against the background of the broad inhibitory spectrum of <b>4</b> and its unique ability to inhibit D816H mutant KIT, we compared the scaffolds of currently available GIST therapeutics and <b>4</b> to potentially generate a novel compound with activity on KIT exon 17, 13, and 14 mutants, including secondary mutant V654A, which is the most likely escape mutation of <b>4</b>.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Basically, the back pocket-binding element of <b>4</b> was preserved because this part is analogous to <b>1</b>, except for an inverted amide bond, which is already optimized to generate a more favorable interaction pattern and the trifluoromethyl substituent. For the latter, we decided to gradually revert to the substitution pattern of <b>1</b> to determine if the selectivity profile of <b>1</b> is retained. The triple bond connecting the back pocket-binding element with the hinge-binding element was also retained because it bypasses the challenging gatekeeper mutation T670I. The gatekeeper position in kinases controls access to the ATP-binding site, playing an important role in ATP-competitive inhibitor selectivity.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48, 49)</a> In the case of KIT, the primary mutation V559D in the juxtamembrane region leads to constitutive activation of the kinase, whereas the bulkier and more lipophilic residue T670I modulates the conformation of the catalytic domain for less favorable binding of <b>1</b>.<a onclick="showRef(event, 'ref18 ref50'); return false;" href="javascript:void(0);" class="ref ref18 ref50">(18, 50)</a> The crystal structure of wild-type KIT in complex with <b>4</b> (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>) guided our structure-based design regarding the hinge-binding element (<a class="ref internalNav" href="#fig1" aria-label="Figures 1">Figures 1</a>B and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In the present study, the main objective was to evaluate the potential for additional interactions with the hinge region, as these should compensate for the loss of van der Waals interactions with most of the known inhibitors due to the second gatekeeper mutation V654A.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> To support our structure–activity relationship (SAR) studies in the development of optimized compounds, we performed molecular dynamics (MD) simulations to gain insights into the conformational changes of the kinase domain in the presence of the secondary mutation. On the basis of the information obtained from the MD simulation and its combination with rational structure-based design on docking studies, we designed, synthesized, and tested a focused library of KIT mutant-selective inhibitors to overcome acquired drug resistance in GISTs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84247" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84247" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Structural Analysis of Wild-Type KIT, KIT V559D/V654A, and KIT V559D/T670I Mutant Variants</h3><div class="NLM_p">We used molecular modeling and MD simulations based on the sequence of KIT and its crystal structure in complex with <b>4</b> (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>) to generate models of two KIT variants. Subsequent docking studies were performed to gain insight into the binding mode of <b>4</b> with respect to the V654A and T670I variants. Docking indicated that <b>4</b> could bind to the mutants in an analogous manner to that observed for wild-type KIT. A detailed visual inspection showed that the highest ranked poses for all docking studies show only negligible deviations from the native binding mode of <b>4</b> in the original crystal structure for wild-type KIT and the T670I and V654A variants. We selected the poses with the smallest RMSD to the binding mode observed for the X-ray structure (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>) (for details, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Supporting Information</a>) to perform 300 ns MD simulations with all three KIT variants in the absence and presence of <b>4</b> to get further insight into possible binding mode differences. The corresponding RMSD profiles for MD simulations are given in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Figure S1</a>.</div><div class="NLM_p">The ligand-bound KIT variants exhibited nearly identical behavior during a 300 ns simulation; the most prominent ligand–protein hydrogen bond interactions were stable in all three trajectories (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S6</a>). Additionally, molecular mechanics Poisson–Boltzmann (Generalized Born) solvent-accessible surface area (MM-PB(GB)SA) calculations (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S7</a>) show similar results for KIT wild type and the variants under investigation. The differences observed in the binding free energies do not reflect the outstanding differences of the enzymes in the binding of <b>4</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Given the uncertainties of those methods,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> we investigated additional factors which might have an impact on the binding affinity of <b>4</b>. In contrast to the trajectories in the presence of <b>4</b>, the MD simulations of wild-type KIT apo structures and the variants elucidated major differences. Particularly variant V654A exhibited higher flexibility with respect to the residues involved in the binding of <b>4</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Figure S2</a>). An MD pocket analysis of the trajectories in the absence of ligands did not reveal major differences in the pocket volume of all three enzymes (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Figure S5</a>). Nevertheless, a clustering of the conformations from MD trajectories with respect to the binding site residues (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S5</a>) of <b>4</b> and subsequent SiteHopper<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a>-based binding site comparison of representatives of the clusters with highest occupancy showed that the wild-type and V654A binding sites are different with respect to shape and physicochemical properties, whereas the differences between wild type and T670I were less pronounced (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S8</a> for more details).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Comparison of the ligand binding surfaces using representative structures of the MD simulation trajectory derived from a residue-based RMSD clustering. The alignment and representations of <b>4</b> bound to wild-type KIT (gray), apo KIT T670I (brown), and apo KIT V654A (blue) structures were generated with SiteHopper,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> respectively. (B) Results of the binding site comparison of mutant KIT T670I bound to <b>4</b> and apo mutant KIT T670I to wild-type KIT with respect to shape and physicochemical properties (hydrogen bond donor, hydrogen bond acceptor, and hydrophobic features). The pockets of the representative structures of the cluster with the highest occupancy for the simulations of the apo enzymes (apo), and the enzymes bound to <b>4</b> (ponatinib) were used. They were compared to the wild-type KIT crystal structure bound to ponatinib (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>). (C) Results of the binding site comparison of ligand-bound mutant KIT V654A and apo mutant KIT V654A to wild-type KIT with respect to shape and physicochemical properties. The comparison was performed as outlined in (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, these differences were not observed for the MD simulations in the presence of bound ligand. Both variants show a higher similarity to the wild type when bound to <b>4</b>. In contrast, the decreasing similarity in the unbound state hints toward major deviations of the variants’ binding site conformation in the absence of ligands. Therefore, we speculate that the difference in binding and activity of <b>4</b> with respect to the investigated variant might result from different binding site conformations of the kinase in the apo state (especially for V654A) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) as well as shifts in the equilibrium between the active and inactive conformation of the kinase that are not observable for the protein–ligand complexes.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53, 54)</a> As no clear SAR for the inhibitors and their activity on V654A was available, we analyzed whether this variant might show different activation properties as compared to the wild type and variant T670I. Intriguingly, in the MD simulation of the V654A apo structure, we observed high flexibility of the α helix C, a structural feature of KIT important for activation of the kinase,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> as well as in the binding pocket itself (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Figure S2</a>). As this helix is a crucial determinant of KIT activation and inactivation,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> we analyzed the conformational variation of the helix along the simulated trajectory by monitoring the angle of the N-terminal axis of the α helix C (residues Leu631 to Leu637) and the unit cell axis <i>x</i> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Figure S3</a>). The data suggest that the V654A mutation perturbs the dynamics of the α helix C and renders KIT in a conformation less suited for binding of type II inhibitors when compared to wild-type KIT. The uniqueness of this behavior as compared to the wild-type enzyme and variant T670I could be shown by principle component analysis (PCA, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Figure S6</a>). The modes, i.e., the most prominent directions of structural changes, indicate a bending motion of the α helix C solely for variant V654A.</div><div class="NLM_p last">Also, we hypothesize that, similar to the activating mechanism of most gatekeeper mutations in protein kinases (T670I in KIT) as shown by Azam et al. for c-ABL and c-SRC, the V654A mutation in KIT induces a stabilization of the regulatory R-spine and therefore the active conformation of the kinase domain.<a onclick="showRef(event, 'ref48 ref55'); return false;" href="javascript:void(0);" class="ref ref48 ref55">(48, 55)</a> Overall, this hampers the rational design of molecules targeting KIT variant V654A. We, therefore, focused our optimization strategy on the development of derivatives of <b>4</b> to more effectively target KIT V654A. Such an approach proved successful, for example, in second- and third-generation BCR-ABL inhibitors.<a onclick="showRef(event, 'ref49 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref49 ref56 ref57">(49, 56, 57)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure-Based Design of Type II Inhibitors against KIT Mutants V654A and T670I</h3><div class="NLM_p">On the basis of our MD simulations and the crystal structure of <b>4</b> in complex with wild-type KIT (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>) as well as the crystal structures of wild-type KIT in the active (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1t46">1t46</a>)<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and autoinhibited (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1t45">1t45</a>)<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> state, we decided to maintain the overall potent scaffold of <b>4</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and change the substitution patterns in R<sup>1</sup>–R<sup>4</sup> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). R<sup>1</sup> was optimized with respect to V654A mutation, keeping the alkyne linker to maximize the effect on the T670I mutation. R<sup>2</sup> was gradually modified to the substitution pattern of <b>1</b> to afford the improved kinase selectivity profile of <b>1</b>. Modeling of mutant V654A revealed an altered surface in this part of the ATP binding pocket due to the size of the mutated amino acid. This slight change might offer the possibility of targeting V654A selectively within the KIT mutant family. Thus, we designed larger hydrophobic substituents at R<sup>3</sup> while reducing the size of the R<sup>4</sup> substituents in line with results from the MD simulations, that suggest that the methyl group in the R<sup>4</sup> position might not be as well tolerated in the mutant forms (T670I and V654A) when compared to wild-type KIT (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). Afterward, we performed molecular docking to examine the feasibility of the anticipated interactions. An ensemble docking approach using the representative structures of a clustering with respect to the binding site of <b>4</b> was applied for all three enzymes. <b>4</b> was redocked to evaluate and control the docking parameters. Given that our compounds are quite similar to <b>4</b>, we predicted high similarities in the binding modes in KIT, suggesting inhibitory activity toward wild-type KIT and the secondary variants V654A, T670I, and D816H.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Core-scaffold of synthesized compounds modeled into the crystal structure of wild-type KIT (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>). The general scaffold and the substitution patterns (red) of the designed compounds are shown (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Given the similarity to <b>4</b>, our modeling studies suggested a comparable binding mode for compounds <b>5</b> and <b>7</b>–<b>10</b>. The compounds occupy three subpockets within the catalytic domain of KIT: the ATP pocket, gatekeeper pocket, and back pocket (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). The hinge-binding moieties form hydrogen bonds to the backbone of the residues within the hinge region. The allosteric or back pocket, which is only accessible when the kinase is in the inactive conformation, is accessed via the substituted phenylbenzamide element. We suggest that the amide’s NH and carbonyl moieties of the compounds establish hydrogen bonds with the side chain carboxylate group of Glu640 in the α helix C and the backbone nitrogen of Asp810 in the DFG motif, respectively. The methylated nitrogen of the methylpiperazine moiety is able to interact with carbonyl groups in the backbone (Ile789/His790) of the activation loop. We focused our optimization efforts on the hinge-binding element, gradually altered the substitution pattern of the back pocket-binding element, and tried to target the slight changes of the binding site surface observed in KIT mutant V559D/V654A. Optimization of the hinge-binding element was mainly focused on compensating for the loss of van der Waals interactions caused by the V654A mutation.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> We presumed that a six-membered ring system incorporating a substitution pattern capable of interacting with the hinge region would be favorable compared to the imidazolo-pyridazine moiety of <b>4</b>. This imidazolo-pyridazine moiety forms one single hydrogen bond via <i>N</i>7 with Cys673 in the hinge region. As MD simulation and docking studies suggested that the V654A mutation disrupts not only the network of hydrophobic interactions related to the compounds but also the conformation of the entire catalytic domain, we designed a hinge-binding element consisting of a single ring system, which was then progressively extended. The substitution pattern of this single ring system was developed to maximize possible interactions with the hinge region. Scaffolds based on pyridine and pyrimidine seemed to be a good choice to achieve this objective. Starting with the hinge-binding element with the least predicted number of interactions with the hinge, we gradually extended the number of possible interactions in different directions of the ATP-binding site. This process allowed us to iteratively test the structure-based hypotheses via matched molecular pair analysis and establish an SAR in order to develop optimized small molecules that are selective and potent against the majority of KIT mutants.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthesis of a Focused Structure-Based Small Molecule Library</h3><div class="NLM_p">We synthesized a focused library of type II inhibitors based on <b>4</b> and paid particular attention to the derivatization of the pyridine/pyrimidine-based hinge-binding element with various substituents in different positions to evaluate interactions across the ATP-binding pocket. We expected a distinctive SAR regarding the potency toward the KIT mutants and explored substitution patterns that are able to engage in favorable interactions. We maintained the alkyne linker of <b>4</b> connecting the hinge-binding element with the back pocket moiety due to its favorable overall orientation and function (interaction with gatekeeper residue Ile670). Exploration of the conformational space in the back pocket required the design of a different compound series. Herein the benzoic acid moiety forming the amide bond was maintained, whereas the trifluoromethyl substituent of the ((<i>N</i>-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline moiety was systematically changed to fluorine and later to hydrogen. We reasoned that this approach would have provided insight in the relevance of this substituent in terms of binding affinity and selectivity. Importantly, this new substitution pattern represents one of the main differences from <b>1</b>.</div><div class="NLM_p">Considering the V654A mutation, we also designed inhibitors targeting the altered binding site in the mutant kinase domain to study the newly created chemical space and examine the impact of this structural motif on selectivity and inhibitory activity. Molecular modeling indicated that derivatization of the benzoic acid moiety’s 2-position would be ideal to deploy such strategy.</div><div class="NLM_p">Compounds <b>5a</b>–<b>d</b>, <b>6a</b>, <b>7a</b>–<b>l</b>, <b>8a</b>–<b>d</b>, <b>9a</b>,<b>b</b>, and <b>10</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) were synthesized using the general route depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Here, benzaldehyde derivatives <b>2d</b>–<b>f</b> were transformed to the corresponding benzylpiperazines <b>3a</b>–<b>c</b> via reductive amination. Alternatively, toluene derivatives <b>1a</b>–<b>c</b> were first selectively brominated and then subjected to an S<sub>N</sub>2 substitution with 1<i>N</i>-methylpiprerazine. Anilines <b>4a</b>–<b>c</b> were obtained by reduction of the arylnitro intermediates <b>3a</b>–<b>c</b> via palladium (Pd/C)-catalyzed hydrogenation. The iodobenzamide precursors <b>5a</b>–<b>f</b> were prepared by amide coupling of anilines <b>4a</b>–<b>c</b> with the corresponding iodobenzoic acid. The reaction conditions were altered to comply with the characteristics of the starting material, but the overall outcome of the modifications remained the same. The aromatic silyl-protected alkynes were either sourced directly from commercial sources or synthesized from the corresponding bromide precursors using Sonogashira reaction conditions. Purification of the protected alkynes was challenging because of several impurities and the relatively unstable protecting group on the one hand and because of the low boiling point of the silyl-protected alkynes on the other hand. Complete evaporation of the solvent was not possible. Thus, the protected alkynes were used without further purification. The second Sonogashira coupling between the silyl-protected alkynes and precursors <b>5a</b>–<b>f</b> were also performed under Pd-catalyzed Sonogashira reaction conditions Here, to minimize the occurrence of dimer and polymer formation, the precursors were heated with the reactants to 80 °C, then cooled to 40 °C, followed by addition of the silyl-protected alkynes. As the reaction mixture was heated to 80 °C again, the silyl protection group was removed in situ by subsequent addition of TBAF. Compounds <b>7a</b>–<b>l</b>, <b>8a</b>–<b>d</b>, <b>9a</b>,<b>b</b>, and <b>10</b> were obtained using this procedure (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Overview of Structure-Based Reversible Binding Type II Small Molecules <b>5a</b>–<b>d</b>, <b>6a</b>, <b>7a</b>–<b>l</b>, <b>8a</b>–<b>d</b>, <b>9a</b>,<b>b</b>, and <b>10</b> for SAR Studies</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0008.gif" alt="" id="fx2" /></img><div></div></div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Derivatives (<b>5a</b>–<b>d</b>, <b>6a</b>, <b>7a</b>–<b>l</b>, <b>8a</b>–<b>d</b>, <b>9a</b>,<b>b</b>, and <b>10</b>) Based on the Structure of <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>N</i>-bromosuccinimide, AIBN, DCE, 80 °C, 12 h (60–66%); (ii) 1<i>N</i>-methylpiperazine, K<sub>2</sub>CO<sub>3</sub>, DCM, rt, 3 h (80–91%); (iii) 1<i>N</i>-methylpiperazine, NaBH(OAc)<sub>3</sub>, THF, rt, 16 h (60–70%); (iv) Pd/C, H<sub>2</sub>, EtOH, 12 h (98%); (v) HOBt, EDC, DIPEA, DMF, DMAP, carboxylic acid-derivative rt, 16 h (49–88%); (vi) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, (<i>i</i>-Pr)<sub>2</sub>NH, R<sup>1</sup>-Br, MeCN, 80 °C, 16 h; (vii) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, (<i>i</i>-Pr)<sub>2</sub>NH, TBAF, MeCN, 80 °C, 16 h (1–22%).</p></p></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Activity-Based in Vitro Characterization of Compounds</h3><div class="NLM_p">We characterized our focused compound library with respect to the inhibition of various clinically relevant KIT mutants, including T670I, V654A, and D816H, as well as wild-type KIT (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), using an activity-based biochemical assay. KIT-mediated phosphorylation of an artificial substrate was quantified through homogeneous time-resolved FRET measurements. Starting with the SAR studies for the improvement of the hinge-binding element supported by our modeling studies, we decided on six-membered heterocycles and also tested precursors <b>5a</b>–<b>d</b> and the alkyne substituted precursor <b>6a</b>. Precursors <b>5a</b>–<b>d</b> had IC<sub>50</sub> values of 6.8, 555, 1039, and 184 nM, respectively, for wild-type KIT but did not inhibit the KIT mutants tested. Notably, the original precursor of <b>4</b> (<b>5a</b>, 6.8 nM) was the most potent inhibitor of wild-type KIT, whereas the alkyne functionalized precursor (<b>6a</b>) exhibited decreased activity (231 nM). According to our modeling studies, 2- and 3-pyridyl substituents were the most probable hinge-binding moieties to form hydrogen bonds with the hinge, mimicking the imidazole-pyridazine hinge-binding element of <b>4</b>. The comparison of compounds <b>7a</b> and <b>7d</b> indicated that the 3-pyridyl hinge-binding element of <b>7d</b> was more potent in all KIT mutants. The IC<sub>50</sub> values of both <b>7a</b> and <b>7d</b> were in the same nanomolar range for wild-type KIT (3.5 and 2.1 nM, respectively), but this changed dramatically for the mutant forms (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). To further evaluate our SAR study, we used 2-pyridyl decorated with electron-rich substituents in the 5- (<b>7b</b>) and 3-position (<b>7c</b>). As 2-pyridyl was the less potent pyridine tested, we expected a more visible increase in potency if the substituents formed additional favorable interactions. <b>7b</b> presented an overall decreased potency, especially for KIT T670I, compared to unsubstituted 2-pyridyl <b>7a</b>. Compound <b>7c</b> substituted in the 3-position with a methoxy group maintained an overall potency profile comparable to <b>7a</b>. As the extension of the six-membered heterocycle did not exhibit the anticipated increase, we evaluated a different strategy.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> Determination of Structure-Based Reversible Binding Type II-Like Small Molecules on the Target Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">IC<sub>50</sub> [nM]</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">KIT<sup>WT</sup></th><th class="colsep0 rowsep0" align="center">KIT<sup>V559D/T670I</sup></th><th class="colsep0 rowsep0" align="center">KIT<sup>V559D/V654A</sup></th><th class="colsep0 rowsep0" align="center">KIT<sup>D816H</sup></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="char" char="±">6.8 ± 21</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="char" char="±">555.7 ± 41.6</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="char" char="±">1039.3 ± 513.9</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="char" char="±">183.7 ± 186.5</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char="±">230.7 ± 1.2</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 0.6</td><td class="colsep0 rowsep0" align="center">116 ± 20.1</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="char" char="±">120.9 ± 154.7</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 1.9</td><td class="colsep0 rowsep0" align="center">158.7 ± 43</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7d</b></td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.6</td><td class="colsep0 rowsep0" align="center">24 ± 3.1</td><td class="colsep0 rowsep0" align="center">1101.6 ± 47.8</td><td class="colsep0 rowsep0" align="center">137.6 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7e</b></td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 0.2</td><td class="colsep0 rowsep0" align="center">150.2 ± 35.3</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">2267.8 ± 105.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7f</b></td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.6</td><td class="colsep0 rowsep0" align="center">21.4 ± 1.2</td><td class="colsep0 rowsep0" align="center">246.6 ± 71.2</td><td class="colsep0 rowsep0" align="center">42.2 ± 13.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7g</b></td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.9</td><td class="colsep0 rowsep0" align="center">106.8 ± 7.2</td><td class="colsep0 rowsep0" align="center">252.5 ± 13.2</td><td class="colsep0 rowsep0" align="center">2614.3 ± 745.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7h</b></td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.9</td><td class="colsep0 rowsep0" align="center">72.0 ± 5.2</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7i</b></td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.5</td><td class="colsep0 rowsep0" align="center">29.8 ± 1.4</td><td class="colsep0 rowsep0" align="center">777.2 ± 88.6</td><td class="colsep0 rowsep0" align="center">99.3 ± 43.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7j</b></td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.9</td><td class="colsep0 rowsep0" align="center">2147.2 ± 213.1</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7k</b></td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.6</td><td class="colsep0 rowsep0" align="center">28.8 ± 1.3</td><td class="colsep0 rowsep0" align="center">908.3 ± 165.0</td><td class="colsep0 rowsep0" align="center">140 ± 13.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7l</b></td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0</td><td class="colsep0 rowsep0" align="center">18.2 ± 6.8</td><td class="colsep0 rowsep0" align="center">313.5 ± 132.2</td><td class="colsep0 rowsep0" align="center">104.3 ± 8.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="char" char="±">239.6 ± 307.6</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 1.8</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="char" char="±">100.3 ± 84.2</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 1.0</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.5</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="char" char="±">6.5 ± 1.1</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">1706.6 ± 803.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char="±">6.2 ± 2.3</td><td class="colsep0 rowsep0" align="center">21 ± 3.6</td><td class="colsep0 rowsep0" align="center">1084.7 ± 304.0</td><td class="colsep0 rowsep0" align="center">325.8 ± 111.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">16.4 ± 3.1</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.7</td><td class="colsep0 rowsep0" align="center">17.4 ± 9.8</td><td class="colsep0 rowsep0" align="center">136.0 ± 39.9</td><td class="colsep0 rowsep0" align="center">20 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.8</td><td class="colsep0 rowsep0" align="center">99.6 ± 27.8</td><td class="colsep0 rowsep0" align="center">124.9 ± 24.6</td><td class="colsep0 rowsep0" align="center">616.8 ± 14.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 1.5</td><td class="colsep0 rowsep0" align="center">2153.3 ± 744.4</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">239.1 ± 168.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">No inhibition.</p></div></div></div><div class="NLM_p">Our docking studies showed that an aptly placed amino group in the <i>para</i>-position to the alkyne linker should be able to secure an additional hydrogen bond with the hinge region (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). To test this hypothesis and simultaneously evaluate heterocyclic diversity, we synthesized 2-aminopyrimidine- and 3-aminopyridazine-containing derivatives (<b>7e</b> and <b>7f</b>, respectively). This selection was made to determine whether the addition of the amine substituent in the <i>para</i>-position leads to increased potency and then whether the nitrogen in the <i>ortho</i>-position leads to decreased potency even though the nitrogen in the <i>meta</i>-position is present. As shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, the pyrimidine scaffold <b>7f</b> demonstrated a significantly increased inhibitory effect in all tested KIT mutants, as well as wild-type KIT in a low nanomolar range (2–247 nM). Interestingly, the 3-aminopyridazine analogue <b>7e</b> also demonstrates inhibition of wild-type KIT in a low nanomolar range (5.8 nM) but a significant decrease in potency for all KIT mutant forms. Our SAR study demonstrated that the hinge-binding element is important for the overall inhibitory effect of this series of scaffolds based on <b>4</b>. Here, a reduction in the size of the hinge-binding element and the addition of an amino substituent postulated to form an additional hydrogen bond with the hinge region led to <b>7f</b>, a small molecule inhibitor of comparable potency to <b>4</b>. With <b>7f</b> in hand, we opted for a few structural analogues to further expand our SAR studies.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Docking pose of <b>7f</b> in complex with wild-type KIT. (B) Close up of the back pocket. Depicted are the residues spanning the hydrophobic pocket in wild-type KIT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Addition of a 2-methoxyethyl side chain to the aminopryrimidine nitrogen atom (<b>7g</b>) resulted in an overall loss of potency for all mutant forms, especially for secondary mutant V654A compared to <b>7f</b>. As hinge-binding moieties, 2-aminopyridin-5-yl (<b>7k</b>) and 2-amino-3-methylpyridin-5-yl motifs (<b>7i</b>) exhibit significantly reduced activity for mutant D816H and secondary mutant T670I. The same behavior was observed for compound <b>7l</b>. Loss of a nitrogen atom in the pyrimidine scaffold of <b>7f</b> and extension at the same site did not seem to be favored. An obvious change in the scaffold of <b>4</b> compared to <b>1</b>, in addition to the hinge-binding motif, is the presence of a trifluoromethyl substituent in the back pocket-binding element. This structural difference prompted us to use the most potent hinge-binding heterocycles of compounds <b>7a</b>–<b>l</b> and synthesize the analogues <b>8a</b>–<b>d</b> without the trifluoromethyl group. Surprisingly, compounds <b>8a</b>–<b>d</b> presented no inhibition of the KIT variants we investigated without apparent trends when the relevant hydrogen-trifluoromethyl matched molecular pairs were considered, as summarized in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. This result prompted us to investigate a substituent in the back pocket-binding element that is able to form similar interactions as the trifluoromethyl group. For compounds <b>9a</b>,<b>b</b>, we decided on fluoro-substitution, but this modification had the same overall result as observed for compounds <b>8a</b>–<b>d</b>. Our observations of compounds <b>8a</b>–<b>d</b> and <b>9a</b>,<b>b</b> strongly indicate that the trifluoromethyl substituent is crucially important for the potency of these inhibitors, as its replacement to both hydrogen and fluorine atoms induces a severe loss of potency in all clinically relevant KIT mutations. Notably, when we repositioned the methyl group decorating the phenylcarboxamide element of <b>7f</b> from its original 4-position on the phenyl to the 2 position (<b>10</b>) to target the secondary mutation V654A, activity on the V654A and T670I mutants was significantly reduced. We next investigated the selectivity of <b>7f</b> and <b>10</b> over other protein kinase families. Ninety different protein kinases were assessed employing the SelectScreen Kinase Profiling Services from Life Technologies (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Figure S4, Table S1</a>). The kinase profiling data underlines the improved selectivity of <b>10</b>.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Activity of Inhibitors against GIST Cells in Culture</h3><div class="NLM_p">In addition to biochemical testing, we investigated the inhibitory effects of compounds <b>5a</b>–<b>d</b>, <b>6a</b>, <b>7a</b>–<b>l</b>, <b>8a</b>–<b>d</b>, <b>9a</b>,<b>b</b>, and <b>10</b> on a human metastatic GIST cell line harboring a 57-bp deletion of exon 11 (GIST-T1) that results in the expression of constitutively active KIT. We also examined the associated gatekeeper mutant T670I (GIST-T1-T670I), the second gatekeeper mutant V654A (GIST430-V654A), and the independent KIT activation loop mutation D816E (GIST-T1-D816E) (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Each cell line was treated for 72 h with compounds <b>5a</b>–<b>d</b>, <b>6a</b>, <b>7a</b>–<b>l</b>, <b>8a</b>–<b>d</b>, <b>9a</b>,<b>b</b>, and <b>10</b> (0–20 μM), with <b>1</b>−<b>4</b> used as controls. The tested compounds reduced the number of viable GIST-T1 cells, especially compounds <b>7a</b>–<b>l</b> with a trifluoromethyl substituent in the back pocket element, with IC<sub>50</sub> values in the range of 20–120 nM. A significant difference between the compounds was found in the investigation of secondary mutants. Basically, all compounds with a different substitution pattern in the back pocket-binding element (<b>8a</b>–<b>d</b>, <b>9a</b>–,<b>b</b>) significantly lost activity in all mutant forms of KIT. In contrast to the biochemical data, the nuances in the effect of the different hinge-binding motifs were observable. Compounds <b>8d</b> and <b>9b</b>, which share the 2-aminopyrimidine as a hinge-binding element, exhibit the best activity within this compound class. Compounds <b>7a</b>–<b>l</b> had a strong effect on imatinib-resistant GIST-T1-T670I cells due to their similarity to <b>4</b> and the favorable interactions between the gatekeeper and alkyne linker. The treatment of GIST-T1-D816E and GIST430-V654A cells followed the same trend observed for the isolated proteins in the biochemical assays. In line with this, compound <b>7f</b> and structurally related analogues <b>7i</b> and <b>7k</b> exhibited a consequential reduction in cell viability in GIST-T1-D816E in line with the observed biochemical data (<b>7f</b>, IC<sub>50</sub> 42.2 nM, GI<sub>50</sub> 141 nM; <b>7i</b>, IC<sub>50</sub> 99.3 nM, GI<sub>50</sub> 474 nM; <b>7i</b>, IC<sub>50</sub> 140.4 nM, GI<sub>50</sub> 221 nM). Interestingly, the cellular effect for most compounds of the trifluoromethyl-substituted series resulted in an improved antiproliferative effect comparing well to the biochemical data for GIST430-V654A cells. In particular, compound <b>7f</b> showed the strongest inhibitory effect across all KIT variants both at protein and cellular level. The 2-aminopyrimidin hinge-binding moiety of compound <b>7f</b> exhibited improved efficacy in GIST430-V654A cells compared to <b>4</b> (51 vs 149 nM). A KIT-negative GIST-48B was used as a disease-specific negative control because it does not express and lost its oncogenic dependency on KIT. Overall, the tested molecules of the trifluoromethyl-substituted compound series exhibited an off-target profile comparable to that of <b>4</b>, with GI<sub>50</sub> values in the range of 1.8–6.2 μM indicating a KIT-specific mechanism of action. In contrast, compounds <b>8a</b>–<b>9b</b> resulted in neither a significant decrease in the proliferation of GIST-negative GIST-48B cells nor a strong inhibitory effect in all KIT variants. An interesting inhibition profile was observed for compound <b>10</b>. Though related precursors <b>5c</b> and <b>5d</b> exhibited no inhibition of wild-type KIT or the KIT mutants, it was apparent that small molecule <b>10</b>, with the reversed substitution pattern in positions R<sup>3</sup> and R<sup>4</sup>, causes very low inhibition of KIT-negative cells (16 μM) while retaining good activity with mutant GIST430-V654A (308 nM) and GIST-T1-D816E cells (381 nM).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. GI<sub>50</sub> Determination of Structure-Based Reversible Binding Type II-Like Small Molecules on the Target Kinase</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">GI<sub>50</sub> [nM]</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">GIST-48B</th><th class="colsep0 rowsep0" align="center">GIST-T1</th><th class="colsep0 rowsep0" align="center">GIST-T1-T670I</th><th class="colsep0 rowsep0" align="center">GIST-T1-D816E</th><th class="colsep0 rowsep0" align="center">GIST430-V654A</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="center">4877 ± 358</td><td class="colsep0 rowsep0" align="center">896 ± 175</td><td class="colsep0 rowsep0" align="center">3342 ± 282</td><td class="colsep0 rowsep0" align="center">9891 ± 1741</td><td class="colsep0 rowsep0" align="center">3905 ± 1799</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">10019 ± 1870</td><td class="colsep0 rowsep0" align="center">15291 ± 2665</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="center">9942 ± 1049</td><td class="colsep0 rowsep0" align="center">11006 ± 825</td><td class="colsep0 rowsep0" align="center">7609 ± 286</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">15858 ± 498</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="center">3627 ± 1346</td><td class="colsep0 rowsep0" align="center">5729 ± 705</td><td class="colsep0 rowsep0" align="center">9512 ± 403</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">7840 ± 891</td><td class="colsep0 rowsep0" align="center">10136 ± 2058</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="center">3627 ± 532</td><td class="colsep0 rowsep0" align="center">55 ± 9</td><td class="colsep0 rowsep0" align="center">97 ± 19</td><td class="colsep0 rowsep0" align="center">1673 ± 328</td><td class="colsep0 rowsep0" align="center">697 ± 76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="center">1860 ± 250</td><td class="colsep0 rowsep0" align="center">121 ± 320</td><td class="colsep0 rowsep0" align="center">4375 ± 1985</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">2005 ± 890</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="center">3793 ± 525</td><td class="colsep0 rowsep0" align="center">82 ± 115</td><td class="colsep0 rowsep0" align="center">165 ± 33</td><td class="colsep0 rowsep0" align="center">991 ± 95</td><td class="colsep0 rowsep0" align="center">564 ± 32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7d</b></td><td class="colsep0 rowsep0" align="center">2705 ± 296</td><td class="colsep0 rowsep0" align="center">51 ± 13</td><td class="colsep0 rowsep0" align="center">76 ± 18</td><td class="colsep0 rowsep0" align="center">332 ± 77</td><td class="colsep0 rowsep0" align="center">333 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7e</b></td><td class="colsep0 rowsep0" align="center">6247 ± 242</td><td class="colsep0 rowsep0" align="center">54 ± 11</td><td class="colsep0 rowsep0" align="center">89 ± 17</td><td class="colsep0 rowsep0" align="center">580 ± 141</td><td class="colsep0 rowsep0" align="center">459 ± 47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7f</b></td><td class="colsep0 rowsep0" align="center">2024 ± 545</td><td class="colsep0 rowsep0" align="center">23 ± 6</td><td class="colsep0 rowsep0" align="center">44 ± 8</td><td class="colsep0 rowsep0" align="center">141 ± 12</td><td class="colsep0 rowsep0" align="center">51 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7g</b></td><td class="colsep0 rowsep0" align="center">5132 ± 511</td><td class="colsep0 rowsep0" align="center">119 ± 21</td><td class="colsep0 rowsep0" align="center">198 ± 25</td><td class="colsep0 rowsep0" align="center">704 ± 110</td><td class="colsep0 rowsep0" align="center">481 ± 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7h</b></td><td class="colsep0 rowsep0" align="center">3037 ± 620</td><td class="colsep0 rowsep0" align="center">59 ± 12</td><td class="colsep0 rowsep0" align="center">184 ± 26</td><td class="colsep0 rowsep0" align="center">2289 ± 382</td><td class="colsep0 rowsep0" align="center">723 ± 45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7i</b></td><td class="colsep0 rowsep0" align="center">2087 ± 147</td><td class="colsep0 rowsep0" align="center">59 ± 11</td><td class="colsep0 rowsep0" align="center">117 ± 29</td><td class="colsep0 rowsep0" align="center">474 ± 37</td><td class="colsep0 rowsep0" align="center">307 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7j</b></td><td class="colsep0 rowsep0" align="center">4146 ± 1116</td><td class="colsep0 rowsep0" align="center">282 ± 78</td><td class="colsep0 rowsep0" align="center">2971 ± 1150</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">4145 ± 94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7k</b></td><td class="colsep0 rowsep0" align="center">2237 ± 156</td><td class="colsep0 rowsep0" align="center">42 ± 8</td><td class="colsep0 rowsep0" align="center">67 ± 12</td><td class="colsep0 rowsep0" align="center">221 ± 42</td><td class="colsep0 rowsep0" align="center">404 ± 335</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7l</b></td><td class="colsep0 rowsep0" align="center">2065 ± 288</td><td class="colsep0 rowsep0" align="center">191 ± 64</td><td class="colsep0 rowsep0" align="center">301 ± 68</td><td class="colsep0 rowsep0" align="center">645 ± 744</td><td class="colsep0 rowsep0" align="center">926 ± 385</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">7097 ± 522</td><td class="colsep0 rowsep0" align="center">12473 ± 3527</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">150 ± 37</td><td class="colsep0 rowsep0" align="center">6352 ± 1825</td><td class="colsep0 rowsep0" align="center">9610 ± 1089</td><td class="colsep0 rowsep0" align="center">4032 ± 97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">4189 ± 727</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="center">6877 ± 1409</td><td class="colsep0 rowsep0" align="center">33 ± 6</td><td class="colsep0 rowsep0" align="center">1224 ± 758</td><td class="colsep0 rowsep0" align="center">1269 ± 53</td><td class="colsep0 rowsep0" align="center">2063 ± 1294</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="center">11966 ± 2280</td><td class="colsep0 rowsep0" align="center">57 ± 15</td><td class="colsep0 rowsep0" align="center">3294 ± 314</td><td class="colsep0 rowsep0" align="center">5358 ± 1309</td><td class="colsep0 rowsep0" align="center">1639 ± 176</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="center">8285 ± 2983</td><td class="colsep0 rowsep0" align="center">31 ± 16</td><td class="colsep0 rowsep0" align="center">1362 ± 576</td><td class="colsep0 rowsep0" align="center">904 ± 490</td><td class="colsep0 rowsep0" align="center">920 ± 105</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="center">15832 ± 390</td><td class="colsep0 rowsep0" align="center">35 ± 3</td><td class="colsep0 rowsep0" align="center">51 ± 1</td><td class="colsep0 rowsep0" align="center">381 ± 33</td><td class="colsep0 rowsep0" align="center">308 ± 26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">40 ± 8</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">1100 ± 632</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="center">2000 ± 450</td><td class="colsep0 rowsep0" align="center">17 ± 8</td><td class="colsep0 rowsep0" align="center">40 ± 19</td><td class="colsep0 rowsep0" align="center">106 ± 60</td><td class="colsep0 rowsep0" align="center">149 ± 36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">40 ± 4</td><td class="colsep0 rowsep0" align="center">90 ± 36</td><td class="colsep0 rowsep0" align="center">5880 ± 1991</td><td class="colsep0 rowsep0" align="center">98 ± 37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">130 ± 77</td><td class="colsep0 rowsep0" align="center">380 ± 48</td><td class="colsep0 rowsep0" align="center">1350 ± 845</td><td class="colsep0 rowsep0" align="center">3000 ± 814</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">No inhibition.</p></div></div></div><div class="NLM_p">For further characterization of target inhibition in vitro, we then selected the three most potent compounds from this study (<b>7e</b>, <b>7f</b>, and <b>10</b>) and performed Western blot analysis in the most relevant cell lines (GIST-T1-D816E and GIST430-V654A; <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). By interrogating KIT-phosphorylation and KIT-related signaling (KIT Y703 (autophosphorylation site)) and related downstream targets Akt (pS473) and MAPK (pT202/Y204), we observed <b>7f</b> to be the most potent compound with strong and almost complete signaling inhibition at 100 nM in GIST430-V654A and GIST-T1-D816E, respectively. Selected compounds <b>7f</b>, <b>7e</b>, and <b>10</b> reduced the cellular amounts of pKIT, pAkt, and pMAPK in GIST-T1 and GIST-T1-D816E cells in a concentration-dependent manner. The reduction in phosphorylated proteins in GIST430-V654A and GIST-T1-D816E cells was most distinct with compound <b>7f</b>, nicely corroborating our biochemical and cellular results. The tested compounds were the most potent in the series of trifluoromethyl-substituted molecules. Therefore, the Western blot analysis emphasized our findings in the cellular and biochemical systems. The different substitution pattern of <b>7e</b> compared to <b>7f</b> illustrates that, in addition to the trifluoromethyl substituent in the back pocket-binding element, the substitution pattern of the hinge-binding element is crucially important for inhibitory activity. The Western blot analysis points to a favorable nitrogen in the heterocycle at the 3-position and an additional hydrogen bond donor at the <i>para</i>-position, whereas the nitrogen in the heterocycle at the 2-position is less favorable.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A,C) Western blot analysis after incubation (3 h) with doses of <b>7e</b>, <b>7f</b>, <b>10</b>, and <b>4</b> in GIST-T1-D816E and GIST430-V654A. (B,D,F) Corresponding dose–response curves of compounds <b>7e</b>, <b>7f</b>, <b>10</b>, and <b>4</b> in GIST cells expressing (A) constitutively active KIT with secondary mutant V654A (GIST430-V654A), (C) constitutively active KIT with secondary mutant D816E (GIST-T1-D816E), and (F) KIT negative cell line GIST-48B after 72 h incubation with the respective inhibitors. (E) GI<sub>50</sub> values on GIST-48B, GIST-T1-D816E, and GIST430-V654A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetic Characterization of Compounds <b>7f</b> and <b>10</b> Compared to FDA Approved KIT Inhibitors</h3><div class="NLM_p last">We evaluated the pharmacokinetic characteristics of <b>7f</b> and <b>10</b> regarding microsomal stability (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S2 and S3, Diagram S1 and S2</a>) plasma stability, cellular absorption (Caco-2 cell assay) as well as compound plasma protein binding (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S4</a>). We compared the values to <b>1</b>, <b>3</b>, and <b>4</b>. The stability in mouse liver microsomes showed an intrinsic clearance (CL<sub>int</sub>) of 36 μL min<sup>–1</sup> mg<sup>–1</sup> for <b>10</b>, which is in the range of the control compounds (18–36 μL min<sup>–1</sup> mg<sup>–1</sup>). In contrast, <b>7f</b> showed three times higher intrinsic clearance. Interestingly, the CL<sub>int</sub> in human liver microsomes was much lower for <b>7f</b> (1 μL min<sup>–1</sup> mg<sup>–1</sup>) when compared to <b>10</b> (9 μL min<sup>–1</sup> mg<sup>–1</sup>) and well in the range of <b>4</b> (1 μL min<sup>–1</sup> mg<sup>–1</sup>). We also investigated the plasma stability of <b>7f</b> and <b>10</b>. <b>7f</b> showed a human plasma stability of 91%, while <b>10</b> showed a plasma stability of 59%. The reversed behavior was determined for mouse plasma stability (50% for <b>7f</b> and 84% for <b>10</b>); both compounds are in the range of the FDA approved inhibitors <b>1</b>, <b>3</b>, and <b>4</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S4</a>). Additionally, our compounds show a plasma protein binding of 98.4% to 99.6%, which are well in the range of <b>4</b> (99.8%) (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S4</a>). We also investigated the cellular absorption by determining influx and efflux across a layer of Caco-2 cells. <b>7f</b> and <b>10</b> show a better permeability when compared with <b>4</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S4</a>). With a ratio under 1, <b>7f</b> and <b>10</b> show no significant efflux and are in the same range as <b>4</b>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Discussion and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Drug resistance to kinase inhibitors due to secondary mutations within the catalytic pocket represents a common mechanism and a grand challenge in targeted cancer therapy.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> In the case of GIST, attempts to harness progression due to secondary mutations have had moderate success as most patients only transiently respond to second- and third-line treatments (<b>2</b> and <b>3</b>).<a onclick="showRef(event, 'ref32 ref36'); return false;" href="javascript:void(0);" class="ref ref32 ref36">(32, 36)</a> The improved activity against exon 13/14 (<b>2</b>) and exon 17 mutant KIT (<b>3</b>) is paid for with side effects resulting from the promiscuous kinase inhibition profile of both drugs. Unfortunately, neither drug is able to inhibit all mutants nor are drug combinations feasible due to the additive toxicity.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">Identifying a compound with strong activity against exon 13/14 and 17 is therefore of utmost clinical relevance not only for GIST but also for KIT-driven leukemias and melanomas.</div><div class="NLM_p">Here, we present the structure-based design and synthesis of a focused library targeting clinically relevant KIT variants. We used the general scaffold of <b>4</b> as structural basis for a rational design to advance said scaffold in terms of reduced toxicity and increased potency for resistant KIT mutation V654A. Therefore, starting from already published X-ray crystallography, we performed molecular mechanics-based MD simulations of the V654A and T670I variants, analyzed their differential structural behavior, and devised structure-based hypotheses for our inhibitor design. Using synthetic chemistry, we produced a focused compound library, paying special attention to variation in the hinge-binding element (resulting in compounds <b>7a</b>–<b>7l</b>), variation in the substitution pattern of the back pocket-binding element (<b>8a</b>,<b>9b</b>), and modification of substituents R<sup>3</sup>and R<sup>4</sup> (<b>5c</b>,<b>d</b> and <b>10</b>), targeting specifically the secondary mutant V654A. Our SAR studies showed that <b>7a</b>–<b>l</b> exhibit similar activities and selectivity profiles toward wild-type KIT analogously to the parent compound <b>4</b>. However, the observed inhibitory profiles were markedly different for the mutant forms, culminating in the identification of <b>7d</b>, <b>7i</b>, <b>7f</b>, and <b>10</b> as the most potent in the series. These results demonstrate that, in a six-membered aromatic heterocyclic ring system as the hinge-binding element, the substitution of the <i>meta</i>- and <i>para</i>-position to the alkyne linker with a proton-acceptor and proton-donor functionality (<b>7f</b>), respectively, results in favorable interactions with all KIT variants. The enhanced potency of <b>7f</b> (2–247 nM for all KIT variants) compared to its related compounds was due to the formation of an extra hydrogen bond to the kinases’ hinge region. Our in silico studies further support these findings (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The results of our MD simulations conform quite well to our biochemical and cellular data. The generally longer incubation time in the cellular context resulted in increased potency as well as the expected observable nuances in the effectivity of the inhibitors. On the basis of the observed higher flexibility of the binding site of KIT V654A in the apo state (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Figure S2</a>), as derived from our MD simulations, a slower binding of the inhibitors is probable, resulting in an increased energy barrier for complex formation.</div><div class="NLM_p">Surprisingly, regression of the substitution pattern of the back pocket-binding element to an imatinib-based substitution pattern with the trifluoromethyl group in lieu of fluorine and hydrogen atoms, led to a fatal loss of activity for <b>8a</b>–<b>9b</b> in terms of the mutant forms of KIT, as well as the anticipated reduction in toxicity. The comparison of modeled compounds <b>7f</b>, <b>8d</b>, and <b>9b</b> pointed to a crucial importance of the trifluoromethyl substituent. According to our docking studies, the trifluoromethyl substituent seems to act as an anchor perfectly embedded in a small subpocket of the back pocket (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).<a onclick="showRef(event, 'ref48 ref59'); return false;" href="javascript:void(0);" class="ref ref48 ref59">(48, 59)</a> This subpocket is highly conserved in many kinases due to its role in forming the regulatory R-spine.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Therefore, in many cases, targeting this pocket leads to enhanced potency but also to poor selectivity and potential toxicity.<a onclick="showRef(event, 'ref59 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref59 ref61 ref62">(59, 61, 62)</a></div><div class="NLM_p">Our promising in vitro results prompted us to extend our SAR studies at a cellular level. We addressed the clinically relevant KIT variants in human, untreated, metastatic GIST-T1, -T670I, and -D816E cells, as well as GIST430-V654A cells. Cellular characterization revealed a reduced viability of all GIST cell lines in the same range as our in vitro characterizations. <b>7f</b> turned out to be the most potent in this series of compounds, with a significant impact on the reduction of viable GIST430-V654A cells (GI<sub>50</sub> 51 nM) compared to FDA-approved compound <b>4</b> (149 nM). This observation proves our approach in altering the hinge-binding element to introduce motifs with more varied substitution patterns capable of forming additional favorable interactions with KIT to compensate for the loss of interactions generated by secondary mutation V654A. Alteration of substituents R<sup>3</sup> and R<sup>4</sup> in <b>10</b> leads to a promising inhibition profile with next to no activity in GIST-negative cells. In addition, these inhibitors suppress the phosphorylation of KIT, its mutant forms, and its downstream cascade.</div><div class="NLM_p last">In summary, using structure-based design, we developed inhibitors for various KIT mutants, paying special attention to secondary mutant V654A. We observed increased inhibitory activity (compound <b>7f</b>) and an optimized inhibition profile concerning toxicity in KIT-negative cells (compound <b>10</b>), which could also be observed in a conducted kinase profiling (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S1 and Figure S4</a>). The pharmacokinetic characterization showed that the inhibitors <b>7f</b> and <b>10</b> are in the range of the FDA approved inhibitors concerning the investigated parameters (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">Table S4</a>). Taken together, these results will aid in the development of next-generation inhibitors to target clinically relevant KIT mutants.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12470" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12470" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p last">Unless otherwise noted, all reagents and solvents were purchased from Acros, Fluka, Sigma-Aldrich, Alfa Aesar, Combiblocks, Apollo, or Merck and used without further purification. Dry solvents were purchased as anhydrous reagents from commercial suppliers. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance DRX 400 spectrometer at 500 and 600 and 126 and 151 MHz, respectively. <sup>1</sup>H chemical shifts are reported in δ (ppm) as s (singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), m (multiplet), and bs (broad singlet) and are referenced to the residual solvent signal: CDCl<sub>3</sub> (7.26), DMSO-<i>d</i><sub>6</sub> (2.50), or MeOD-<i>d</i><sub>4</sub> (3.34). <sup>13</sup>C spectra are referenced to the residual solvent signal: CDCl<sub>3</sub> (77.1), DMSO-<i>d</i><sub>6</sub> (39.52), or MeOD-<i>d</i><sub>4</sub> (49.86). High-resolution electrospray ionization mass spectra (ESI-FTMS) were recorded on a Thermo LTQ Orbitrap (high-resolution mass spectrometer from Thermo Electron) coupled to an Accela HPLC system supplied with a Hypersil GOLD column (Thermo Electron). Analytical TLC was carried out on Merck 60 F245 aluminum-backed silica gel plates. Compounds were purified by column chromatography using Baker silica gel (40–70 μm particle size). Preparative HPLC was conducted on an Agilent HPLC system. The purification of all final compounds to >95% purity was conducted by high-performance liquid chromatography (HPLC). The purity was determined using Agilent 1200 series HPLC systems with UV detection at 210 nm (system: Agilent Eclipse XDB-C18 4.6 mm × 150 mm, 5 μM, 10–100% CH<sub>3</sub>CN in H<sub>2</sub>O, with 0.1% TFA, for 15 min at 1.0 mL/min).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Reagents and Materials</h3><div class="NLM_p last">All supplies for the KIT HTRF assay kit were purchased from CisBio (Bagnols-sur-Cèze, France). Small volume (20 μL fill volume) white round-bottom 384-well plates were obtained from Greiner Bio-One GmbH (Solingen, Germany).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Activity-Based Assay for IC<sub>50</sub> Determination</h3><div class="NLM_p last">IC<sub>50</sub> determinations for KIT kinases were measured with the KinEASE-TK assay from Cisbio according to the manufacturer’s instructions. A biotinylated poly-Glu-Tyr substrate peptide was phosphorylated by the specific kinase of interest. After completion of the reaction, an antiphosphotyrosine antibody labeled with europium cryptate and streptavidin labeled with the fluorophore XL665 were added. FRET between europium cryptate and XL665 was measured to quantify the phosphorylation of the substrate peptide. ATP concentrations were set at their respective <i>K</i><sub>M</sub> values (30 μM for wild-type KIT, 20 μM for KIT V559D/T670I, 12 μM for KIT D816H, and 50 μM for V559D/V654A). A substrate concentration of 330 nM was used for KIT wild-type, 450 nM was used for KIT V559D/T670I, 1 μM was used for KIT D816H and 1 μM was used for KIT V559D/V654A, respectively. Kinase and inhibitor were preincubated for 30 min before the reaction was started by addition of ATP and substrate peptide. A PerkinElmer EnVision multimode plate reader was used to measure the fluorescence of the samples at 620 nm (Eu-labeled antibody) and 665 nm (XL665 labeled streptavidin) 50 μs after excitation at 320 nm. The quotient of both intensities for reactions at eight different inhibitor concentrations was then analyzed using the Quattro software suite for IC<sub>50</sub> value determination. Each reaction was performed in duplicate, and at least three independent determinations of each IC<sub>50</sub> were made.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Gist Cell Lines</h3><div class="NLM_p last">GIST-T1 and GIST-T1 T670I were cultured in DMEM (Gibco), and GIST430-V654A, GIST-T1-D816E, and GIST-48B were cultured in IMDM (Gibco), supplemented with 10–15% FBS (Biochrome) and 1% Pen/Step/Ampho (Gibco). GIST430-V654A, GIST-T1-T670I, and GIST-D816E Media were supplemented with <b>1</b> 100 nM, 200 nM, and 1 μM, respectively. GIST-T1 was established (by Takahiro Taguchi, Kochi University, Japan) from a human, untreated, metastatic GIST containing a 57 bp deletion in KIT exon 11 and is highly sensitive to <b>1</b> at low nanomolar doses<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> GIST-T1-D816E and GIST-T1-T670I were generated by continuous treatment of parental GIST-T1 with <b>1</b> until a resistant subline emerged. GIST-T1-D816E was created in SB’s lab, and GIST-T1-T670I was generated and kindly provided by Prof. Brian Rubin (Cleveland Clinic, Cleveland, OH). GIST430-V654A was established from a pretreated GIST specimen and harbors, in addition to its activating exon 11 mutation, the V654A gatekeeper mutation. GIST-48B, despite retaining the activating KIT mutation in all cells, expresses KIT transcript and protein at essentially undetectable levels and served as a negative control for KIT-inhibition in our studies. GIST430-V654A and GIST-48B cell lines have been established at the Brigham and Women’s Hospital in Boston, USA, by the Group of Professor Jonathan A. Fletcher.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Cellular Studies</h3><div class="NLM_p last">Cells were seeded at cell numbers that ensure linearity and optimal signal intensity (GIST-T1 T670I 750 cells/well, GIST430-V654A 2000 cells/well, GIST-T1-D816E 800 cells/well, and GIST-48B 400 cells/well, 384-well format, 25 μL). After culturing for 24 h in serum and antibiotics containing media in humidified chambers at 37 °C/5% CO<sub>2</sub>, the cells were incubated for 72 h with KIT inhibitors in serial dilutions (1.4 nM to 20 μM), with DMSO and staurosporine as control. Compound dilutions were generated using the acoustic dispensing system ECHO 520 Liquid Handler from Labcyte (Sunnyvale, California, USA) and the according dose response software Echo Dose Response v1.5.4. Viability studies were carried out on day 3 using the CellTiterGlo Assay (Promega, USA), which is based on quantification of cellular ATP, indicating the presence of metabolically active cells. For these studies, CellTiterGlo reagent was prepared according to the instructions of the kit and diluted 1:1 by GIBCO DPBS. Thereon, reagent and assay plates were equilibrated at room temperature for 20 min. Equal volumes of the reagent were added to the volume of culture medium present in each well (25 μL). The plates were shaken for 3 min on an orbital shaker to induce cell lysis. The microplates were then incubated at room temperature for 20 min for stabilization of the luminescent signal. Following incubation, the luminescence was recorded on the EnVision microplate reader (PerkinElmer) using 500 ms integration time. The data was then analyzed using the Quattro Software Suite for EC<sub>50</sub> determination. All experimental points were measured in duplicates for each plate and were replicated in at least two plates.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Reagents and Antibodies</h3><div class="NLM_p last"><b>1</b>, <b>2</b>, <b>3</b>, and <b>4</b> were purchased from LC Laboratories (Woburn, MA). Rabbit polyclonal antibody KIT was purchased from DAKO (Carpinteria, CA). A Beta Actin antibody was purchased from Sigma (St. Louis, MO). All other antibodies used for this study were purchased from Cell Signaling (Beverly, MA).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Western Blotting</h3><div class="NLM_p last">Cells were seeded in 6-well plates and allowed to attach overnight. After 3 h of treatment with the respective compounds or DMSO as vehicle control, preparation of protein lysates and consecutive SDS-PAGE and Western blotting were carried out as previously described.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Membranes were incubated overnight at 4 °C with specific antibodies against KIT and KIT-signaling intermediates. Changes in protein expression and phosphorylation as visualized by chemiluminescence were captured and quantified using a FUJI LAS3000 system with Science Lab 2001 ImageGauge 4.0 software (Fujifilm Medial Systems, Stamford, CT, USA).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Microsomal Stability (Phase I) Assay</h3><div class="NLM_p last">LCMS-based measuring of degradation of compounds at 3 μM assay concentration was used to determine the metabolic stability under oxidative terms in human and mouse microsomes over 60 min at 37 °C. Calculating the compound half-life <i>t</i><sub>1/2</sub>, the in vitro intrinsic clearance CL<sub>int</sub> is given.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Plasma Stability</h3><div class="NLM_p last">LCMS-based measuring of the ratio of remaining compound at 5 μM assay concentration after 60 min incubation at 37 °C in human and mouse plasma.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Plasma Protein Binding</h3><div class="NLM_p last">Assessment of plasma protein binding was measured by equilibrium dialysis by incubating the compound of interest at a concentration of 5 μM for 6 h at 37 °C in 50% plasma in buffer (v/v) followed by LCMS-based determination of final compound concentrations. The resulting fraction unbound at 50% plasma (<i>f</i><sub>u50%</sub>) is extrapolated to the fraction unbound at 100% plasma (<i>f</i><sub>u100%</sub>) using the following equation: <i>f</i><sub>u100%</sub> = <i>f</i><sub>u50%</sub>/(2 – <i>f</i><sub>u50%</sub>)</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Caco-2 Assay</h3><div class="NLM_p last">To measure cellular permeability, compounds were applied at a concentration of 10 μM in HBSS to either the apical (A) or basolateral (B) side of a Caco-2 cell monolayer and incubated for 2 h at 37 °C. Compound concentrations on each side of the monolayer were determined by LC-MS/MS and the apparent permeability (<i>P</i><sub>app</sub>) was calculated in the apical to basolateral (A → B) and basolateral to apical (B → A) directions according to the following equation: <i>P</i><sub>app</sub>(A → B) = (Δ<i>C</i><sub>B</sub> × <i>V</i><sub>B</sub> × 0.001)/(Δ<i>t</i> × <i>A</i> × <i>C</i><sub>t0,A</sub>).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00841">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00841" class="ext-link">10.1021/acs.jmedchem.7b00841</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">RMSD profiles for the MD simulations of wild-type KIT, KIT<sup>T670I</sup>, and KIT<sup>V654A</sup> in the presence and absence of ponatinib; RMSF values of the active site of wild-type KIT, KIT<sup>T670I</sup>, and KIT<sup>V654A</sup>; angle between the axis of the α helix C and the unit cell vector x during a 300 ns MD simulation; kinome dendrogram derived from the SelectScreen; Analysis of the ponatinib binding site volume for the MD simulations in the absence of ponatinib; PCA results for the MD simulations in the absence of ponatinib; data of the SelectScreen; in vitro intrinsic clearance CL<sub>int</sub> in human and murine liver microsomes; relative compound degradation of <b>7f</b>, <b>10</b>, ponatinib, imatinib, and regorafenib; pharmacokinetic parameters of <b>7f</b>, <b>10</b>, ponatinib, imatinib, and regorafenib; results of the RMSD-based binding site clustering analyses; hydrogen bond occupancies for the MD simulations with ponatinib; free energies of binding as estimated by MM-PB(GB)SA calculations; binding site comparison results; detailed synthetic procedures for the preparation of inhibitors for KIT mutants (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_001.csv">jm7b00841_si_001.csv (4.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf">jm7b00841_si_002.pdf (2.7 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00841" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sebastian Bauer</span> - <span class="hlFld-Affiliation affiliation">Department
of Medical Oncology, Sarcoma Centre West
German Cancer Centre University Duisburg−Essen, Medical School, Hufelandstraße 55, D-45122 Essen, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Germany
and German Cancer Consortium (DKTK), Partner
Site University Hospital Essen, D-45147 Essen, Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#651600070416110c040b4b070410001725100e48001616000b4b0100"><span class="__cf_email__" data-cfemail="f182949390828598909fdf9390849483b1849adc948282949fdf9594">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Rauh</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link">http://orcid.org/0000-0002-1970-7642</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#adc9ccc3c4c8c183dfccd8c5edd9d8c9c2dfd9c0d8c3c983c9c8"><span class="__cf_email__" data-cfemail="7e1a1f10171b12500c1f0b163e0a0b1a110c0a130b101a501a1b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helena Kaitsiotou</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina Keul</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julia Hardick</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Mühlenberg</span> - <span class="hlFld-Affiliation affiliation">Department
of Medical Oncology, Sarcoma Centre West
German Cancer Centre University Duisburg−Essen, Medical School, Hufelandstraße 55, D-45122 Essen, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Germany
and German Cancer Consortium (DKTK), Partner
Site University Hospital Essen, D-45147 Essen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julia Ketzer</span> - <span class="hlFld-Affiliation affiliation">Department
of Medical Oncology, Sarcoma Centre West
German Cancer Centre University Duisburg−Essen, Medical School, Hufelandstraße 55, D-45122 Essen, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Germany
and German Cancer Consortium (DKTK), Partner
Site University Hospital Essen, D-45147 Essen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christiane Ehrt</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jasmin Krüll</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Federico Medda</span> - <span class="hlFld-Affiliation affiliation">Taros
Chemicals GmbH & Co. KG, Emil-Figge-Straße 76a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oliver Koch</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße 4a, D-44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabrizio Giordanetto</span> - <span class="hlFld-Affiliation affiliation">Taros
Chemicals GmbH & Co. KG, Emil-Figge-Straße 76a, D-44227 Dortmund, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d46e3644-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was cofunded by the German Federal Ministry for Education and Research (NGFNPlus and e:Med) (grant no. BMBF 01GS08104, 01ZX1303C) and by the Deutsche Forschungsgemeinschaft (DFG). D.R. thanks the German federal state North Rhine Westphalia (NRW) and the European Union (European Regional Development Fund: Investing In Your Future) (EFRE-800400). C.E. is funded by the Kekulé Mobility Fellowship of the Chemical Industry Fund (FCI). O.K. is funded by the German Federal Ministry for Education and Research (BMBF, Medizinische Chemie in Dortmund, grant BMBF 1316053).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i32" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i32"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i33" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i33"> Abbreviations Used</h2><tr><td class="NLM_term">KIT</td><td class="NLM_def"><p class="first last">mast/stem cell growth factor receptor kinase</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumors</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship: relationship between the chemical structure of a molecule and its biological activity on a target</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">MD</td><td class="NLM_def"><p class="first last">molecular dynamics</p></td></tr><tr><td class="NLM_term">GI<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration for 50% of maximal inhibition of cell proliferation</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration causing 50% inhibition of enzyme activity</p></td></tr><tr><td class="NLM_term">PCA</td><td class="NLM_def"><p class="first last">principle component analysis</p></td></tr><tr><td class="NLM_term">MM-PB(GB)SA</td><td class="NLM_def"><p class="first last">molecular mechanics Poisson–Boltzmann (Generalized Born) solvent-accessible surface area</p></td></tr><tr><td class="NLM_term">R-spine regulatory spine</td><td class="NLM_def"><p class="first last">highly conserved motif, found in every active kinase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15371" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15371" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 64 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Tsujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furitsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span> </span><span class="NLM_article-title">Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell-line p-815 generated by a point mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">2619</span><span class="NLM_x">–</span> <span class="NLM_lpage">2626</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1994&pages=2619-2626&author=T.+Tsujimuraauthor=T.+Furitsuauthor=M.+Morimotoauthor=K.+Isozakiauthor=S.+Nomuraauthor=Y.+Matsuzawaauthor=Y.+Kitamuraauthor=Y.+Kanakura&title=Ligand-independent+activation+of+c-kit+receptor+tyrosine+kinase+in+a+murine+mastocytoma+cell-line+p-815+generated+by+a+point+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DFuritsu%26aufirst%3DT.%26aulast%3DMorimoto%26aufirst%3DM.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DS.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26atitle%3DLigand-independent%2520activation%2520of%2520c-kit%2520receptor%2520tyrosine%2520kinase%2520in%2520a%2520murine%2520mastocytoma%2520cell-line%2520p-815%2520generated%2520by%2520a%2520point%2520mutation%26jtitle%3DBlood%26date%3D1994%26volume%3D83%26spage%3D2619%26epage%3D2626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Tsujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furitsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span> </span><span class="NLM_article-title">Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line rbl-2h3</span> <span class="citation_source-journal">Int. Arch. Allergy Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span><span class="refDoi"> DOI: 10.1159/000236870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1159%2F000236870" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2004&pages=377-385&author=T.+Tsujimuraauthor=T.+Furitsuauthor=M.+Morimotoauthor=Y.+Kanayamaauthor=S.+Nomuraauthor=Y.+Matsuzawaauthor=Y.+Kitamuraauthor=Y.+Kanakura&title=Substitution+of+an+aspartic+acid+results+in+constitutive+activation+of+c-kit+receptor+tyrosine+kinase+in+a+rat+tumor+mast+cell+line+rbl-2h3&doi=10.1159%2F000236870"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1159%2F000236870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000236870%26sid%3Dliteratum%253Aachs%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DFuritsu%26aufirst%3DT.%26aulast%3DMorimoto%26aufirst%3DM.%26aulast%3DKanayama%26aufirst%3DY.%26aulast%3DNomura%26aufirst%3DS.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26atitle%3DSubstitution%2520of%2520an%2520aspartic%2520acid%2520results%2520in%2520constitutive%2520activation%2520of%2520c-kit%2520receptor%2520tyrosine%2520kinase%2520in%2520a%2520rat%2520tumor%2520mast%2520cell%2520line%2520rbl-2h3%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2004%26volume%3D106%26spage%3D377%26epage%3D385%26doi%3D10.1159%2F000236870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Furitsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitayama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koshimizu, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugahara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterfield, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashman, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span> </span><span class="NLM_article-title">Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast-cell leukemia-cell line causing ligand-independent activation of c-kit product</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">1736</span><span class="NLM_x">–</span> <span class="NLM_lpage">1744</span><span class="refDoi"> DOI: 10.1172/JCI116761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1172%2FJCI116761" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1993&pages=1736-1744&author=T.+Furitsuauthor=T.+Tsujimuraauthor=T.+Tonoauthor=H.+Ikedaauthor=H.+Kitayamaauthor=U.+Koshimizuauthor=H.+Sugaharaauthor=J.+H.+Butterfieldauthor=L.+K.+Ashmanauthor=Y.+Kanayamaauthor=Y.+Matsuzawaauthor=Y.+Kitamuraauthor=Y.+Kanakura&title=Identification+of+mutations+in+the+coding+sequence+of+the+protooncogene+c-kit+in+a+human+mast-cell+leukemia-cell+line+causing+ligand-independent+activation+of+c-kit+product&doi=10.1172%2FJCI116761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1172%2FJCI116761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI116761%26sid%3Dliteratum%253Aachs%26aulast%3DFuritsu%26aufirst%3DT.%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DTono%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DKitayama%26aufirst%3DH.%26aulast%3DKoshimizu%26aufirst%3DU.%26aulast%3DSugahara%26aufirst%3DH.%26aulast%3DButterfield%26aufirst%3DJ.%2BH.%26aulast%3DAshman%26aufirst%3DL.%2BK.%26aulast%3DKanayama%26aufirst%3DY.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520mutations%2520in%2520the%2520coding%2520sequence%2520of%2520the%2520protooncogene%2520c-kit%2520in%2520a%2520human%2520mast-cell%2520leukemia-cell%2520line%2520causing%2520ligand-independent%2520activation%2520of%2520c-kit%2520product%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1993%26volume%3D92%26spage%3D1736%26epage%3D1744%26doi%3D10.1172%2FJCI116761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Linnekin, D.</span><span> </span><span class="NLM_article-title">Early signaling pathways activated by c-kit in hematopoietic cells</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1016/S1357-2725(99)00078-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS1357-2725%2899%2900078-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10582339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVWitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=1053-1074&author=D.+Linnekin&title=Early+signaling+pathways+activated+by+c-kit+in+hematopoietic+cells&doi=10.1016%2FS1357-2725%2899%2900078-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Early signaling pathways activated by c-Kit in hematopoietic cells</span></div><div class="casAuthors">Linnekin, D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1053-1074</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 171 refs.  C-Kit is a receptor tyrosine kinase that binds stem cell factor (SCF).  Structurally, c-Kit contains five Ig-like domains extracellularly and a catalytic domain divided into two regions by a 77 amino acid insert intracellularly.  Studies in white spotting and steel mice have shown that functional SCF and c-Kit are crit. in the survival and development of stem cells involved in hematopoiesis, pigmentation and reprodn.  Mutations in c-Kit are assocd. with a variety of human diseases.  Interaction of SCF with c-Kit rapidly induces receptor dimerization and increases in autophosphorylation activity.  Downstream of c-Kit, multiple signal transduction components are activated, including phosphatidylinositol-3-kinase, Src family members, the JAK/STAT pathway and the Ras-Raf-MAP kinase cascade.  Structure-function studies have begun to address the role of these signaling components in SCF-mediated responses.  This review will focus on the biochem. mechanism of action of SCF in hematopoietic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-8E1wr3VU-rVg90H21EOLACvtfcHk0ljUxW7Gs_7V6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVWitrc%253D&md5=f8fc51c696dbb65c6885bd55d0e0bde8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2899%2900078-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252899%252900078-3%26sid%3Dliteratum%253Aachs%26aulast%3DLinnekin%26aufirst%3DD.%26atitle%3DEarly%2520signaling%2520pathways%2520activated%2520by%2520c-kit%2520in%2520hematopoietic%2520cells%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D1999%26volume%3D31%26spage%3D1053%26epage%3D1074%26doi%3D10.1016%2FS1357-2725%2899%2900078-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Carvajal, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajewski, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutzky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolchok, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teitcher, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giobbie-Hurder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodi, F. S.</span><span> </span><span class="NLM_article-title">Phase ii study of nilotinib in melanoma harboring kit alterations following progression to prior kit inhibition</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2289</span><span class="NLM_x">–</span> <span class="NLM_lpage">2296</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F1078-0432.CCR-14-1630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25695690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2289-2296&author=R.+D.+Carvajalauthor=D.+P.+Lawrenceauthor=J.+S.+Weberauthor=T.+F.+Gajewskiauthor=R.+Gonzalezauthor=J.+Lutzkyauthor=S.+J.+O%E2%80%99Dayauthor=O.+Hamidauthor=J.+D.+Wolchokauthor=P.+B.+Chapmanauthor=R.+J.+Sullivanauthor=J.+B.+Teitcherauthor=N.+Ramaiyaauthor=A.+Giobbie-Hurderauthor=C.+R.+Antonescuauthor=M.+C.+Heinrichauthor=B.+C.+Bastianauthor=C.+L.+Corlessauthor=J.+A.+Fletcherauthor=F.+S.+Hodi&title=Phase+ii+study+of+nilotinib+in+melanoma+harboring+kit+alterations+following+progression+to+prior+kit+inhibition&doi=10.1158%2F1078-0432.CCR-14-1630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition</span></div><div class="casAuthors">Carvajal, Richard D.; Lawrence, Donald P.; Weber, Jeffrey S.; Gajewski, Thomas F.; Gonzalez, Rene; Lutzky, Jose; O'Day, Steven J.; Hamid, Omid; Wolchok, Jedd D.; Chapman, Paul B.; Sullivan, Ryan J.; Teitcher, Jerrold B.; Ramaiya, Nikhil; Giobbie-Hurder, Anita; Antonescu, Cristina R.; Heinrich, Michael C.; Bastian, Boris C.; Corless, Christopher L.; Fletcher, Jonathan A.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2289-2296</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases are unknown.  Exptl. Design: We conducted a phase II study of nilotinib 400 mg twice a day in two cohorts of patients with melanomas harboring KIT mutations or amplification: (A) those refractory or intolerant to a prior KIT inhibitor; and (B) those with brain metastases.  The primary endpoint was 4-mo disease control rate.  Secondary endpoints included response rate, time-to-progression (TTP), and overall survival (OS).  A Simon two-stage and a single-stage design was planned to assess for the primary endpoint in cohorts A and B, resp.  Results: Twenty patients were enrolled and 19 treated (11 in cohort A; 8 in cohort B).  Three patients on cohort A [27%; 95% confidence interval (CI), 8%-56%] and 1 on cohort B (12.5%; 90% CI, 0.6%-47%) achieved the primary endpoint.  Two partial responses were obsd. in cohort A (18.2%; 90% CI, 3%-47%); none were obsd. in cohort B. The median TTP and OS was 3.3 (90% CI, 2.1-3.9 mo) and 9.1 mo (90% CI, 4.3-14.2 mo), resp., in all treated patients.  Conclusions: Nilotinib may achieve disease control in patients with melanoma harboring KIT alterations and whose disease progressed after imatinib therapy.  The efficacy of this agent in KIT-altered melanoma with brain metastasis is limited.  Clin Cancer Res; 21(10); 2289-96. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0uI0vh_bEsLVg90H21EOLACvtfcHk0liJcvHgbDTubQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOktbY%253D&md5=317cf98d4a3ea47bd52f7f4509cd61da</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1630%26sid%3Dliteratum%253Aachs%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DLawrence%26aufirst%3DD.%2BP.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DLutzky%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DTeitcher%26aufirst%3DJ.%2BB.%26aulast%3DRamaiya%26aufirst%3DN.%26aulast%3DGiobbie-Hurder%26aufirst%3DA.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DPhase%2520ii%2520study%2520of%2520nilotinib%2520in%2520melanoma%2520harboring%2520kit%2520alterations%2520following%2520progression%2520to%2520prior%2520kit%2520inhibition%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2289%26epage%3D2296%26doi%3D10.1158%2F1078-0432.CCR-14-1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Curtin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, B. C.</span><span> </span><span class="NLM_article-title">Somatic activation of kit in distinct subtypes of melanoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4340</span><span class="NLM_x">–</span> <span class="NLM_lpage">4246</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.2984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1200%2FJCO.2006.06.2984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=16908931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGju7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4340-4246&author=J.+A.+Curtinauthor=K.+Busamauthor=D.+Pinkelauthor=B.+C.+Bastian&title=Somatic+activation+of+kit+in+distinct+subtypes+of+melanoma&doi=10.1200%2FJCO.2006.06.2984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic activation of KIT in distinct subtypes of melanoma</span></div><div class="casAuthors">Curtin, John A.; Busam, Klaus; Pinkel, Daniel; Bastian, Boris C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4340-4346</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Melanomas on mucosal membranes, acral skin (soles, palms, and nail bed), and skin with chronic sun-induced damage have infrequent mutations in BRAF and NRAS, genes within the mitogen-activated protein (MAP) kinase pathway commonly mutated in melanomas on intermittently sun-exposed skin.  This raises the question of whether other aberrations are occurring in the MAP kinase cascade in the melanoma types with infrequent mutations of BRAF and NRAS.  We analyzed array comparative genomic hybridization data from 102 primary melanomas (38 from mucosa, 28 from acral skin, and 18 from skin with and 18 from skin without chronic sun-induced damage) for DNA copy no. aberrations specific to melanoma subtypes where mutations in BRAF and NRAS are infrequent.  A narrow amplification on 4q12 was found, and candidate genes within it were analyzed.  Oncogenic mutations in KIT were found in three of seven tumors with amplifications.  Examn. of all 102 primary melanomas found mutations and/or copy no. increases of KIT in 39% of mucosal, 36% of acral, and 28% of melanomas on chronically sun-damaged skin, but not in any (0%) melanomas on skin without chronic sun damage.  Seventy-nine percent of tumors with mutations and 53% of tumors with multiple copies of KIT demonstrated increased KIT protein levels.  KIT is an important oncogene in melanoma.  Because the majority of the KIT mutations we found in melanoma also occur in imatinib-responsive cancers of other types, imatinib may offer an immediate therapeutic benefit for a significant proportion of the global melanoma burden.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmjtnnmCP8IbVg90H21EOLACvtfcHk0liJcvHgbDTubQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGju7bM&md5=daf0bb9b2dfabc78170cb5e596a402e2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2984%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DJ.%2BA.%26aulast%3DBusam%26aufirst%3DK.%26aulast%3DPinkel%26aufirst%3DD.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26atitle%3DSomatic%2520activation%2520of%2520kit%2520in%2520distinct%2520subtypes%2520of%2520melanoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4340%26epage%3D4246%26doi%3D10.1200%2FJCO.2006.06.2984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Ashman, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, R.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of c-kit in cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1517/13543784.2013.740010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1517%2F13543784.2013.740010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23127174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWqtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=103-115&author=L.+K.+Ashmanauthor=R.+Griffith&title=Therapeutic+targeting+of+c-kit+in+cancer&doi=10.1517%2F13543784.2013.740010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of c-KIT in cancer</span></div><div class="casAuthors">Ashman, Leonie K.; Griffith, Renate</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-115</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Mutated forms of the receptor tyrosine kinase c-KIT are "drivers" in several cancers and are attractive targets for therapy.  While benefits have been obtained from use of inhibitors of KIT kinase activity such as imatinib, esp. in gastrointestinal stromal tumors (GIST), primary resistance occurs with certain oncogenic mutations.  Furthermore, resistance frequently develops due to secondary mutations.  Approaches to addressing both of these issues as well as combination therapies to optimize use of KIT kinase inhibitors are discussed.Areas covered: This review covers the occurrence of oncogenic KIT mutations in different cancers and the mol. basis of their action.  The action of KIT kinase inhibitors, esp. imatinib, sunitinib, dasatinib and PKC412, on different primary and secondary mutants is discussed.  Outcomes of clin. trials in GIST, acute myeloid leukemia (AML), systemic mastocytosis and melanoma and their implications for future directions are considered.Expert opinion: Anal. of KIT mutations in individual patients is an essential prerequisite to the use of kinase inhibitors for therapy, and monitoring for development of secondary mutations that confer drug resistance is necessary.  However, it is unlikely that KIT inhibitors alone can lead to cure.  KIT mutations alone do not seem to be sufficient for transformation; thus identification and co-targeting of synergistic oncogenic pathways should lead to improved outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYeFNMHL4QSrVg90H21EOLACvtfcHk0liJcvHgbDTubQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWqtbbI&md5=9e653c915071f0e90cf366bcb2b51be9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.740010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.740010%26sid%3Dliteratum%253Aachs%26aulast%3DAshman%26aufirst%3DL.%2BK.%26aulast%3DGriffith%26aufirst%3DR.%26atitle%3DTherapeutic%2520targeting%2520of%2520c-kit%2520in%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D103%26epage%3D115%26doi%3D10.1517%2F13543784.2013.740010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Abbaspour Babaei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamalidehghan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huri, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadipour, F.</span><span> </span><span class="NLM_article-title">Receptor tyrosine kinase (c-kit) inhibitors: A potential therapeutic target in cancer cells</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2459</span><span class="refDoi"> DOI: 10.2147/DDDT.S89114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.2147%2FDDDT.S89114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=27536065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=2443-2459&author=M.+Abbaspour+Babaeiauthor=B.+Kamalidehghanauthor=M.+Saleemauthor=H.+Z.+Huriauthor=F.+Ahmadipour&title=Receptor+tyrosine+kinase+%28c-kit%29+inhibitors%3A+A+potential+therapeutic+target+in+cancer+cells&doi=10.2147%2FDDDT.S89114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells</span></div><div class="casAuthors">Abbaspour Babaei Maryam; Ahmadipour Fatemeh; Kamalidehghan Behnam; Saleem Mohammad; Huri Hasniza Zaman</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2443-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">c-Kit, a receptor tyrosine kinase, is involved in intracellular signaling, and the mutated form of c-Kit plays a crucial role in occurrence of some cancers.  The function of c-Kit has led to the concept that inhibiting c-Kit kinase activity can be a target for cancer therapy.  The promising results of inhibition of c-Kit for treatment of cancers have been observed in some cancers such as gastrointestinal stromal tumor, acute myeloid leukemia, melanoma, and other tumors, and these results have encouraged attempts toward improvement of using c-Kit as a capable target for cancer therapy.  This paper presents the findings of previous studies regarding c-Kit as a receptor tyrosine kinase and an oncogene, as well as its gene targets and signaling pathways in normal and cancer cells.  The c-Kit gene location, protein structure, and the role of c-Kit in normal cell have been discussed.  Comprehending the molecular mechanism underlying c-Kit-mediated tumorogenesis is consequently essential and may lead to the identification of future novel drug targets.  The potential mechanisms by which c-Kit induces cellular transformation have been described.  This study aims to elucidate the function of c-Kit for future cancer therapy.  In addition, it has c-Kit inhibitor drug properties and their functions have been listed in tables and demonstrated in schematic pictures.  This review also has collected previous studies that targeted c-Kit as a novel strategy for cancer therapy.  This paper further emphasizes the advantages of this approach, as well as the limitations that must be addressed in the future.  Finally, although c-Kit is an attractive target for cancer therapy, based on the outcomes of treatment of patients with c-Kit inhibitors, it is unlikely that Kit inhibitors alone can lead to cure.  It seems that c-Kit mutations alone are not sufficient for tumorogenesis, but do play a crucial role in cancer occurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfTnK2L7idhRwLZxei1HN8fW6udTcc2eYXrzwkVHT7urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D&md5=c45d232471e049dc8d42a98fc5aa1d76</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S89114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S89114%26sid%3Dliteratum%253Aachs%26aulast%3DAbbaspour%2BBabaei%26aufirst%3DM.%26aulast%3DKamalidehghan%26aufirst%3DB.%26aulast%3DSaleem%26aufirst%3DM.%26aulast%3DHuri%26aufirst%3DH.%2BZ.%26aulast%3DAhmadipour%26aufirst%3DF.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520%2528c-kit%2529%2520inhibitors%253A%2520A%2520potential%2520therapeutic%2520target%2520in%2520cancer%2520cells%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D2443%26epage%3D2459%26doi%3D10.2147%2FDDDT.S89114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Poveda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sevilla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecumberri, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Beveridge, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estival, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicente, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubió, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Broto, J.</span><span> </span><span class="NLM_article-title">Seom clinical guideline for gastrointestinal sarcomas (gist) (2016)</span> <span class="citation_source-journal">Clin. Transl. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1221</span><span class="NLM_x">–</span> <span class="NLM_lpage">1228</span><span class="refDoi"> DOI: 10.1007/s12094-016-1579-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1007%2Fs12094-016-1579-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=27896638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWms7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1221-1228&author=A.+Povedaauthor=V.+Martinezauthor=C.+Serranoauthor=I.+Sevillaauthor=M.+J.+Lecumberriauthor=R.+D.+de+Beveridgeauthor=A.+Estivalauthor=D.+Vicenteauthor=J.+Rubi%C3%B3author=J.+Martin-Broto&title=Seom+clinical+guideline+for+gastrointestinal+sarcomas+%28gist%29+%282016%29&doi=10.1007%2Fs12094-016-1579-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)</span></div><div class="casAuthors">Poveda, A.; Martinez, V.; Serrano, C.; Sevilla, I.; Lecumberri, M. J.; de Beveridge, R. D.; Estival, A.; Vicente, D.; Rubio, J.; Martin-Broto, J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1221-1228</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, and this disease has served as a paradigmatic model for successful rational development of targeted therapies.  The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies.  The Spanish Society of Medical Oncol. (SEOM) guidelines provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients.  We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in ref. centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5KtCyjpxGOrVg90H21EOLACvtfcHk0lg_GuHjI-pf_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWms7nJ&md5=d96fe59f5b0d990e0713991b199d195d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs12094-016-1579-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-016-1579-9%26sid%3Dliteratum%253Aachs%26aulast%3DPoveda%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DV.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DSevilla%26aufirst%3DI.%26aulast%3DLecumberri%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BBeveridge%26aufirst%3DR.%2BD.%26aulast%3DEstival%26aufirst%3DA.%26aulast%3DVicente%26aufirst%3DD.%26aulast%3DRubi%25C3%25B3%26aufirst%3DJ.%26aulast%3DMartin-Broto%26aufirst%3DJ.%26atitle%3DSeom%2520clinical%2520guideline%2520for%2520gastrointestinal%2520sarcomas%2520%2528gist%2529%2520%25282016%2529%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2016%26volume%3D18%26spage%3D1221%26epage%3D1228%26doi%3D10.1007%2Fs12094-016-1579-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">The GIST paradigm: Lessons for other kinase-driven cancers</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">252</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1002/path.2798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1002%2Fpath.2798" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2011&pages=252-262&author=C.+R.+Antonescu&title=The+GIST+paradigm%3A+Lessons+for+other+kinase-driven+cancers&doi=10.1002%2Fpath.2798"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpath.2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2798%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DThe%2520GIST%2520paradigm%253A%2520Lessons%2520for%2520other%2520kinase-driven%2520cancers%26jtitle%3DJ.%2520Pathol.%26date%3D2011%26volume%3D223%26spage%3D252%26epage%3D262%26doi%3D10.1002%2Fpath.2798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Søreide, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandvik, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Søreide, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giljaca, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jureckova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulusu, V. R.</span><span> </span><span class="NLM_article-title">Global epidemiology of gastrointestinal stromal tumours (gist): A systematic review of population-based cohort studies</span> <span class="citation_source-journal">Cancer Epidemiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1016/j.canep.2015.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.canep.2015.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=26618334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A280%3ADC%252BC28vmtFeisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=39-46&author=K.+S%C3%B8reideauthor=O.+M.+Sandvikauthor=J.+A.+S%C3%B8reideauthor=V.+Giljacaauthor=A.+Jureckovaauthor=V.+R.+Bulusu&title=Global+epidemiology+of+gastrointestinal+stromal+tumours+%28gist%29%3A+A+systematic+review+of+population-based+cohort+studies&doi=10.1016%2Fj.canep.2015.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies</span></div><div class="casAuthors">Soreide Kjetil; Sandvik Oddvar M; Soreide Jon Arne; Giljaca Vanja; Jureckova Andrea; Bulusu V Ramesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer epidemiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Gastrointestinal stromal tumours (GISTs) are rare, yet the most common mesenchymal tumour within the digestive tract.  Lack of diagnostic criteria and no specific code in the ICD system has prevented epidemiological evaluation except from overt malignant cases in the past.  A global estimate of incidence and disease patterns has thus not been available.  METHODS:  A systematic literature search of all available population-based studies on GIST published between January 2000 and December 2014 were reviewed.  Descriptive epidemiological data are presented.  RESULTS:  The search found 29 studies of more than 13,550 patients from 19 countries that reported sufficient data for regional or national population-based statistics.  Age at diagnosis ranged from 10 to 100 years, with median age being mid 60s across most studies.  Gender distribution was equal across studies.  On average, 18% of patients had an incidental diagnosis (range from 5% to 40%).  Anatomical location of primary tumour in 9747 GISTs demonstrated gastric location as the most frequent (55.6%) followed by small bowel (31.8%), colorectal (6.0%), other/various location (5.5%) and oesophagus (0.7%).  Most studies reported incidence at 10-15 per million per year.  Notably, lowest incidence was in China (Shanxi province) with 4.3 per million per year.  Highest incidence rates were reported also from China (Hong Kong and Shanghai areas), and in Taiwan and Norway (Northern part), with up to 19-22 per million per year.  CONCLUSIONS:  Epidemiology of GIST demonstrates some consistent features across geographical regions.  Whether the reported extreme differences in incidence reflect real variation in population risk warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQbNna3Ac64v_I8Jvzw4xCfW6udTcc2eaXV6dUQ2ZwF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vmtFeisg%253D%253D&md5=9f67bfc194b674715c083ad06e3a1101</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.canep.2015.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canep.2015.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B8reide%26aufirst%3DK.%26aulast%3DSandvik%26aufirst%3DO.%2BM.%26aulast%3DS%25C3%25B8reide%26aufirst%3DJ.%2BA.%26aulast%3DGiljaca%26aufirst%3DV.%26aulast%3DJureckova%26aufirst%3DA.%26aulast%3DBulusu%26aufirst%3DV.%2BR.%26atitle%3DGlobal%2520epidemiology%2520of%2520gastrointestinal%2520stromal%2520tumours%2520%2528gist%2529%253A%2520A%2520systematic%2520review%2520of%2520population-based%2520cohort%2520studies%26jtitle%3DCancer%2520Epidemiol.%26date%3D2016%26volume%3D40%26spage%3D39%26epage%3D46%26doi%3D10.1016%2Fj.canep.2015.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhammad, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=T.+G.+Muhammadauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0lgD6l-8ejdlcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%26aufirst%3DT.%2BG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">PDGFRA activating mutations in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span><span class="refDoi"> DOI: 10.1126/science.1079666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1126%2Fscience.1079666" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=708-710&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=A.+Duensingauthor=L.+McGreeveyauthor=C.+J.+Chenauthor=N.+Josephauthor=S.+Singerauthor=D.+J.+Griffithauthor=A.+Haleyauthor=A.+Townauthor=G.+D.+Demetriauthor=C.+D.+Fletcherauthor=J.+A.+Fletcher&title=PDGFRA+activating+mutations+in+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.1079666"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079666%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DPDGFRA%2520activating%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D708%26epage%3D710%26doi%3D10.1126%2Fscience.1079666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Kit mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1567</span><span class="NLM_x">–</span> <span class="NLM_lpage">1572</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)61103-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0002-9440%2810%2961103-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=12000708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVKrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2002&pages=1567-1572&author=C.+L.+Corlessauthor=L.+McGreeveyauthor=A.+Haleyauthor=A.+Townauthor=M.+C.+Heinrich&title=Kit+mutations+are+common+in+incidental+gastrointestinal+stromal+tumors+one+centimeter+or+less+in+size&doi=10.1016%2FS0002-9440%2810%2961103-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size</span></div><div class="casAuthors">Corless, Christopher L.; McGreevey, Laura; Haley, Andrea; Town, Ajia; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1567-1572</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms of the gut wall that express the receptor Tyr kinase KIT.  Somatic mutations that result in constitutive activation of KIT kinase were identified in a no. of studies of GISTs, although the reported frequency of these mutations has varied over a wide range (20 to 92%).  Several reports have suggested that KIT gene mutations are more common in malignant GISTs than in benign lesions, and it was proposed that mutations in exon 11 of KIT are a neg. prognostic factor.  To maximize sensitivity for KIT mutations the authors have adapted denaturing high-pressure liq. chromatog. as a method for screening PCR amplimers of exons 9, 11, 13, and 17 from GIST genomic DNA.  This approach was used to assess the frequency of KIT mutations in 13 morphol. benign, incidentally discovered, GISTs identified at autopsy, endoscopy, or laparotomy for unrelated disease.  Representing the smallest pathol. recognizable GISTs, these lesions ranged in size from 4 to 10 mm in diam. and were all immunohistochem. pos. for KIT.  11 Of the 13 tumors had sequence-confirmed mutations in KIT, including 10 mutations in exon 11 (77%) and one mutation in exon 9 (7.7%).  The remaining 2 tumors were wild type for exons 9, 11, and 17; one of these was also analyzed for exon 13 and was wild type in this exon as well.  The mutations found in the incidental GISTs were identical to those that were documented in larger GISTs.  In addn., the overall frequency of mutations in the incidental tumors (85%) did not differ significantly from that the authors previously reported in a series of 72 advanced/metastatic GISTs (86%), strongly supporting the view that activating mutations in KIT are acquired very early in the development of most GISTs.  The findings suggest that KIT mutations per se are of little prognostic importance in GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0Z6pTmQr7LVg90H21EOLACvtfcHk0lgD6l-8ejdlcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVKrt7c%253D&md5=6bd426c9c39db050d7f6008384cd9fcb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2961103-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252961103-0%26sid%3Dliteratum%253Aachs%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DKit%2520mutations%2520are%2520common%2520in%2520incidental%2520gastrointestinal%2520stromal%2520tumors%2520one%2520centimeter%2520or%2520less%2520in%2520size%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2002%26volume%3D160%26spage%3D1567%26epage%3D1572%26doi%3D10.1016%2FS0002-9440%2810%2961103-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogendoorn, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1016/S0140-6736(04)17098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2804%2917098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.+Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-free+survival+in+gastrointestinal+stromal+tumours+with+high-dose+imatinib%3A+Randomised+trial&doi=10.1016%2FS0140-6736%2804%2917098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917098-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-free%2520survival%2520in%2520gastrointestinal%2520stromal%2520tumours%2520with%2520high-dose%2520imatinib%253A%2520Randomised%2520trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D1127%26epage%3D1134%26doi%3D10.1016%2FS0140-6736%2804%2917098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumours: Origin and molecular oncology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">865</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span><span class="refDoi"> DOI: 10.1038/nrc3143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Fnrc3143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=22089421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOisb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=865-878&author=C.+L.+Corlessauthor=C.+M.+Barnettauthor=M.+C.+Heinrich&title=Gastrointestinal+stromal+tumours%3A+Origin+and+molecular+oncology&doi=10.1038%2Fnrc3143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumours: origin and molecular oncology</span></div><div class="casAuthors">Corless, Christopher L.; Barnett, Christine M.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">865-878</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are a paradigm for the development of personalized treatment for cancer patients.  The nearly simultaneous discovery of a biomarker that is reflective of their origin and the presence of gain-of-function kinase mutations in these tumors set the stage for more accurate diagnosis and the development of kinase inhibitor therapy.  Subsequent studies of genotype and phenotype have led to a mol. classification of GIST and to treatment optimization on the basis of mol. subtype.  The study of drug-resistant tumors has advanced our understanding of kinase biol., enabling the development of novel kinase inhibitors.  Further improvements in GIST treatment may require targeting GIST stem cell populations and/or addnl. genomic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY7ze-9Y_FbVg90H21EOLACvtfcHk0lhKzuJxQ_O66Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOisb3I&md5=345c2287f7cdf8775b2a05114ccf5563</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrc3143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3143%26sid%3Dliteratum%253Aachs%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBarnett%26aufirst%3DC.%2BM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DGastrointestinal%2520stromal%2520tumours%253A%2520Origin%2520and%2520molecular%2520oncology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D865%26epage%3D878%26doi%3D10.1038%2Fnrc3143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Jensen, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilfillan, A. M.</span><span> </span><span class="NLM_article-title">Pharmacological targeting of the kit growth factor receptor: A therapeutic consideration for mast cell disorders</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1572</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1038/bjp.2008.204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Fbjp.2008.204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=18500355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1572-82&author=B.+M.+Jensenauthor=C.+Akinauthor=A.+M.+Gilfillan&title=Pharmacological+targeting+of+the+kit+growth+factor+receptor%3A+A+therapeutic+consideration+for+mast+cell+disorders&doi=10.1038%2Fbjp.2008.204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders</span></div><div class="casAuthors">Jensen, B. M.; Akin, C.; Gilfillan, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1572-1582</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  KIT is a member of the tyrosine kinase family of growth factor receptors which is expressed on a variety of hematopoietic cells including mast cells.  Stem cell factor (SCF)-dependent activation of KIT is crit. for mast cell homeostasis and function.  However, when KIT is inappropriately activated, accumulation of mast cells in tissues results in mastocytosis.  Such dysregulated KIT activation is a manifestation of specific activating point mutations within KIT, with the human D816V mutation considered as a hallmark of human systemic mastocytosis.  A no. of other activating mutations in KIT have recently been identified and these mutations may also contribute to aberrant mast cell growth.  In addn. to its role in mast cell growth, differentiation and survival, localized concn. gradients of SCF may control the targeting of mast cells to specific tissues and, once resident within these tissues, mast cell activation by antigen may also be amplified by SCF.  Thus, KIT inhibitors may have potential application in multiple conditions linked to mast cells including systemic mastocytosis, anaphylaxis, and asthma.  In this review, we discuss the role of KIT in the context of mast cells in these disease states and how recent advances in the development of inhibitors of KIT activity and function may offer novel therapies for the treatment of these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohk3jlK_jsBLVg90H21EOLACvtfcHk0lhKzuJxQ_O66Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Grur8%253D&md5=15f0bd37c493278fbc58c2a2d33348f4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.204%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DB.%2BM.%26aulast%3DAkin%26aufirst%3DC.%26aulast%3DGilfillan%26aufirst%3DA.%2BM.%26atitle%3DPharmacological%2520targeting%2520of%2520the%2520kit%2520growth%2520factor%2520receptor%253A%2520A%2520therapeutic%2520consideration%2520for%2520mast%2520cell%2520disorders%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1572%26epage%3D82%26doi%3D10.1038%2Fbjp.2008.204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Gramza, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7510</span><span class="NLM_x">–</span> <span class="NLM_lpage">7518</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F1078-0432.CCR-09-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=20008851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGgurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=7510-7518&author=A.+W.+Gramzaauthor=C.+L.+Corlessauthor=M.+C.+Heinrich&title=Resistance+to+tyrosine+kinase+inhibitors+in+gastrointestinal+stromal+tumors&doi=10.1158%2F1078-0432.CCR-09-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Gramza, Ann W.; Corless, Christopher L.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7510-7518</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GIST) are the most common type of sarcoma in the gastrointestinal tract.  Surgery is the primary treatment modality, but many patients suffer disease recurrence or metastasis.  Fortunately, the management of advanced GIST has been revolutionized by the use of small mol. kinase inhibitors that target the underlying pathogenetic mutant kinases found in the vast majority of cases.  Approx. 85% of GISTs have oncogenic mutations in KIT, allowing for constitutive kinase activation that is responsible for cellular proliferation and survival.  About 5 to 7% of GISTs have activating mutations of the homologous platelet-derived growth factor receptor alpha (PDGFRA) kinase.  The progression-free and overall survival of patients with advanced disease is greatly improved by treatment with the kinase inhibitors imatinib and sunitinib.  However, the emergence of drug-resistant tumor clones limits the long-term benefit of these drugs in most patients.  Resistance to these kinase inhibitors is assocd. with distinctive clin. and mol. features, with the development of secondary mutations of the oncogenic kinase being the most common mechanism.  We review the mol. basis of GIST response and/or resistance to TKIs, and discuss strategies to prevent and/or overcome drug resistance.  These concepts are directly relevant to the development of targeted mol. therapy for other solid tumors. (Clin Cancer Res 2009;15(24):7510-8).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGTFj7EbnBtLVg90H21EOLACvtfcHk0lhKzuJxQ_O66Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGgurrO&md5=1c61da01fe3c61ff7f099b0defd50526</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0190%26sid%3Dliteratum%253Aachs%26aulast%3DGramza%26aufirst%3DA.%2BW.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DResistance%2520to%2520tyrosine%2520kinase%2520inhibitors%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D7510%26epage%3D7518%26doi%3D10.1158%2F1078-0432.CCR-09-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumour</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">382</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">983</span><span class="refDoi"> DOI: 10.1016/S0140-6736(13)60106-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2813%2960106-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23623056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFCmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2013&pages=973-983&author=H.+Joensuuauthor=P.+Hohenbergerauthor=C.+L.+Corless&title=Gastrointestinal+stromal+tumour&doi=10.1016%2FS0140-6736%2813%2960106-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu, Heikki; Hohenberger, Peter; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">9896</span>),
    <span class="NLM_cas:pages">973-983</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that arise in the gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in the abdomen.  They can occur at any age, the median age being 60-65 years, and typically cause bleeding, anemia, and pain.  GISTs have variable malignant potential, ranging from small lesions with a benign behavior to fatal sarcomas.  Most tumors stain pos. for the mast/stem cell growth factor receptor KIT and anoctamin 1 and harbor a kinase-activating mutation in either KIT or PDGFRA.  Tumors without such mutations could have alterations in genes of the succinate dehydrogenase complex or in BRAF, or rarely RAS family genes.  About 60% of patients are cured by surgery.  Adjuvant treatment with imatinib is recommended for patients with a substantial risk of recurrence, if the tumor has an imatinib-sensitive mutation.  Tyrosine kinase inhibitors substantially improve survival in advanced disease, but secondary drug resistance is common.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUnoEP2zf4WbVg90H21EOLACvtfcHk0ljzgMBkTd7lZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFCmu74%253D&md5=11113c24bdb425aac4341372dea2e9bc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2960106-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252960106-3%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DGastrointestinal%2520stromal%2520tumour%26jtitle%3DLancet%26date%3D2013%26volume%3D382%26spage%3D973%26epage%3D983%26doi%3D10.1016%2FS0140-6736%2813%2960106-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Zimmermann, J.</span><span> </span><span class="NLM_article-title">Pyrimidin derivatives and process for their preparation</span>. EP0564409B1, 19.01.2000,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=J.+Zimmermann&title=Pyrimidin+derivatives+and+process+for+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26atitle%3DPyrimidin%2520derivatives%2520and%2520process%2520for%2520their%2520preparation%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Sun, C. L.; Wei, C. C.; Tang, P. C.; Koenig, M.; Zhou, Y.; Vojkovsky, T.; Nematalla, A. S.</span><span> </span><span class="NLM_article-title">Prodrugs of a 3-(pyrrolo-2-ylmethylidene)-2-indolinobne derivatives</span>. US 2003/0100555 A1, 29.05.2003,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=C.+L.+Sun&author=C.+C.+Wei&author=P.+C.+Tang&author=M.+Koenig&author=Y.+Zhou&author=T.+Vojkovsky&author=A.+S.+Nematalla&title=Prodrugs+of+a+3-%28pyrrolo-2-ylmethylidene%29-2-indolinobne+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%2BL.%26atitle%3DProdrugs%2520of%2520a%25203-%2528pyrrolo-2-ylmethylidene%2529-2-indolinobne%2520derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Boyer, S.; Dumas, J.; Phillips, B.; Scott, W. J.; Smith, R. A.; Chen, J.; Jones, B.; Wang, G.</span><span> </span><span class="NLM_article-title">2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders</span>. WO2004078746 A3, 01.03.2004,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=S.+Boyer&author=J.+Dumas&author=B.+Phillips&author=W.+J.+Scott&author=R.+A.+Smith&author=J.+Chen&author=B.+Jones&author=G.+Wang&title=2-Oxo-1%2C3%2C5-perhydrotriazapine+derivatives+useful+in+the+treatment+of+hyper-proliferative%2C+angiogenesis%2C+and+inflammatory+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DS.%26atitle%3D2-Oxo-1%252C3%252C5-perhydrotriazapine%2520derivatives%2520useful%2520in%2520the%2520treatment%2520of%2520hyper-proliferative%252C%2520angiogenesis%252C%2520and%2520inflammatory%2520disorders%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cioffi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno-Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Abl protein-tyrosine kinase inhibitor sti571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10991971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ygur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=139-145&author=E.+Buchdungerauthor=C.+L.+Cioffiauthor=N.+Lawauthor=D.+Stoverauthor=S.+Ohno-Jonesauthor=B.+J.+Drukerauthor=N.+B.+Lydon&title=Abl+protein-tyrosine+kinase+inhibitor+sti571+inhibits+in+vitro+signal+transduction+mediated+by+c-kit+and+platelet-derived+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors</span></div><div class="casAuthors">Buchdunger, Elisabeth; Cioffi, Catherine L.; Law, Norman; Stover, David; Ohno-Jones, Sayuri; Druker, Brian J.; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139-145</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">STI571 (formerly known as CGP 57148B) is a protein-tyrosine kinase inhibitor that is currently in clin. trials for the treatment of chronic myelogenous leukemia.  STI571 selectively inhibits the Abl and platelet-derived growth factor (PDGF) receptor tyrosine kinases in vitro and blocks cellular proliferation and tumor growth of Bcr-abl- or v-abl-expressing cells.  We have further investigated the profile of STI571 against related receptor tyrosine kinases.  STI571 was found to potently inhibit the kinase activity of the α- and β-PDGF receptors and the receptor for stem cell factor, but not the closely related c-Fms, Flt-3, Kdr, Flt-1, and Tek tyrosine kinases.  Addnl., no inhibition of c-Met or nonreceptor tyrosine kinases such as Src and Jak-2 has been obsd.  In cell-based assays, STI571 selectively inhibited PDGF and stem cell factor-mediated cellular signaling, including ligand-stimulated receptor autophosphorylation, inositol phosphate formation, and mitogen-activated protein kinase activation and proliferation.  These results expand the profile of STI571 and suggest that in addn. to chronic myelogenous leukemia, STI571 may have clin. potential in the treatment of diseases that involve abnormal activation of c-Kit or PDGF receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogymen0UOTarVg90H21EOLACvtfcHk0ljzgMBkTd7lZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ygur4%253D&md5=b15a49df360ae0d00c34f7cc5d3b0fe8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DLaw%26aufirst%3DN.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DOhno-Jones%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DAbl%2520protein-tyrosine%2520kinase%2520inhibitor%2520sti571%2520inhibits%2520in%2520vitro%2520signal%2520transduction%2520mediated%2520by%2520c-kit%2520and%2520platelet-derived%2520growth%2520factor%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D139%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3z)-ylidenemethyl]-2,4- dimethyl-1h-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span><span class="refDoi"> DOI: 10.1021/jm0204183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.+Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1h-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase&doi=10.1021%2Fjm0204183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0liX2epHRu2rUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.%2BY.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1h-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119%26doi%3D10.1021%2Fjm0204183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zopf, D.</span><span> </span><span class="NLM_article-title">Regorafenib (bay 73–4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1002/ijc.25864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1002%2Fijc.25864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=21170960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=245-255&author=S.+M.+Wilhelmauthor=J.+Dumasauthor=L.+Adnaneauthor=M.+Lynchauthor=C.+A.+Carterauthor=G.+Schutzauthor=K.+H.+Thierauchauthor=D.+Zopf&title=Regorafenib+%28bay+73%E2%80%934506%29%3A+A+new+oral+multikinase+inhibitor+of+angiogenic%2C+stromal+and+oncogenic+receptor+tyrosine+kinases+with+potent+preclinical+antitumor+activity&doi=10.1002%2Fijc.25864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span></div><div class="casAuthors">Wilhelm, Scott M.; Dumas, Jacques; Adnane, Lila; Lynch, Mark; Carter, Christopher A.; Schuetz, Gunnar; Thierauch, Karl-Heinz; Zopf, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-255</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Angiogenesis, a crit. driver of tumor development, is controlled by interconnected signaling pathways.  Vascular endothelial growth factor receptor (VEGFR) 2 and tyrosine kinase with Ig and epidermal growth factor homol. domain 2 play crucial roles in the biol. of normal and tumor vasculature.  Regorafenib (BAY 73-4506), a novel oral multikinase inhibitor, potently inhibits these endothelial cell kinases in biochem. and cellular kinase phosphorylation assays.  Furthermore, regorafenib inhibits addnl. angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF.  The antiangiogenic effect of regorafenib was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging.  Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts.  In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 h after the last dosing and correlated with tumor growth inhibition (TGI).  A significant redn. in tumor microvessel area was obsd. in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg.  Regorafenib exhibited potent dose-dependent TGI in various preclin. human xenograft models in mice, with tumor shrinkages obsd. in breast MDA-MB-231 and renal 786-O carcinoma models.  Pharmacodynamic analyses of the breast model revealed strong redn. in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2.  These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQpQXfCq04rVg90H21EOLACvtfcHk0liX2epHRu2rUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D&md5=13eee29ef1f1f03fd1ed311ea613f566</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fijc.25864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25864%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DSchutz%26aufirst%3DG.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26aulast%3DZopf%26aufirst%3DD.%26atitle%3DRegorafenib%2520%2528bay%252073%25E2%2580%25934506%2529%253A%2520A%2520new%2520oral%2520multikinase%2520inhibitor%2520of%2520angiogenic%252C%2520stromal%2520and%2520oncogenic%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520preclinical%2520antitumor%2520activity%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D245%26epage%3D255%26doi%3D10.1002%2Fijc.25864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Carroll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno-Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing bcr-abl, tel-abl, and tel-pdgfr fusion proteins</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">4947</span><span class="NLM_x">–</span> <span class="NLM_lpage">4952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1997&pages=4947-4952&author=M.+Carrollauthor=S.+Ohno-Jonesauthor=S.+Tamuraauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=N.+B.+Lydonauthor=D.+G.+Gillilandauthor=B.+J.+Druker&title=CGP+57148%2C+a+tyrosine+kinase+inhibitor%2C+inhibits+the+growth+of+cells+expressing+bcr-abl%2C+tel-abl%2C+and+tel-pdgfr+fusion+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DOhno-Jones%26aufirst%3DS.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DCGP%252057148%252C%2520a%2520tyrosine%2520kinase%2520inhibitor%252C%2520inhibits%2520the%2520growth%2520of%2520cells%2520expressing%2520bcr-abl%252C%2520tel-abl%252C%2520and%2520tel-pdgfr%2520fusion%2520proteins%26jtitle%3DBlood%26date%3D1997%26volume%3D90%26spage%3D4947%26epage%3D4952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Pogorzelski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falkenhorst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1097/CCO.0000000000000303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1097%2FCCO.0000000000000303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=27163723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFGksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&pages=331-337&author=M.+Pogorzelskiauthor=J.+Falkenhorstauthor=S.+Bauer&title=Molecular+subtypes+of+gastrointestinal+stromal+tumor+requiring+specific+treatments&doi=10.1097%2FCCO.0000000000000303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments</span></div><div class="casAuthors">Pogorzelski, Michael; Falkenhorst, Johanna; Bauer, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-337</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: This article reviews and discusses the current literature on how mol. subtyping of gastrointestinal stromal tumor (GIST) impacts decision-making in clin. practice.  Recent findings: Genotyping has not yet been used for prognostication of localized GIST.  Recent findings indicate that mutations in platelet-derived growth factor receptor alpha (PDGFRA) and stem cell growth factor receptor (KIT) exon 11 duplication mutations are assocd. with a favorable prognosis.  Subgroup analyses of randomized trials provide first evidence on how genotyping predicts clin. benefit in the adjuvant setting.  In the palliative setting, genotyping should be performed for dose selection but may also be relevant in patients who are intolerant to imatinib.  For patients whose tumors harbor the notoriously resistant D842V PDGFRA mutations, novel inhibitors have entered clin. trials, which may end the therapeutic deadlock.  Several novel targets have been identified that are currently being investigated in GIST, including inhibitors against fibroblast growth factor receptor, hepatocyte growth factor receptor, mitogen-activated protein, and phosphoinositide 3-kinase.  Preliminary clin. data suggest that predictive markers will be needed to define sensitive mol. subgroups.  Summary: Genotyping should be an integral part of clin. management of GIST as it aids in prognostication, prediction of efficacy, and selection of drugs and dosing.  Genotyping reduces the risk of both unnecessary adjuvant treatment as well as undertreatment and overtreatment in the palliative setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsPtEF-K010LVg90H21EOLACvtfcHk0liiVW025pOYNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFGksLw%253D&md5=81c18afbb38bb139809ffed76358885b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2FCCO.0000000000000303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0000000000000303%26sid%3Dliteratum%253Aachs%26aulast%3DPogorzelski%26aufirst%3DM.%26aulast%3DFalkenhorst%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DMolecular%2520subtypes%2520of%2520gastrointestinal%2520stromal%2520tumor%2520requiring%2520specific%2520treatments%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2016%26volume%3D28%26spage%3D331%26epage%3D337%26doi%3D10.1097%2FCCO.0000000000000303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owzar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borden, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bramwell, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertagnolli, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Correlation of kinase genotype and clinical outcome in the north American intergroup phase iii trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: Calgb 150105 study by cancer and leukemia group b and southwest oncology group</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5360</span><span class="NLM_x">–</span> <span class="NLM_lpage">5367</span><span class="refDoi"> DOI: 10.1200/JCO.2008.17.4284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1200%2FJCO.2008.17.4284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=18955451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5360-5367&author=M.+C.+Heinrichauthor=K.+Owzarauthor=C.+L.+Corlessauthor=D.+Hollisauthor=E.+C.+Bordenauthor=C.+D.+Fletcherauthor=C.+W.+Ryanauthor=M.+Von+Mehrenauthor=C.+D.+Blankeauthor=C.+Rankinauthor=R.+S.+Benjaminauthor=V.+H.+Bramwellauthor=G.+D.+Demetriauthor=M.+M.+Bertagnolliauthor=J.+A.+Fletcher&title=Correlation+of+kinase+genotype+and+clinical+outcome+in+the+north+American+intergroup+phase+iii+trial+of+imatinib+mesylate+for+treatment+of+advanced+gastrointestinal+stromal+tumor%3A+Calgb+150105+study+by+cancer+and+leukemia+group+b+and+southwest+oncology+group&doi=10.1200%2FJCO.2008.17.4284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of kinase genotype and clinical outcome in the north American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group</span></div><div class="casAuthors">Heinrich, Michael C.; Owzar, Kouros; Corless, Christopher L.; Hollis, Donna; Borden, Ernest C.; Fletcher, Christopher D. M.; Ryan, Christopher W.; von Mehren, Margaret; Blanke, Charles D.; Rankin, Cathryn; Benjamin, Robert S.; Bramwell, Vivien H.; Demetri, George D.; Bertagnolli, Monica M.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5360-5367</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Imatinib mesylate is std. treatment for patients who have advanced gastrointestinal stromal tumor (GIST), but not all patients benefit equally.  In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing.  We examd. the relationship between kinase genotype and treatment outcome for 428 patients enrolled on the North American phase III study SWOG S0033/CALGB 150105 and treated with either 400 mg or 800 mg daily doses of imatinib.  The presence of KIT exon 11-mutant genotype (n = 283) correlated with improved treatment outcome when compared with KIT exon 9-mutant (n = 32) and wild-type (WT; n = 67) genotypes for objective response (complete response [CR]/partial response [PR], 71.7% v 44.4% [P = .007]; and 44.6% [P = .0002], resp.); time to tumor progression (TTP; median 24.7 mo v 16.7 and 12.8 mo, resp.); and overall survival (OS; median 60.0 mo v 38.4 and 49.0 mo, resp.).  The survival outcomes for patients with exon 9-mutant, exon 11-mutant or WT GIST were not affected by imatinib dose.  However, there was evidence of improved response rates for patients with exon 9-mutant tumors treated with imatinib 800 mg vs. 400 mg (CR/PR, 67% v 17%; P = .02).  Patients who had CD117-neg. GIST had similar TTP but inferior OS compared with patients who had CD117-pos. disease, which suggests that patients who have CD117-neg. GIST may benefit from imatinib treatment.  In addn., we identified novel but rare mutations of the KIT extracellular domain (exons 8 and 9).  We confirmed the favorable impact of KIT exon 11 genotype when compared with KIT exon 9 and wild-type genotype for patients with advanced GIST who are treated with imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEsXG_BaegR7Vg90H21EOLACvtfcHk0liiVW025pOYNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCmug%253D%253D&md5=e172b60b8246817b8dd79fa23794f2fc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.17.4284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.17.4284%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DOwzar%26aufirst%3DK.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DHollis%26aufirst%3DD.%26aulast%3DBorden%26aufirst%3DE.%2BC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3DVon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DRankin%26aufirst%3DC.%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DBramwell%26aufirst%3DV.%2BH.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBertagnolli%26aufirst%3DM.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DCorrelation%2520of%2520kinase%2520genotype%2520and%2520clinical%2520outcome%2520in%2520the%2520north%2520American%2520intergroup%2520phase%2520iii%2520trial%2520of%2520imatinib%2520mesylate%2520for%2520treatment%2520of%2520advanced%2520gastrointestinal%2520stromal%2520tumor%253A%2520Calgb%2520150105%2520study%2520by%2520cancer%2520and%2520leukemia%2520group%2520b%2520and%2520southwest%2520oncology%2520group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5360%26epage%3D5367%26doi%3D10.1200%2FJCO.2008.17.4284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyvraz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeijer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Kit mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1103</span><span class="refDoi"> DOI: 10.1016/j.ejca.2006.01.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.ejca.2006.01.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=1093-1103&author=M.+Debiec-Rychterauthor=R.+Sciotauthor=A.+Le+Cesneauthor=M.+Schlemmerauthor=P.+Hohenbergerauthor=A.+T.+van+Oosteromauthor=J.+Y.+Blayauthor=S.+Leyvrazauthor=M.+Stulauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=J.+Verweijauthor=M.+Van+Glabbekeauthor=A.+Hagemeijerauthor=I.+Judson&title=Kit+mutations+and+dose+selection+for+imatinib+in+patients+with+advanced+gastrointestinal+stromal+tumours&doi=10.1016%2Fj.ejca.2006.01.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.01.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.01.030%26sid%3Dliteratum%253Aachs%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSchlemmer%26aufirst%3DM.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DLeyvraz%26aufirst%3DS.%26aulast%3DStul%26aufirst%3DM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DKit%2520mutations%2520and%2520dose%2520selection%2520for%2520imatinib%2520in%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D1093%26epage%3D1103%26doi%3D10.1016%2Fj.ejca.2006.01.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4774</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.2265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1200%2FJCO.2006.06.2265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=16954519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4764-4774&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+Von+Mehrenauthor=C.+D.+Fletcherauthor=K.+Sandauauthor=K.+McDougallauthor=W.+B.+Ouauthor=C.+J.+Chenauthor=J.+A.+Fletcher&title=Molecular+correlates+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1200%2FJCO.2006.06.2265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Blanke, Charles D.; Demetri, George D.; Joensuu, Heikki; Roberts, Peter J.; Eisenberg, Burton L.; von Mehren, Margaret; Fletcher, Christopher D. M.; Sandau, Katrin; McDougall, Karen; Ou, Wen-bin; Chen, Chang-Jie; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4764-4774</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT or platelet-derived growth factor alpha (PDGFRA) kinases, which are targets for imatinib.  In clin. studies, 75% to 90% of patients with advanced GISTs experience clin. benefit from imatinib.  However, imatinib resistance is an increasing clin. problem.  Patients and Methods One hundred forty-seven patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clin. study of imatinib.  Specimens from pretreatment and/or imatinib-resistant tumors were analyzed to identify mol. correlates of imatinib resistance.  Secondary kinase mutations of KIT or PDGFRA that were identified in imatinib-resistant GISTs were biochem. profiled for imatinib sensitivity.  Results Mol. studies were performed using specimens from 10 patients with primary and 33 patients with secondary resistance.  Imatinib-resistant tumors had levels of activated KIT that were similar to or greater than those typically found in untreated GISTs.  Secondary kinase mutations were rare in GISTs with primary resistance but frequently found in GISTs with secondary resistance (10% v 67%, P = .002).  Evidence for clonal evolution and/or polyclonal secondary kinase mutations was seen in three (18.8%) of 16 patients.  Secondary kinase mutations were nonrandomly distributed and were assocd. with decreased imatinib sensitivity compared with typical KIT exon 11 mutations.  Using RNAi technol., we demonstrated that imatinib-resistant GIST cells remain dependent on KIT kinase activity for activation of crit. downstream signaling pathways.  Conclusion Different mol. mechanisms are responsible for primary and secondary imatinib resistance in GISTs.  These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw_n35sjCddLVg90H21EOLACvtfcHk0lhQuDf3eD-16Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN&md5=25f7b94dd02d55c2fb56cea499cb7ab8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2265%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3DVon%2BMehren%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSandau%26aufirst%3DK.%26aulast%3DMcDougall%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520correlates%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4764%26epage%3D4774%26doi%3D10.1200%2FJCO.2006.06.2265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolova, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Long-term results from a randomized phase ii trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing kit</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">620</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1200/JCO.2007.13.4403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1200%2FJCO.2007.13.4403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=18235121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1alsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=620-625&author=C.+D.+Blankeauthor=G.+D.+Demetriauthor=M.+Von+Mehrenauthor=M.+C.+Heinrichauthor=B.+Eisenbergauthor=J.+A.+Fletcherauthor=C.+L.+Corlessauthor=C.+D.+Fletcherauthor=P.+J.+Robertsauthor=D.+Heinzauthor=E.+Wehreauthor=Z.+Nikolovaauthor=H.+Joensuu&title=Long-term+results+from+a+randomized+phase+ii+trial+of+standard-+versus+higher-dose+imatinib+mesylate+for+patients+with+unresectable+or+metastatic+gastrointestinal+stromal+tumors+expressing+kit&doi=10.1200%2FJCO.2007.13.4403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT</span></div><div class="casAuthors">Blanke, Charles D.; Demetri, George D.; von Mehren, Margaret; Heinrich, Michael C.; Eisenberg, Burton; Fletcher, Jonathan A.; Corless, Christopher I.; Fletcher, Christopher D. M.; Roberts, Peter J.; Heinz, Daniela; Wehre, Elisabeth; Nikolova, Zariana; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">620-625</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown.  A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST detailed high response rates at both the 400 and the 600 mg/d dose levels.  We conducted a long-term anal. of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status.  Patients and Methods: Patients with advanced GIST were enrolled onto an open-label, multicenter trial and were randomly assigned (1:1) to receive imatinib 400 vs. 600 mg/d.  Data were prospectively collected on KIT mutational status, total tumor area, and other potential prognostic factors.  Patients were followed for a median of 63 mo.  Results: One hundred forty-seven patients were enrolled: 73 were in arm A (imatinib 400 mg/d), and 74 were in arm B (imatinib 600 mg/d).  Response rates, median progression-free survival, and median overall survival were essentially identical on both arms, and median survival was 57 mo for all patients.  Forty-one patients overall (28%) remained on the drug long-term.  Female sex, the presence of an exon 11 mutation, and normal albumin and neutrophil levels were independently assocd. with better survival.  Conclusion: Nearly 50% of patients with advanced GIST who were treated with imatinib mesylate survived for more than 5 years, regardless of a 400 or 600 mg/d starting dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyVblFUfMWELVg90H21EOLACvtfcHk0lhQuDf3eD-16Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1alsL0%253D&md5=c46d47e909e201a380a236246a2af159</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.4403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.4403%26sid%3Dliteratum%253Aachs%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DVon%2BMehren%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinz%26aufirst%3DD.%26aulast%3DWehre%26aufirst%3DE.%26aulast%3DNikolova%26aufirst%3DZ.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DLong-term%2520results%2520from%2520a%2520randomized%2520phase%2520ii%2520trial%2520of%2520standard-%2520versus%2520higher-dose%2520imatinib%2520mesylate%2520for%2520patients%2520with%2520unresectable%2520or%2520metastatic%2520gastrointestinal%2520stromal%2520tumors%2520expressing%2520kit%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D620%26epage%3D625%26doi%3D10.1200%2FJCO.2007.13.4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1338</span><span class="refDoi"> DOI: 10.1016/S0140-6736(06)69446-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2806%2969446-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=17046465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOrtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1329-1338&author=G.+D.+Demetriauthor=A.+T.+van+Oosteromauthor=C.+R.+Garrettauthor=M.+E.+Blacksteinauthor=M.+H.+Shahauthor=J.+Verweijauthor=G.+McArthurauthor=I.+R.+Judsonauthor=M.+C.+Heinrichauthor=J.+A.+Morganauthor=J.+Desaiauthor=C.+D.+Fletcherauthor=S.+Georgeauthor=C.+L.+Belloauthor=X.+Huangauthor=C.+M.+Baumauthor=P.+G.+Casali&title=Efficacy+and+safety+of+sunitinib+in+patients+with+advanced+gastrointestinal+stromal+tumour+after+failure+of+imatinib%3A+A+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2806%2969446-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span></div><div class="casAuthors">Demetri, George D.; van Oosterom, Allan T.; Garrett, Christopher R.; Blackstein, Martin E.; Shah, Manisha H.; Verweij, Jaap; McArthur, Grant; Judson, Ian R.; Heinrich, Michael C.; Morgan, Jeffrey A.; Desai, Jayesh; Fletcher, Christopher D.; George, Suzanne; Bello, Carlo L.; Huang, Xin; Baum, Charles M.; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9544</span>),
    <span class="NLM_cas:pages">1329-1338</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">No effective therapeutic options for patients with unresectable imatinib-resistant gastrointestinal stromal tumor are available.  We did a randomized, double-blind, placebo-controlled, multicenter, international trial to assess tolerability and anticancer efficacy of sunitinib, a multitargeted tyrosine kinase inhibitor, in patients with advanced gastrointestinal stromal tumor who were resistant to or intolerant of previous treatment with imatinib.  Blinded sunitinib or placebo was given orally once daily at a 50-mg starting dose in 6-wk cycles with 4 wk on and 2 wk off treatment.  The primary endpoint was time to tumor progression.  Intention-to-treat, modified intention-to-treat, and per-protocol analyses were done.  This study is registered at ClinicalTrials.gov, no. NCT00075218.  Three hundred and twelve patients were randomized in a 2:1 ratio to receive sunitinib (n = 207) or placebo (n=105); the trial was unblinded early when a planned interim anal. showed significantly longer time to tumor progression with sunitinib.  Median time to tumor progression was 27.3 wk (95% CI 16.0-32.1) in patients receiving sunitinib and 6.4 wk (4.4-10.0) in those on placebo (hazard ratio 0.33; p < 0.0001).  Therapy was reasonably well tolerated; the most common treatment-related adverse events were fatigue, diarrhea, skin discoloration, and nausea.  We noted significant clin. benefit, including disease control and superior survival, with sunitinib compared with placebo in patients with advanced gastrointestinal stromal tumor after failure and discontinuation of imatinib.  Tolerability was acceptable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6YRQ18H894LVg90H21EOLACvtfcHk0lilhF7btEoMXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOrtL%252FL&md5=b21e01faede44c98f645be945c2638c0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969446-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969446-4%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sunitinib%2520in%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumour%2520after%2520failure%2520of%2520imatinib%253A%2520A%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1329%26epage%3D1338%26doi%3D10.1016%2FS0140-6736%2806%2969446-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badalamenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (grid): An international, multicentre, randomised, placebo-controlled, phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1016/S0140-6736(12)61857-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2812%2961857-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23177515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=295-302&author=G.+D.+Demetriauthor=P.+Reichardtauthor=Y.+K.+Kangauthor=J.+Y.+Blayauthor=P.+Rutkowskiauthor=H.+Gelderblomauthor=P.+Hohenbergerauthor=M.+Leahyauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=G.+Badalamentiauthor=M.+Blacksteinauthor=A.+Le+Cesneauthor=P.+Sch%C3%B6ffskiauthor=R.+G.+Makiauthor=S.+Bauerauthor=B.+B.+Nguyenauthor=J.+Xuauthor=T.+Nishidaauthor=J.+Chungauthor=C.+Kappelerauthor=I.+Kussauthor=D.+Laurentauthor=P.+G.+Casali&title=Efficacy+and+safety+of+regorafenib+for+advanced+gastrointestinal+stromal+tumours+after+failure+of+imatinib+and+sunitinib+%28grid%29%3A+An+international%2C+multicentre%2C+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961857-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">Demetri, George D.; Reichardt, Peter; Kang, Yoon-Koo; Blay, Jean-Yves; Rutkowski, Piotr; Gelderblom, Hans; Hohenberger, Peter; Leahy, Michael; von Mehren, Margaret; Joensuu, Heikki; Badalamenti, Giuseppe; Blackstein, Martin; Le Cesne, Axel; Schoffski, Patrick; Maki, Robert G.; Bauer, Sebastian; Nguyen, Binh Bui; Xu, Jianming; Nishida, Toshirou; Chung, John; Kappeler, Christian; Kuss, Iris; Laurent, Dirk; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">9863</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Until now, only imatinib and sunitinib have proven clin. benefit in patients with gastrointestinal stromal tumors (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression.  We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.We did this phase 3 trial at 57 hospitals in 17 countries.  Patients with histol. confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratified by treatment line and geog. region) to receive either oral regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 wk of each 4 wk cycle.  The study sponsor, participants, and investigators were masked to treatment assignment.  The primary endpoint was progression-free survival (PFS).  At disease progression, patients assigned placebo could crossover to open-label regorafenib.  Analyses were by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT01271712.From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib (n=133) or matching placebo (n=66).  Data cutoff was Jan 26, 2012.  Median PFS per independent blinded central review was 4·8 mo (IQR 1·4-9·2) for regorafenib and 0·9 mo (0·9-1·8) for placebo (hazard ratio [HR] 0·27, 95% CI 0·19-0·39; p<0·0001).  After progression, 56 patients (85%) assigned placebo crossed over to regorafenib.  Drug-related adverse events were reported in 130 (98%) patients assigned regorafenib and 45 (68%) patients assigned placebo.  The most common regorafenib-related adverse events of grade 3 or higher were hypertension (31 of 132, 23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of 132, 5%).The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on std. treatments.  As far as we are aware, this is the first clin. trial to show benefit from a kinase inhibitor in this highly refractory population of patients.Bayer HealthCare Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2GIfYXBPyLVg90H21EOLACvtfcHk0lilhF7btEoMXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL&md5=f8ee42424a9b3bd7558b1a2f1461af33</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961857-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961857-1%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DM.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBadalamenti%26aufirst%3DG.%26aulast%3DBlackstein%26aufirst%3DM.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%2BB.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DKuss%26aufirst%3DI.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520regorafenib%2520for%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%2520%2528grid%2529%253A%2520An%2520international%252C%2520multicentre%252C%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D295%26epage%3D302%26doi%3D10.1016%2FS0140-6736%2812%2961857-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Garner, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vodala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Ponatinib inhibits polyclonal drug-resistant kit oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (gist) patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5745</span><span class="NLM_x">–</span> <span class="NLM_lpage">5755</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F1078-0432.CCR-14-1397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25239608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5745-5755&author=A.+P.+Garnerauthor=J.+M.+Gozgitauthor=R.+Anjumauthor=S.+Vodalaauthor=A.+Schrockauthor=T.+Zhouauthor=C.+Serranoauthor=G.+Eilersauthor=M.+Zhuauthor=J.+Ketzerauthor=S.+Wardwellauthor=Y.+Ningauthor=Y.+Songauthor=A.+Kohlmannauthor=F.+Wangauthor=T.+Clacksonauthor=M.+C.+Heinrichauthor=J.+A.+Fletcherauthor=S.+Bauerauthor=V.+M.+Rivera&title=Ponatinib+inhibits+polyclonal+drug-resistant+kit+oncoproteins+and+shows+therapeutic+potential+in+heavily+pretreated+gastrointestinal+stromal+tumor+%28gist%29+patients&doi=10.1158%2F1078-0432.CCR-14-1397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients</span></div><div class="casAuthors">Garner, Andrew P.; Gozgit, Joseph M.; Anjum, Rana; Vodala, Sadanand; Schrock, Alexa; Zhou, Tianjun; Serrano, Cesar; Eilers, Grant; Zhu, Meijun; Ketzer, Julia; Wardwell, Scott; Ning, Yaoyu; Song, Youngchul; Kohlmann, Anna; Wang, Frank; Clackson, Tim; Heinrich, Michael C.; Fletcher, Jonathan A.; Bauer, Sebastian; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5745-5755</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST).  Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic.  Here, we explore the KIT-inhibitory activity of ponatinib in preclin. models and describe initial characterization of its activity in patients with GIST.  Exptl. Design: The cellular and in vivo activities of ponatinib, imatinib, sunitinib, and regorafenib against mutant KIT were evaluated using an accelerated mutagenesis assay and a panel of engineered and GIST-derived cell lines.  The ponatinib-KIT costructure was also detd.  The clin. activity of ponatinib was examd. in three patients with GIST previously treated with all three FDA-approved agents.  Results: In engineered and GIST-derived cell lines, ponatinib potently inhibited KIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop.  Ponatinib also induced regression in engineered and GIST-derived tumor models contg. these secondary mutations.  In a mutagenesis screen, 40 nmol/L ponatinib was sufficient to suppress outgrowth of all secondary mutants except V654A, which was suppressed at 80 nmol/L.  This inhibitory profile could be rationalized on the basis of structural analyses.  Ponatinib (30 mg daily) displayed encouraging clin. activity in two of three patients with GIST.  Conclusion:Ponatinib possesses potent activity against most major clin. relevant KIT mutants and has demonstrated preliminary evidence of activity in patients with refractory GIST.  These data strongly support further evaluation of ponatinib in patients with GIST.  Clin Cancer Res; 20(22); 5745-55. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGG18CSl3XLVg90H21EOLACvtfcHk0lilhF7btEoMXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E&md5=7537e45f37546f9e0cb799bdf05ed847</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1397%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DVodala%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520inhibits%2520polyclonal%2520drug-resistant%2520kit%2520oncoproteins%2520and%2520shows%2520therapeutic%2520potential%2520in%2520heavily%2520pretreated%2520gastrointestinal%2520stromal%2520tumor%2520%2528gist%2529%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5745%26epage%3D5755%26doi%3D10.1158%2F1078-0432.CCR-14-1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Emerging agents for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors: Current status and future directions</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1323</span><span class="NLM_x">–</span> <span class="NLM_lpage">1334</span><span class="refDoi"> DOI: 10.1007/s40265-015-0440-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1007%2Fs40265-015-0440-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1323-1334&author=S.+Bauerauthor=H.+Joensuu&title=Emerging+agents+for+the+treatment+of+advanced%2C+imatinib-resistant+gastrointestinal+stromal+tumors%3A+Current+status+and+future+directions&doi=10.1007%2Fs40265-015-0440-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0440-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0440-8%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEmerging%2520agents%2520for%2520the%2520treatment%2520of%2520advanced%252C%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%253A%2520Current%2520status%2520and%2520future%2520directions%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1323%26epage%3D1334%26doi%3D10.1007%2Fs40265-015-0440-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badalamenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GRID study investigators</span><span> </span><span class="NLM_article-title">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (grid): An international, multicentre, randomised, placebo-controlled, phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1016/S0140-6736(12)61857-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2812%2961857-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23177515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=295-302&author=G.+D.+Demetriauthor=P.+Reichardtauthor=Y.+K.+Kangauthor=J.+Y.+Blayauthor=P.+Rutkowskiauthor=H.+Gelderblomauthor=P.+Hohenbergerauthor=M.+Leahyauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=G.+Badalamentiauthor=M.+Blacksteinauthor=A.+Le+Cesneauthor=P.+Schoffskiauthor=R.+G.+Makiauthor=S.+Bauerauthor=B.+B.+Nguyenauthor=J.+Xuauthor=T.+Nishidaauthor=J.+Chungauthor=C.+Kappelerauthor=I.+Kussauthor=D.+Laurentauthor=P.+G.+Casaliauthor=GRID+study+investigators&title=Efficacy+and+safety+of+regorafenib+for+advanced+gastrointestinal+stromal+tumours+after+failure+of+imatinib+and+sunitinib+%28grid%29%3A+An+international%2C+multicentre%2C+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961857-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">Demetri, George D.; Reichardt, Peter; Kang, Yoon-Koo; Blay, Jean-Yves; Rutkowski, Piotr; Gelderblom, Hans; Hohenberger, Peter; Leahy, Michael; von Mehren, Margaret; Joensuu, Heikki; Badalamenti, Giuseppe; Blackstein, Martin; Le Cesne, Axel; Schoffski, Patrick; Maki, Robert G.; Bauer, Sebastian; Nguyen, Binh Bui; Xu, Jianming; Nishida, Toshirou; Chung, John; Kappeler, Christian; Kuss, Iris; Laurent, Dirk; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">9863</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Until now, only imatinib and sunitinib have proven clin. benefit in patients with gastrointestinal stromal tumors (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression.  We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.We did this phase 3 trial at 57 hospitals in 17 countries.  Patients with histol. confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratified by treatment line and geog. region) to receive either oral regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 wk of each 4 wk cycle.  The study sponsor, participants, and investigators were masked to treatment assignment.  The primary endpoint was progression-free survival (PFS).  At disease progression, patients assigned placebo could crossover to open-label regorafenib.  Analyses were by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT01271712.From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib (n=133) or matching placebo (n=66).  Data cutoff was Jan 26, 2012.  Median PFS per independent blinded central review was 4·8 mo (IQR 1·4-9·2) for regorafenib and 0·9 mo (0·9-1·8) for placebo (hazard ratio [HR] 0·27, 95% CI 0·19-0·39; p<0·0001).  After progression, 56 patients (85%) assigned placebo crossed over to regorafenib.  Drug-related adverse events were reported in 130 (98%) patients assigned regorafenib and 45 (68%) patients assigned placebo.  The most common regorafenib-related adverse events of grade 3 or higher were hypertension (31 of 132, 23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of 132, 5%).The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on std. treatments.  As far as we are aware, this is the first clin. trial to show benefit from a kinase inhibitor in this highly refractory population of patients.Bayer HealthCare Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2GIfYXBPyLVg90H21EOLACvtfcHk0lgZI4ppZ8JVkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL&md5=f8ee42424a9b3bd7558b1a2f1461af33</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961857-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961857-1%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DM.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBadalamenti%26aufirst%3DG.%26aulast%3DBlackstein%26aufirst%3DM.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%2BB.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DKuss%26aufirst%3DI.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520regorafenib%2520for%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%2520%2528grid%2529%253A%2520An%2520international%252C%2520multicentre%252C%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D295%26epage%3D302%26doi%3D10.1016%2FS0140-6736%2812%2961857-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, L.</span><span> </span><span class="NLM_article-title">Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: A meta-analysis of recent clinical trials</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2061</span><span class="NLM_x">–</span> <span class="NLM_lpage">2067</span><span class="refDoi"> DOI: 10.2147/DDDT.S63840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.2147%2FDDDT.S63840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25378911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGitLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=2061-2067&author=L.+Wuauthor=Z.+Zhangauthor=H.+Yaoauthor=K.+Liuauthor=Y.+Wenauthor=L.+Xiong&title=Clinical+efficacy+of+second-generation+tyrosine+kinase+inhibitors+in+imatinib-resistant+gastrointestinal+stromal+tumors%3A+A+meta-analysis+of+recent+clinical+trials&doi=10.2147%2FDDDT.S63840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials</span></div><div class="casAuthors">Wu, Lile; Zhang, Zhongqiang; Yao, Hongliang; Liu, Kuijie; Wen, Yu; Xiong, Li</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2061-2067, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Primary and secondary resistance to imatinib, a selective receptor tyrosine kinase inhibitor (TKI), is a serious clin. problem in the control of advanced gastrointestinal stromal tumors (GIST).  Here we report on a meta-anal. we performed to evaluate the efficacy of second-generation TKIs in the treatment of patients with imatinib-resistant GIST.  Methods: Randomized controlled trials evaluating the clin. efficacy of second-generation TKIs were identified by searching PubMed and EMBASE from 2000 to Feb. 2014.  Outcomes subjected to anal. were progression-free survival and overall survival.  Statistical analyses were performed using Review Manager version 5.1.0 (Cochrane Collaboration, Oxford, UK).  Weighted hazard ratios (HR) with 95% confidence intervals (CIs) were calcd. for the outcomes.  Fixed-effects or random-effects models were used, depending on the degree of heterogeneity across the selected studies.  Results: Three randomized controlled trials were selected for meta-anal.  Among imatinib-resistant or imatinib-intolerant patients, 541 received second-generation TKIs (sunitinib, nilotinib, or regorafenib) and 267 controls received placebo or best supportive care.  Progression-free survival was significantly improved in the TKI-treated group (HR 0.38; 95% CI 0.24-0.59; P<0.0001).  No statistically significant difference was detected in overall survival between the treatment group and the control group (HR 0.85; 95% CI 0.71-1.03; P = 0.09).  In the subgroup of patients who were resistant or intolerant to both imatinib and sunitinib, TKI therapy (nilotinib or regorafenib) improved progression-free survival (HR 0.40; 95% CI 0.19-0.84; P = 0.02) but not overall survival (HR 0.83; 95% CI 0.63-1.08; P = 0.17).  Regorafenib was shown to be effective in terms of progression-free survival across different subpopulations of patients who were resistant to both imatinib and sunitinib.  Conclusion: Second-generation TKIs (sunitinib, nilotinib, and regorafenib) are effective in improving progression-free survival but not overall survival in patients with GIST who are resistant or intolerant to imatinib or to imatinib and sunitinib.  Regorafenib is promising as a third-line treatment option for patients with advanced GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbHHObRMJNKLVg90H21EOLACvtfcHk0lgO7WmmKIPnOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGitLnK&md5=b33a7d7375400e6a4fa8ccf1c20d7242</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S63840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S63840%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DXiong%26aufirst%3DL.%26atitle%3DClinical%2520efficacy%2520of%2520second-generation%2520tyrosine%2520kinase%2520inhibitors%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%253A%2520A%2520meta-analysis%2520of%2520recent%2520clinical%2520trials%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D2061%26epage%3D2067%26doi%3D10.2147%2FDDDT.S63840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitagawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span> </span><span class="NLM_article-title">The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines</span> <span class="citation_source-journal">Gastric Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1007/s10120-015-0526-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1007%2Fs10120-015-0526-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=3-14&author=T.+Nishidaauthor=J.+Y.+Blayauthor=S.+Hirotaauthor=Y.+Kitagawaauthor=Y.+K.+Kang&title=The+standard+diagnosis%2C+treatment%2C+and+follow-up+of+gastrointestinal+stromal+tumors+based+on+guidelines&doi=10.1007%2Fs10120-015-0526-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10120-015-0526-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10120-015-0526-8%26sid%3Dliteratum%253Aachs%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DKitagawa%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DY.%2BK.%26atitle%3DThe%2520standard%2520diagnosis%252C%2520treatment%252C%2520and%2520follow-up%2520of%2520gastrointestinal%2520stromal%2520tumors%2520based%2520on%2520guidelines%26jtitle%3DGastric%2520Cancer%26date%3D2016%26volume%3D19%26spage%3D3%26epage%3D14%26doi%3D10.1007%2Fs10120-015-0526-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Zhang, Y.; Hodous, B. L.; Kim, J. L.; Wilson, K. J.; Wilson, D.</span><span> </span><span class="NLM_article-title">Compositions useful for treating disorders related to kit</span>. WO2015/057873,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Zhang&author=B.+L.+Hodous&author=J.+L.+Kim&author=K.+J.+Wilson&author=D.+Wilson&title=Compositions+useful+for+treating+disorders+related+to+kit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DCompositions%2520useful%2520for%2520treating%2520disorders%2520related%2520to%2520kit%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Flynn, D. L.; Petillo, P. A.; Kaufman, M. D.</span><span> </span><span class="NLM_article-title">Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities</span>. US 8278331,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+L.+Flynn&author=P.+A.+Petillo&author=M.+D.+Kaufman&title=Cyclopropane+amides+and+analogs+exhibiting+anti-cancer+and+anti-proliferative+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DCyclopropane%2520amides%2520and%2520analogs%2520exhibiting%2520anti-cancer%2520and%2520anti-proliferative%2520activities%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span>Plx9486 ± plx3397; <span class="NLM_publisher-name">Plexxikon</span>: <span class="NLM_publisher-loc">San Antonio, TX</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.plexxikon.com/pipeline/plx9486-plx3397/" class="extLink">http://www.plexxikon.com/pipeline/plx9486-plx3397/</a> (accessed September 10, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Plx9486+%C2%B1+plx3397%3B+Plexxikon%3A+San+Antonio%2C+TX%2C+2017%3B+http%3A%2F%2Fwww.plexxikon.com%2Fpipeline%2Fplx9486-plx3397%2F+%28accessed+September+10%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DPlx9486%2520%25C2%25B1%2520plx3397%26pub%3DPlexxikon%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span> </span><span class="NLM_article-title">BLU-285, DCC-2618 show activity against gist</span>.  <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-NB2016-165</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F2159-8290.CD-NB2016-165" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BLU-285%2C+DCC-2618+show+activity+against+gist.+Cancer+Discovery+2017%2C+7%2C+121%E2%80%93122%2C+10.1158%2F2159-8290.CD-NB2016-165."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-NB2016-165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-NB2016-165%26sid%3Dliteratum%253Aachs%26atitle%3DBLU-285%252C%2520DCC-2618%2520show%2520activity%2520against%2520gist%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D121%26epage%3D122%26doi%3D10.1158%2F2159-8290.CD-NB2016-165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">Ap24534, a pan-bcr-abl inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span><span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=Ap24534%2C+a+pan-bcr-abl+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+t315i+mutant+and+overcomes+mutation-based+resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0lgO7WmmKIPnOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAp24534%252C%2520a%2520pan-bcr-abl%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520t315i%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-n-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (ap24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (bcr-abl) kinase including the t315i gatekeeper mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4701</span><span class="NLM_x">–</span> <span class="NLM_lpage">4719</span><span class="refDoi"> DOI: 10.1021/jm100395q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&author=W.+S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-n-%7B4-%5B%284-methylpiperazin-1-y+l%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28ap24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-abelson+%28bcr-abl%29+kinase+including+the+t315i+gatekeeper+mutant&doi=10.1021%2Fjm100395q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-[4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl]benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant</span></div><div class="casAuthors">Huang, Wei-Sheng; Metcalf, Chester A.; Sundaramoorthi, Raji; Wang, Yihan; Zou, Dong; Thomas, R. Mathew; Zhu, Xiaotian; Cai, Lisi; Wen, David; Liu, Shuangying; Romero, Jan; Qi, Jiwei; Chen, Ingrid; Banda, Geetha; Lentini, Scott P.; Das, Sasmita; Xu, Qihong; Keats, Jeff; Wang, Frank; Wardwell, Scott; Ning, Yaoyu; Snodgrass, Joseph T.; Broudy, Marc I.; Russian, Karin; Zhou, Tianjun; Commodore, Lois; Narasimhan, Narayana I.; Mohemmad, Qurish K.; Iuliucci, John; Rivera, Victor M.; Dalgarno, David C.; Sawyer, Tomi K.; Clackson, Tim; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4701-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents.  This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation.  A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of Ile315 side chain.  Extensive SAR studies led to the discovery of development candidate benzamide I (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC50s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines.  Daily oral administration of I significantly prolonged survival of mice injected i.v. with BCR-ABLT315I expressing Ba/F3 cells.  These data, coupled with a favorable ADME profile, support the potential of I to be an effective treatment for CML, including patients refractory to all currently approved therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoci2zVFUazgLVg90H21EOLACvtfcHk0liVqmXhni2dYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D&md5=0dcd7b4ff31164b1d9883e897b7058ff</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-n-%257B4-%255B%25284-methylpiperazin-1-y%2520l%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528ap24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-abelson%2520%2528bcr-abl%2529%2520kinase%2520including%2520the%2520t315i%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4701%26epage%3D4719%26doi%3D10.1021%2Fjm100395q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bixby, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauro, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinn, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span> </span><span class="NLM_article-title">Ponatinib in refractory philadelphia chromosome-positive leukemias</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">2075</span><span class="NLM_x">–</span> <span class="NLM_lpage">2088</span><span class="refDoi"> DOI: 10.1056/NEJMoa1205127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1056%2FNEJMoa1205127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23190221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyltrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2075-2088&author=J.+E.+Cortesauthor=H.+Kantarjianauthor=N.+P.+Shahauthor=D.+Bixbyauthor=M.+J.+Mauroauthor=I.+Flinnauthor=T.+O%E2%80%99Hareauthor=S.+Huauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=T.+Clacksonauthor=C.+D.+Turnerauthor=F.+G.+Haluskaauthor=B.+J.+Drukerauthor=M.+W.+Deiningerauthor=M.+Talpaz&title=Ponatinib+in+refractory+philadelphia+chromosome-positive+leukemias&doi=10.1056%2FNEJMoa1205127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib in refractory Philadelphia chromosome-positive leukemias</span></div><div class="casAuthors">Cortes, Jorge E.; Kantarjian, Hagop; Shah, Neil P.; Bixby, Dale; Mauro, Michael J.; Flinn, Ian; O'Hare, Thomas; Hu, Simin; Narasimhan, Narayana I.; Rivera, Victor M.; Clackson, Tim; Turner, Christopher D.; Haluska, Frank G.; Druker, Brian J.; Deininger, Michael W. N.; Talpaz, Moshe</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2075-2088</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-pos. acute lymphoblastic leukemia (Ph-pos. ALL) is frequently caused by mutations in the BCR-ABL kinase domain.  Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T3151, which is uniformly resistant to tyrosine kinase inhibitors.  Methods: In this phase 1 dose-escalation study, we enrolled 81 patients with resistant hematol. cancers, including 60 with CML and 5 with Ph-pos. ALL.  Ponatinib was administered once daily at doses ranging from 2 to 60 mg.  Median follow-up was 56 wk (range, 2 to 140).  Results: Dose-limiting toxic effects included elevated lipase or amylase levels and pancreatitis.  Common adverse events were rash, myelosuppression, and constitutional symptoms.  Among Ph-pos. patients, 91% had received two or more approved tyrosine kinase inhibitors, and 51% had received all three approved tyrosine kinase inhibitors.  Of 43 patients with chronic-phase CML, 98% had a complete hematol. response, 72% had a major cytogenetic response, and 44% had a major mol. response.  Of 12 patients who had chronic-phase CML with the T315I mutation, 100% had a complete hematol. response and 92% had a major cytogenetic response.  Of 13 patients with chronic-phase CML without detectable mutations, 100% had a complete hematol. response and 62% had a major cytogenetic response.  Responses among patients with chronic-phase CML were durable.  Of 22 patients with accelerated-phase or blast-phase CML or Ph-pos. ALL, 36% had a major hematol. response and 32% had a major cytogenetic response.  Conclusion: Ponatinib was highly active in heavily pretreated patients with Ph-pos. leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrYE8Da39kZ7Vg90H21EOLACvtfcHk0lgufluuozm7nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyltrvJ&md5=8a563e3fc96860a13a16958c9e816834</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1205127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1205127%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DBixby%26aufirst%3DD.%26aulast%3DMauro%26aufirst%3DM.%2BJ.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DTurner%26aufirst%3DC.%2BD.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DTalpaz%26aufirst%3DM.%26atitle%3DPonatinib%2520in%2520refractory%2520philadelphia%2520chromosome-positive%2520leukemias%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2075%26epage%3D2088%26doi%3D10.1056%2FNEJMoa1205127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Dorer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knickerbocker, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span> </span><span class="NLM_article-title">Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.1016/j.leukres.2016.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.leukres.2016.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=27505637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSgsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=84-91&author=D.+J.+Dorerauthor=R.+K.+Knickerbockerauthor=M.+Baccaraniauthor=J.+E.+Cortesauthor=A.+Hochhausauthor=M.+Talpazauthor=F.+G.+Haluska&title=Impact+of+dose+intensity+of+ponatinib+on+selected+adverse+events%3A+Multivariate+analyses+from+a+pooled+population+of+clinical+trial+patients&doi=10.1016%2Fj.leukres.2016.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients</span></div><div class="casAuthors">Dorer, David J.; Knickerbocker, Ronald K.; Baccarani, Michele; Cortes, Jorge E.; Hochhaus, Andreas; Talpaz, Moshe; Haluska, Frank G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-91</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ponatinib is approved for adults with refractory chronic myeloid leukemia or Philadelphia chromosome-pos. acute lymphoblastic leukemia, including those with the T315I BCR-ABL1 mutation.  We pooled data from 3 clin. trials (N = 671) to det. the impact of ponatinib dose intensity on the following adverse events: arterial occlusive events (cardiovascular, cerebrovascular, and peripheral vascular events), venous thromboembolic events, cardiac failure, thrombocytopenia, neutropenia, hypertension, pancreatitis, increased lipase, increased alanine aminotransferase, increased aspartate aminotransferase, rash, arthralgia, and hypertriglyceridemia.  Multivariate analyses allowed adjustment for covariates potentially related to changes in dosing or an event.  Logistic regression anal. identified significant assocns. between dose intensity and most events after adjusting for covariates.  Pancreatitis, rash, and cardiac failure had the strongest assocns. with dose intensity (odds ratios >2).  Time-to-event analyses showed significant assocns. between dose intensity and risk of arterial occlusive events and each subcategory.  Further, these analyses suggested that a lag exists between a change in dose and the resulting change in event risk.  No significant assocn. between dose intensity and risk of venous thromboembolic events was evident.  Collectively, these findings suggest a potential causal relationship between ponatinib dose and certain adverse events and support prospective investigations of approaches to lower av. ponatinib dose intensity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vv1oh3lIkbVg90H21EOLACvtfcHk0lgufluuozm7nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSgsLfP&md5=f68545645a3ade3680728652196ff35f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2016.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2016.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DDorer%26aufirst%3DD.%2BJ.%26aulast%3DKnickerbocker%26aufirst%3DR.%2BK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26atitle%3DImpact%2520of%2520dose%2520intensity%2520of%2520ponatinib%2520on%2520selected%2520adverse%2520events%253A%2520Multivariate%2520analyses%2520from%2520a%2520pooled%2520population%2520of%2520clinical%2520trial%2520patients%26jtitle%3DLeuk.%2520Res.%26date%3D2016%26volume%3D48%26spage%3D84%26epage%3D91%26doi%3D10.1016%2Fj.leukres.2016.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Jain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemmaraju, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daver, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gachimova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrajoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornblau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: A phase 2 study</span> <span class="citation_source-journal">Lancet Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e376</span><span class="NLM_x">–</span> <span class="NLM_lpage">e383</span><span class="refDoi"> DOI: 10.1016/S2352-3026(15)00127-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS2352-3026%2815%2900127-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=26436130" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=e376-e383&author=P.+Jainauthor=H.+Kantarjianauthor=E.+Jabbourauthor=G.+N.+Gonzalezauthor=G.+Borthakurauthor=N.+Pemmarajuauthor=N.+Daverauthor=E.+Gachimovaauthor=A.+Ferrajoliauthor=S.+Kornblauauthor=F.+Ravandiauthor=S.+O%E2%80%99Brienauthor=J.+Cortes&title=Ponatinib+as+first-line+treatment+for+patients+with+chronic+myeloid+leukaemia+in+chronic+phase%3A+A+phase+2+study&doi=10.1016%2FS2352-3026%2815%2900127-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2815%2900127-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252815%252900127-1%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DGonzalez%26aufirst%3DG.%2BN.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DGachimova%26aufirst%3DE.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DKornblau%26aufirst%3DS.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DPonatinib%2520as%2520first-line%2520treatment%2520for%2520patients%2520with%2520chronic%2520myeloid%2520leukaemia%2520in%2520chronic%2520phase%253A%2520A%2520phase%25202%2520study%26jtitle%3DLancet%2520Haematol.%26date%3D2015%26volume%3D2%26spage%3De376%26epage%3De383%26doi%3D10.1016%2FS2352-3026%2815%2900127-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span><span class="refDoi"> DOI: 10.1038/nsmb.1486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Fnsmb.1486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=18794843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1109-1118&author=M.+Azamauthor=M.+A.+Seeligerauthor=N.+S.+Grayauthor=J.+Kuriyanauthor=G.+Q.+Daley&title=Activation+of+tyrosine+kinases+by+mutation+of+the+gatekeeper+threonine&doi=10.1038%2Fnsmb.1486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span></div><div class="casAuthors">Azam, Mohammad; Seeliger, Markus A.; Gray, Nathanael S.; Kuriyan, John; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1109-1118</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinases targeted by small-mol. inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site.  Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-α and -β, and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells.  Structural anal. reveals that a network of hydrophobic interactions - the hydrophobic spine - characteristic of the active kinase conformation is stabilized by the gatekeeper substitution.  Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase.  Furthermore, a small-mol. inhibitor (compd. 14) that maximizes complementarity with the dismantled spine inhibits the gatekeeper mutation of BCR-ABL-T315I.  These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEoZTY5SkbALVg90H21EOLACvtfcHk0lgufluuozm7nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM&md5=4afc4e5a0850a4510ced3fa5fbda97fa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1486%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivation%2520of%2520tyrosine%2520kinases%2520by%2520mutation%2520of%2520the%2520gatekeeper%2520threonine%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D1109%26epage%3D1118%26doi%3D10.1038%2Fnsmb.1486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Barouch-Bentov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, K.</span><span> </span><span class="NLM_article-title">Mechanisms of drug resistance in kinases</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span><span class="refDoi"> DOI: 10.1517/13543784.2011.546344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1517%2F13543784.2011.546344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=21235428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVenur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=153-208&author=R.+Barouch-Bentovauthor=K.+Sauer&title=Mechanisms+of+drug+resistance+in+kinases&doi=10.1517%2F13543784.2011.546344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug resistance in kinases</span></div><div class="casAuthors">Barouch-Bentov, Rina; Sauer, Karsten</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-208</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Because of their important roles in disease and excellent "druggability", kinases have become the second largest drug target family.  The great success of the BCR-ABL inhibitor imatinib in treating chronic myelogenous leukemia illustrates the high potential of kinase inhibitor (KI) therapeutics, but also unveils a major limitation: the development of drug resistance.  This is a significant concern as KIs reach large patient populations for an expanding array of indications.  We provide an up-to-date understanding of the mechanisms through which KIs function and through which cells can become KI-resistant.  We review current and future approaches to overcome KI resistance, focusing on currently approved KIs and KIs in clin. trials.  We then discuss approaches to improve KI efficacy and overcome drug resistance and novel approaches to develop less drug resistance-prone KI therapeutics.  Although drug resistance is a concern for current KI therapeutics, recent progress in our understanding of the underlying mechanisms and promising technol. advances may overcome this limitation and provide powerful new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJUpdpkWU6bVg90H21EOLACvtfcHk0li3YIHNUImTbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVenur8%253D&md5=cccffaca08cbcfb1e0d2c1d580c9e797</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.546344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.546344%26sid%3Dliteratum%253Aachs%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DSauer%26aufirst%3DK.%26atitle%3DMechanisms%2520of%2520drug%2520resistance%2520in%2520kinases%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D153%26epage%3D208%26doi%3D10.1517%2F13543784.2011.546344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Targeting gain of function and resistance mutations in abl and kit by hybrid compound design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5757</span><span class="NLM_x">–</span> <span class="NLM_lpage">5772</span><span class="refDoi"> DOI: 10.1021/jm4004076</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004076" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5757-5772&author=A.+Richtersauthor=J.+Ketzerauthor=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=R.+Schneiderauthor=J.+M.+Heuckmannauthor=S.+Heynckauthor=M.+L.+Sosauthor=A.+Guptaauthor=A.+Ungerauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+Bauerauthor=D.+Rauh&title=Targeting+gain+of+function+and+resistance+mutations+in+abl+and+kit+by+hybrid+compound+design&doi=10.1021%2Fjm4004076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm4004076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004076%26sid%3Dliteratum%253Aachs%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520gain%2520of%2520function%2520and%2520resistance%2520mutations%2520in%2520abl%2520and%2520kit%2520by%2520hybrid%2520compound%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5757%26epage%3D5772%26doi%3D10.1021%2Fjm4004076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Batista, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolbert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geballe, M. T.</span><span> </span><span class="NLM_article-title">SiteHopper - a unique tool for binding site comparison</span> <span class="citation_source-journal">J. Cheminf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="refDoi"> DOI: 10.1186/1758-2946-6-S1-P57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1186%2F1758-2946-6-S1-P57" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=57&author=J.+H.+Batistaauthor=P.+C.+D.+Hawkinsauthor=R.+Tolbertauthor=M.+T.+Geballe&title=SiteHopper+-+a+unique+tool+for+binding+site+comparison&doi=10.1186%2F1758-2946-6-S1-P57"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-6-S1-P57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-6-S1-P57%26sid%3Dliteratum%253Aachs%26aulast%3DBatista%26aufirst%3DJ.%2BH.%26aulast%3DHawkins%26aufirst%3DP.%2BC.%2BD.%26aulast%3DTolbert%26aufirst%3DR.%26aulast%3DGeballe%26aufirst%3DM.%2BT.%26atitle%3DSiteHopper%2520-%2520a%2520unique%2520tool%2520for%2520binding%2520site%2520comparison%26jtitle%3DJ.%2520Cheminf.%26date%3D2014%26volume%3D6%26spage%3D57%26doi%3D10.1186%2F1758-2946-6-S1-P57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Genheden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryde, U.</span><span> </span><span class="NLM_article-title">The mm/pbsa and mm/gbsa methods to estimate ligand-binding affinities</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span><span class="refDoi"> DOI: 10.1517/17460441.2015.1032936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1517%2F17460441.2015.1032936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25835573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=449-461&author=S.+Genhedenauthor=U.+Ryde&title=The+mm%2Fpbsa+and+mm%2Fgbsa+methods+to+estimate+ligand-binding+affinities&doi=10.1517%2F17460441.2015.1032936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities</span></div><div class="casAuthors">Genheden, Samuel; Ryde, Ulf</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">449-461</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The mol. mechanics energies combined with the Poisson-Boltzmann or generalized Born and surface area continuum solvation (MM/PBSA and MM/GBSA) methods are popular approaches to est. the free energy of the binding of small ligands to biol. macromols.  They are typically based on mol. dynamics simulations of the receptor-ligand complex and are therefore intermediate in both accuracy and computational effort between empirical scoring and strict alchem. perturbation methods.  They have been applied to a large no. of systems with varying success.  Areas covered: The authors review the use of MM/PBSA and MM/GBSA methods to calc. ligand-binding affinities, with an emphasis on calibration, testing and validation, as well as attempts to improve the methods, rather than on specific applications.  Expert opinion: MM/PBSA and MM/GBSA are attractive approaches owing to their modular nature and that they do not require calcns. on a training set.  They have been used successfully to reproduce and rationalize exptl. findings and to improve the results of virtual screening and docking.  However, they contain several crude and questionable approxns., for example, the lack of conformational entropy and information about the no. and free energy of water mols. in the binding site.  Moreover, there are many variants of the method and their performance varies strongly with the tested system.  Likewise, most attempts to ameliorate the methods with more accurate approaches, for example, quantum-mech. calcns., polarizable force fields or improved solvation have deteriorated the results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTBKte1pAZR7Vg90H21EOLACvtfcHk0li3YIHNUImTbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGktr8%253D&md5=b123b88809f275564f95a2271ebd159f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1032936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1032936%26sid%3Dliteratum%253Aachs%26aulast%3DGenheden%26aufirst%3DS.%26aulast%3DRyde%26aufirst%3DU.%26atitle%3DThe%2520mm%252Fpbsa%2520and%2520mm%252Fgbsa%2520methods%2520to%2520estimate%2520ligand-binding%2520affinities%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D449%26epage%3D461%26doi%3D10.1517%2F17460441.2015.1032936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuckmantel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Proteus in the world of proteins: Conformational changes in protein kinases</span> <span class="citation_source-journal">Arch. Pharm. (Weinheim, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span><span class="refDoi"> DOI: 10.1002/ardp.201000028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1002%2Fardp.201000028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=20336692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2010&pages=193-206&author=M.+Rabillerauthor=M.+Getlikauthor=S.+Kl%C3%BCterauthor=A.+Richtersauthor=S.+Tuckmantelauthor=J.+R.+Simardauthor=D.+Rauh&title=Proteus+in+the+world+of+proteins%3A+Conformational+changes+in+protein+kinases&doi=10.1002%2Fardp.201000028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Proteus in the world of proteins: Conformational changes in protein kinases</span></div><div class="casAuthors">Rabiller, Matthias; Getlik, Matthaeus; Klueter, Sabine; Richters, Andre; Tueckmantel, Sandra; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-206</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The 512 protein kinases encoded by the human genome are a prime example of Nature's ability to create diversity by introducing variations to a highly conserved theme.  The activity of each kinase domain is controlled by layers of regulatory mechanisms involving different combinations of post-translational modifications, intramol. contacts, and intermol. interactions.  Ultimately, they all achieve their effect by favoring particular conformations that promote or prevent the kinase domain from catalyzing protein phosphorylation.  The central role of kinases in various diseases has encouraged extensive investigations of their biol. function and 3-dimensional structures, yielding a more detailed understanding of the mechanisms that regulate protein kinase activity by conformational changes.  Here, the authors discuss these regulatory mechanisms and show how conformational changes can be exploited for the design of specific inhibitors that lock protein kinases in inactive conformations.  In addn., the authors highlight recent developments to monitor ligand-induced structural changes in protein kinases and for screening and identifying inhibitors that stabilize enzymically incompetent kinase conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRChkP9MKuIbVg90H21EOLACvtfcHk0ljl-Iim2wko8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D&md5=0833f19b8565afc03c39bf5fb5a87175</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fardp.201000028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201000028%26sid%3Dliteratum%253Aachs%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DTuckmantel%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DProteus%2520in%2520the%2520world%2520of%2520proteins%253A%2520Conformational%2520changes%2520in%2520protein%2520kinases%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2010%26volume%3D343%26spage%3D193%26epage%3D206%26doi%3D10.1002%2Fardp.201000028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span> </span><span class="NLM_article-title">Protein kinases: Evolution of dynamic regulatory proteins</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1016/j.tibs.2010.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.tibs.2010.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=20971646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=65-77&author=S.+S.+Taylorauthor=A.+P.+Kornev&title=Protein+kinases%3A+Evolution+of+dynamic+regulatory+proteins&doi=10.1016%2Fj.tibs.2010.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases: evolution of dynamic regulatory proteins</span></div><div class="casAuthors">Taylor, Susan S.; Kornev, Alexandr P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic protein kinases have evolved as a family of highly dynamic mols. with a strictly organized internal architecture.  A single hydrophobic F-helix serves as a central scaffold for the assembly of the entire mol.  Two non-consecutive hydrophobic structures termed "spines" anchor all of the elements important for catalysis to the F-helix.  They make firm, but flexible, connections within the mol., providing a high level of internal dynamics of the protein kinase.  During the course of evolution, protein kinases developed a universal regulatory mechanism assocd. with a large activation segment that can be dynamically folded and unfolded in the course of cell functioning.  Protein kinases thus represent a unique, highly dynamic, and precisely regulated set of switches that control most biol. events in eukaryotic cells.  A comparison of 155 publicly available protein kinase structures of the human kinome, which includes 518 protein kinases divided into 7 major subfamilies, demonstrates a high level of structural plasticity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruzcRXGPlBN7Vg90H21EOLACvtfcHk0ljl-Iim2wko8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOrtLg%253D&md5=f663148962d22944914e804e34fc947c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2010.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2010.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26atitle%3DProtein%2520kinases%253A%2520Evolution%2520of%2520dynamic%2520regulatory%2520proteins%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2011%26volume%3D36%26spage%3D65%26epage%3D77%26doi%3D10.1016%2Fj.tibs.2010.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haste, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, L. F.</span><span> </span><span class="NLM_article-title">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">17783</span><span class="NLM_x">–</span> <span class="NLM_lpage">17788</span><span class="refDoi"> DOI: 10.1073/pnas.0607656103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1073%2Fpnas.0607656103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=17095602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17783-17788&author=A.+P.+Kornevauthor=N.+M.+Hasteauthor=S.+S.+Taylorauthor=L.+F.+Ten+Eyck&title=Surface+comparison+of+active+and+inactive+protein+kinases+identifies+a+conserved+activation+mechanism&doi=10.1073%2Fpnas.0607656103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span></div><div class="casAuthors">Kornev, Alexandr P.; Haste, Nina M.; Taylor, Susan S.; Ten Eyck, Lynn F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">17783-17788</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The surface comparison of different serine-threonine and tyrosine kinases reveals a set of 30 residues whose spatial positions are highly conserved.  The comparison between active and inactive conformations identified the residues whose positions are the most sensitive to activation.  Based on these results, we propose a model of protein kinase activation.  This model explains how the presence of a phosphate group in the activation loop dets. the position of the catalytically important aspartate in the Asp-Phe-Gly (DFG) motif.  According to the model, the most important feature of the activation is a "spine" formation that is dynamically assembled in all active kinases.  The spine is comprised of four hydrophobic residues that we detected in a set of 23 eukaryotic and prokaryotic kinases.  It spans the mol. and plays a coordinating role in activated kinases.  The spine is disordered in the inactive kinases and can explain how stabilization of the whole mol. is achieved upon phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwv4ByA5owH7Vg90H21EOLACvtfcHk0ljl-Iim2wko8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ&md5=f474acffd8b17d8352ac9f6fc9bbbf8f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607656103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607656103%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHaste%26aufirst%3DN.%2BM.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DTen%2BEyck%26aufirst%3DL.%2BF.%26atitle%3DSurface%2520comparison%2520of%2520active%2520and%2520inactive%2520protein%2520kinases%2520identifies%2520a%2520conserved%2520activation%2520mechanism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D17783%26epage%3D17788%26doi%3D10.1073%2Fpnas.0607656103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: The new wave of bcr-abl inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1038/nrd2324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Fnrd2324" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&author=A.+Quint%C3%A1s-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Flying+under+the+radar%3A+The+new+wave+of+bcr-abl+inhibitors&doi=10.1038%2Fnrd2324"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnrd2324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2324%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520The%2520new%2520wave%2520of%2520bcr-abl%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D834%26epage%3D848%26doi%3D10.1038%2Fnrd2324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of drug resistance in tyrosine kinases cabl and ckit</span> <span class="citation_source-journal">Crit. Rev. Biochem. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span><span class="refDoi"> DOI: 10.3109/10409238.2011.578612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.3109%2F10409238.2011.578612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=21539479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlyrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=295-309&author=J.+P.+DiNittoauthor=J.+C.+Wu&title=Molecular+mechanisms+of+drug+resistance+in+tyrosine+kinases+cabl+and+ckit&doi=10.3109%2F10409238.2011.578612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit</span></div><div class="casAuthors">DiNitto, Jonathan P.; Wu, Joe C.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The inhibition of protein kinases has gained general acceptance as an effective approach to treat a wide range of cancers.  However, in many cases, prolonged administration of kinase inhibitors often leads to acquired resistance, and the therapeutic effect is subsequently diminished.  The wealth of recent studies using biochem., kinetic, and structural approaches have revealed the mol. basis for the clin. obsd. resistance.  In this review, we highlight several of the most common mol. mechanisms that lead to acquired resistance to kinase inhibitors obsd. with the cAbl (cellular form of the Abelson leukemia virus tyrosine kinase) and the type III receptor tyrosine kinase cKit, including a newly identified mechanism resulting from accelerated kinase activation caused by mutations in the activation loop.  Strategies to overcome the loss of drug sensitivity that represents a challenge currently facing the field and the emerging approaches to circumvent resistance are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDF-2H4LKT5bVg90H21EOLACvtfcHk0lhy_1VZU19yLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlyrsbw%253D&md5=28a337d17c0d117b731b8b1f7763df96</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.3109%2F10409238.2011.578612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10409238.2011.578612%26sid%3Dliteratum%253Aachs%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26atitle%3DMolecular%2520mechanisms%2520of%2520drug%2520resistance%2520in%2520tyrosine%2520kinases%2520cabl%2520and%2520ckit%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D46%26spage%3D295%26epage%3D309%26doi%3D10.3109%2F10409238.2011.578612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheibe, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">Structural basis for the autoinhibition and sti-571 inhibition of c-kit tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">31655</span><span class="NLM_x">–</span> <span class="NLM_lpage">31663</span><span class="refDoi"> DOI: 10.1074/jbc.M403319200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1074%2Fjbc.M403319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=15123710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31655-31663&author=C.+D.+Molauthor=D.+R.+Douganauthor=T.+R.+Schneiderauthor=R.+J.+Skeneauthor=M.+L.+Krausauthor=D.+N.+Scheibeauthor=G.+P.+Snellauthor=H.+Zouauthor=B.+C.+Sangauthor=K.+P.+Wilson&title=Structural+basis+for+the+autoinhibition+and+sti-571+inhibition+of+c-kit+tyrosine+kinase&doi=10.1074%2Fjbc.M403319200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase</span></div><div class="casAuthors">Mol, Clifford D.; Dougan, Douglas R.; Schneider, Thomas R.; Skene, Robert J.; Kraus, Michelle L.; Scheibe, Daniel N.; Snell, Gyorgy P.; Zou, Hua; Sang, Bi-Ching; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31655-31663</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers.  The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known.  We report the 1.9-Å resoln. crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase.  Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure.  A 1.6-Å crystal structure of c-Kit in complex with STI-571 (Imatinib or Gleevec) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state.  Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJsKx1IzXQbVg90H21EOLACvtfcHk0lhy_1VZU19yLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D&md5=df6065a62b44e4c2e6b020da0f797ab4</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403319200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DScheibe%26aufirst%3DD.%2BN.%26aulast%3DSnell%26aufirst%3DG.%2BP.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520and%2520sti-571%2520inhibition%2520of%2520c-kit%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D31655%26epage%3D31663%26doi%3D10.1074%2Fjbc.M403319200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Lambert, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duhme-Klair, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramjee, M. K.</span><span> </span><span class="NLM_article-title">The background, discovery and clinical development of bcr-abl inhibitors</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">992</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span><span class="refDoi"> DOI: 10.1016/j.drudis.2013.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.drudis.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23769978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=992-1000&author=G.+K.+Lambertauthor=A.+K.+Duhme-Klairauthor=T.+Morganauthor=M.+K.+Ramjee&title=The+background%2C+discovery+and+clinical+development+of+bcr-abl+inhibitors&doi=10.1016%2Fj.drudis.2013.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The background, discovery and clinical development of BCR-ABL inhibitors</span></div><div class="casAuthors">Lambert, Gemma K.; Duhme-Klair, Anne-Kathrin; Morgan, Trevor; Ramjee, Manoj K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19-20</span>),
    <span class="NLM_cas:pages">992-1000</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The story of the inhibition of BCR-ABL as a treatment for chronic myelogenous leukemia serves to illustrate key aspects of the kinase drug discovery and development process.  Firstly, elucidation of the disease mechanism enabled identification of the mol. target(s) which catalyzed pharmaceutical research and resulted in Gleevec (Novartis) as the first FDA approved BCR-ABL inhibitor.  However, clin. success was soon tempered by the emergence of drug resistance through various mechanisms.  Using rational drug design, several hypotheses were devised to overcome resistance issues leading to the development of second generation inhibitors, providing clinicians and patients with greater therapeutic choice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2YF6Gz_LpYbVg90H21EOLACvtfcHk0lhy_1VZU19yLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtL%252FM&md5=e824d8f8d5957eb193bf004c7ec2b642</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DG.%2BK.%26aulast%3DDuhme-Klair%26aufirst%3DA.%2BK.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DRamjee%26aufirst%3DM.%2BK.%26atitle%3DThe%2520background%252C%2520discovery%2520and%2520clinical%2520development%2520of%2520bcr-abl%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D992%26epage%3D1000%26doi%3D10.1016%2Fj.drudis.2013.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Doroshow, J. H.</span><span> </span><span class="NLM_article-title">Overcoming resistance to targeted anticancer drugs</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">1852</span><span class="NLM_x">–</span> <span class="NLM_lpage">1853</span><span class="refDoi"> DOI: 10.1056/NEJMe1311325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1056%2FNEJMe1311325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=24180495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGhtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=1852-1853&author=J.+H.+Doroshow&title=Overcoming+resistance+to+targeted+anticancer+drugs&doi=10.1056%2FNEJMe1311325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming resistance to targeted anticancer drugs</span></div><div class="casAuthors">Doroshow, James H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1852-1853</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAG6F_vlJI97Vg90H21EOLACvtfcHk0lh4bIjLaDWcZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGhtb7P&md5=2b62cc5b32994f1480cb5d91ecc3df99</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1311325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1311325%26sid%3Dliteratum%253Aachs%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26atitle%3DOvercoming%2520resistance%2520to%2520targeted%2520anticancer%2520drugs%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D1852%26epage%3D1853%26doi%3D10.1056%2FNEJMe1311325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Rey, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Launay-Vacher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tournigand, C.</span><span> </span><span class="NLM_article-title">Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: An overview for pharmacists</span> <span class="citation_source-journal">Target Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span><span class="refDoi"> DOI: 10.1007/s11523-014-0333-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1007%2Fs11523-014-0333-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25213039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A280%3ADC%252BC2M7gsVymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=199-213&author=J.+B.+Reyauthor=V.+Launay-Vacherauthor=C.+Tournigand&title=Regorafenib+as+a+single-agent+in+the+treatment+of+patients+with+gastrointestinal+tumors%3A+An+overview+for+pharmacists&doi=10.1007%2Fs11523-014-0333-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists</span></div><div class="casAuthors">Rey Jean-Baptiste; Launay-Vacher Vincent; Tournigand Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-213</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Regorafenib (BAY 73-4506, Stivarga® Bayer HealthCare Pharmaceutical Inc) is an oral multikinase inhibitor with a distinct and wide-ranging profile of tyrosine kinase inhibition, resulting in antiangiogenic and antiproliferative properties in tumors.  Single-agent regorafenib administered as a 160-mg daily dose for the first 21 days of a 28-day cycle is approved for use in patients with pretreated metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumor (GIST) progressing on imatinib and sunitinib, following publication of data from the phase III CORRECT and GRID studies respectively.  Regorafenib is currently under phase III investigation in patients with hepatocellular carcinoma and is in several phase II studies in patients with gastrointestinal (GI) tumors.  This review describes the clinical development of regorafenib in patients with GI cancers, and highlights the key issues important for the modern day clinical pharmacist who forms part of the multidisciplinary team ensuring safe and effective delivery of the drug to the patient.  This information is considered of particular importance to the clinical pharmacist for the future development of regorafenib in this treatment setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToN26KJumfTNXdcedVHT5tfW6udTcc2eYBuIdW4DKwmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7gsVymsg%253D%253D&md5=a832c4d640e4dae531c7f52c3dfb591c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs11523-014-0333-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-014-0333-x%26sid%3Dliteratum%253Aachs%26aulast%3DRey%26aufirst%3DJ.%2BB.%26aulast%3DLaunay-Vacher%26aufirst%3DV.%26aulast%3DTournigand%26aufirst%3DC.%26atitle%3DRegorafenib%2520as%2520a%2520single-agent%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520gastrointestinal%2520tumors%253A%2520An%2520overview%2520for%2520pharmacists%26jtitle%3DTarget%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D199%26epage%3D213%26doi%3D10.1007%2Fs11523-014-0333-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agaram, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Adamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">Sorafenib inhibits the imatinib-resistant kitt670i gatekeeper mutation in gastrointestinal stromal tumor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4874</span><span class="NLM_x">–</span> <span class="NLM_lpage">4881</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F1078-0432.CCR-07-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=17699867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4874-4881&author=T.+Guoauthor=N.+P.+Agaramauthor=G.+C.+Wongauthor=G.+Homauthor=D.+D%E2%80%99Adamoauthor=R.+G.+Makiauthor=G.+K.+Schwartzauthor=D.+Veachauthor=B.+D.+Clarksonauthor=S.+Singerauthor=R.+P.+DeMatteoauthor=P.+Besmerauthor=C.+R.+Antonescu&title=Sorafenib+inhibits+the+imatinib-resistant+kitt670i+gatekeeper+mutation+in+gastrointestinal+stromal+tumor&doi=10.1158%2F1078-0432.CCR-07-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor</span></div><div class="casAuthors">Guo, Tianhua; Agaram, Narasimhan P.; Wong, Grace C.; Hom, Glory; D'Adamo, David; Maki, Robert G.; Schwartz, Gary K.; Veach, Darren; Clarkson, Bayard D.; Singer, Samuel; DeMatteo, Ronald P.; Besmer, Peter; Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4874-4881</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain.  We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly obsd. imatinib-resistant KIT mutations (KITV654A, KITT670I, KITD820Y, and KITN822K) expressed in the Ba/F3 cellular system.  EXPTL. DESIGN: In vitro drug screening of stable Ba/F3 KIT mutants recapitulating the genotype of imatinib-resistant patients harboring primary and secondary KIT mutations was investigated.  Comparison was made to imatinib-sensitive Ba/F3 KIT mutant cells as well as Ba/F3 cells expressing only secondary KIT mutations.  The efficacy of drug treatment was evaluated by proliferation and apoptosis assays, in addn. to biochem. inhibition of KIT activation.  RESULTS: Sorafenib was potent against all imatinib-resistant Ba/F3 KIT double mutants tested, including the gatekeeper secondary mutation KITWK557-8del/T670I, which was resistant to other kinase inhibitors.  Although all three drugs tested decreased cell proliferation and inhibited KIT activation against exon 13 (KITV560del/V654A) and exon 17 (KITV559D/D820Y) double mutants, nilotinib did so at lower concns.  CONCLUSIONS: Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual mol. mechanisms of resistance.  The Ba/F3 KITWK557-8del/T670I cells were sensitive only to sorafenib inhibition, whereas nilotinib was more potent on imatinib-resistant KITV560del/V654A and KITV559D/D820Y mutant cells than dasatinib and sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqllTJoDeevKbVg90H21EOLACvtfcHk0lh4bIjLaDWcZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D&md5=f1643671ada85f1bcd05faa04cd88b52</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0484%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DAgaram%26aufirst%3DN.%2BP.%26aulast%3DWong%26aufirst%3DG.%2BC.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%2BD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DSorafenib%2520inhibits%2520the%2520imatinib-resistant%2520kitt670i%2520gatekeeper%2520mutation%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4874%26epage%3D4881%26doi%3D10.1158%2F1078-0432.CCR-07-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyonaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamasaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimaru, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuri, K.</span><span> </span><span class="NLM_article-title">Conventional and molecular cytogenetic characterization of a new human cell line, gist-t1, established from gastrointestinal stromal tumor</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1038/labinvest.3780461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Flabinvest.3780461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=12004007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A280%3ADC%252BD383msVOjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2002&pages=663-665&author=T.+Taguchiauthor=H.+Sonobeauthor=S.+Toyonagaauthor=I.+Yamasakiauthor=T.+Shuinauthor=A.+Takanoauthor=K.+Arakiauthor=K.+Akimaruauthor=K.+Yuri&title=Conventional+and+molecular+cytogenetic+characterization+of+a+new+human+cell+line%2C+gist-t1%2C+established+from+gastrointestinal+stromal+tumor&doi=10.1038%2Flabinvest.3780461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor</span></div><div class="casAuthors">Taguchi Takahiro; Sonobe Hiroshi; Toyonaga Shin-ichi; Yamasaki Ichiro; Shuin Taro; Takano Atsushi; Araki Keijiro; Akimaru Kunihiro; Yuri Kazunari</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory investigation; a journal of technical methods and pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-5</span>
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfLoSxovx6e8RAV4D_Ins_fW6udTcc2eY_Q1ajidn98bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD383msVOjsg%253D%253D&md5=2a397ed59d4b02cde55eb3253dc2cb13</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.3780461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.3780461%26sid%3Dliteratum%253Aachs%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSonobe%26aufirst%3DH.%26aulast%3DToyonaga%26aufirst%3DS.%26aulast%3DYamasaki%26aufirst%3DI.%26aulast%3DShuin%26aufirst%3DT.%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DAraki%26aufirst%3DK.%26aulast%3DAkimaru%26aufirst%3DK.%26aulast%3DYuri%26aufirst%3DK.%26atitle%3DConventional%2520and%2520molecular%2520cytogenetic%2520characterization%2520of%2520a%2520new%2520human%2520cell%2520line%252C%2520gist-t1%252C%2520established%2520from%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DLab.%2520Invest.%26date%3D2002%26volume%3D82%26spage%3D663%26epage%3D665%26doi%3D10.1038%2Flabinvest.3780461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumbrink, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Indazole-based covalent inhibitors to target drug-resistant epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2361</span><span class="NLM_x">–</span> <span class="NLM_lpage">2372</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2361-2372&author=S.+Tomassiauthor=J.+Lategahnauthor=J.+Engelauthor=M.+Keulauthor=H.+L.+Tumbrinkauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=S.+Bauerauthor=D.+Rauh&title=Indazole-based+covalent+inhibitors+to+target+drug-resistant+epidermal+growth+factor+receptor&doi=10.1021%2Facs.jmedchem.6b01626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor</span></div><div class="casAuthors">Tomassi, Stefano; Lategahn, Jonas; Engel, Julian; Keul, Marina; Tumbrink, Hannah L.; Ketzer, Julia; Muehlenberg, Thomas; Baumann, Matthias; Schultz-Fademrecht, Carsten; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2361-2372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The specific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthrough in targeted cancer therapy and marks a drastic change in the treatment of non-small cell lung cancer (NSCLC).  The recurrent emergence of resistance to these targeted drugs requires the development of novel chem. entities that efficiently inhibit drug-resistant EGFR.  Herein, the authors report the optimization process for a hit compd. that has emerged from a phenotypic screen resulting in indazole-based compds.  These inhibitors are conformationally less flexible, target gatekeeper mutated drug resistant EGFR-L858R/T790M and covalently alkylate Cys 797.  Western blot anal., as well as characterization of the binding kinetics and kinase selectivity profiling, substantiates the authors' approach of targeting drug-resistant EGFR-L858R/T790M with inhibitors incorporating the indazole as hinge binder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwwmG17YkaV7Vg90H21EOLACvtfcHk0lj_zoHCZjcRaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D&md5=25e24252dc5a03ec5349359289ebd808</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01626%26sid%3Dliteratum%253Aachs%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DIndazole-based%2520covalent%2520inhibitors%2520to%2520target%2520drug-resistant%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2361%26epage%3D2372%26doi%3D10.1021%2Facs.jmedchem.6b01626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Acetylene Group, Friend or Foe in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (11)
                                     , 5625-5663. <a href="https://doi.org/10.1021/acs.jmedchem.9b01617" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01617%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAcetylene%252BGroup%25252C%252BFriend%252Bor%252BFoe%252Bin%252BMedicinal%252BChemistry%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D29092019%26date%3D19022020%26date%3D07022020%26volume%3D63%26issue%3D11%26spage%3D5625%26epage%3D5663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gary  Chinigo</span>, <span class="hlFld-ContribAuthor ">Yiqing  Feng</span>, <span class="hlFld-ContribAuthor ">Susan  Hoy</span>, <span class="hlFld-ContribAuthor ">Ricardo  Lira</span>, <span class="hlFld-ContribAuthor ">Matthew  Perry</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridazines and Their Benzo Derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00082-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00082-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00082-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00082-2%26sid%3Dliteratum%253Aachs%26atitle%3DPyridazines%252Band%252BTheir%252BBenzo%252BDerivatives%26aulast%3DChinigo%26aufirst%3DGary%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huayao  Li</span>, <span class="hlFld-ContribAuthor ">Lijuan  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Zhuang</span>, <span class="hlFld-ContribAuthor ">Cun  Liu</span>, <span class="hlFld-ContribAuthor ">Chao  Zhou</span>, <span class="hlFld-ContribAuthor ">Jing  Yang</span>, <span class="hlFld-ContribAuthor ">Chundi  Gao</span>, <span class="hlFld-ContribAuthor ">Gongxi  Liu</span>, <span class="hlFld-ContribAuthor ">Changgang  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis. </span><span class="cited-content_cbyCitation_journal-name">Molecular Genetics & Genomic Medicine</span><span> <strong>2019,</strong> <em>7 </em>
                                    (9)
                                     <a href="https://doi.org/10.1002/mgg3.851" title="DOI URL">https://doi.org/10.1002/mgg3.851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/mgg3.851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmgg3.851%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Genetics%2520%2526%2520Genomic%2520Medicine%26atitle%3DIdentification%252Bof%252Bkey%252Bcandidate%252Btargets%252Band%252Bpathways%252Bfor%252Bthe%252Btargeted%252Btreatment%252Bof%252Bleukemia%252Bstem%252Bcells%252Bof%252Bchronic%252Bmyelogenous%252Bleukemia%252Busing%252Bbioinformatics%252Banalysis%26aulast%3DLi%26aufirst%3DHuayao%26date%3D2019%26date%3D2019%26volume%3D7%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structural alignment of kinase inhibitors, approved by the FDA for the treatment of GIST, bound to wild-type KIT (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>) (<b>1</b> (green, pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4bkj">4bkj</a>), <b>2</b> (yellow, pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3g0e">3g0e</a>), <b>3</b> (blue, modeled), and <b>4</b> (red, pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>)). Unique substitution patterns and hinge binding elements of the inhibitors highlighted (right). (B) X-ray crystal structure of <b>4</b> in complex with wild-type KIT (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>) with modeled secondary mutations (sticks and surfaces). Hydrogen bonds are depicted by blue dotted lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Comparison of the ligand binding surfaces using representative structures of the MD simulation trajectory derived from a residue-based RMSD clustering. The alignment and representations of <b>4</b> bound to wild-type KIT (gray), apo KIT T670I (brown), and apo KIT V654A (blue) structures were generated with SiteHopper,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> respectively. (B) Results of the binding site comparison of mutant KIT T670I bound to <b>4</b> and apo mutant KIT T670I to wild-type KIT with respect to shape and physicochemical properties (hydrogen bond donor, hydrogen bond acceptor, and hydrophobic features). The pockets of the representative structures of the cluster with the highest occupancy for the simulations of the apo enzymes (apo), and the enzymes bound to <b>4</b> (ponatinib) were used. They were compared to the wild-type KIT crystal structure bound to ponatinib (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>). (C) Results of the binding site comparison of ligand-bound mutant KIT V654A and apo mutant KIT V654A to wild-type KIT with respect to shape and physicochemical properties. The comparison was performed as outlined in (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Core-scaffold of synthesized compounds modeled into the crystal structure of wild-type KIT (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i">4u0i</a>). The general scaffold and the substitution patterns (red) of the designed compounds are shown (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Derivatives (<b>5a</b>–<b>d</b>, <b>6a</b>, <b>7a</b>–<b>l</b>, <b>8a</b>–<b>d</b>, <b>9a</b>,<b>b</b>, and <b>10</b>) Based on the Structure of <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>N</i>-bromosuccinimide, AIBN, DCE, 80 °C, 12 h (60–66%); (ii) 1<i>N</i>-methylpiperazine, K<sub>2</sub>CO<sub>3</sub>, DCM, rt, 3 h (80–91%); (iii) 1<i>N</i>-methylpiperazine, NaBH(OAc)<sub>3</sub>, THF, rt, 16 h (60–70%); (iv) Pd/C, H<sub>2</sub>, EtOH, 12 h (98%); (v) HOBt, EDC, DIPEA, DMF, DMAP, carboxylic acid-derivative rt, 16 h (49–88%); (vi) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, (<i>i</i>-Pr)<sub>2</sub>NH, R<sup>1</sup>-Br, MeCN, 80 °C, 16 h; (vii) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, (<i>i</i>-Pr)<sub>2</sub>NH, TBAF, MeCN, 80 °C, 16 h (1–22%).</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Docking pose of <b>7f</b> in complex with wild-type KIT. (B) Close up of the back pocket. Depicted are the residues spanning the hydrophobic pocket in wild-type KIT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/medium/jm-2017-00841r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A,C) Western blot analysis after incubation (3 h) with doses of <b>7e</b>, <b>7f</b>, <b>10</b>, and <b>4</b> in GIST-T1-D816E and GIST430-V654A. (B,D,F) Corresponding dose–response curves of compounds <b>7e</b>, <b>7f</b>, <b>10</b>, and <b>4</b> in GIST cells expressing (A) constitutively active KIT with secondary mutant V654A (GIST430-V654A), (C) constitutively active KIT with secondary mutant D816E (GIST-T1-D816E), and (F) KIT negative cell line GIST-48B after 72 h incubation with the respective inhibitors. (E) GI<sub>50</sub> values on GIST-48B, GIST-T1-D816E, and GIST430-V654A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00841/20171103/images/large/jm-2017-00841r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00841&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 64 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Tsujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furitsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span> </span><span class="NLM_article-title">Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell-line p-815 generated by a point mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">2619</span><span class="NLM_x">–</span> <span class="NLM_lpage">2626</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1994&pages=2619-2626&author=T.+Tsujimuraauthor=T.+Furitsuauthor=M.+Morimotoauthor=K.+Isozakiauthor=S.+Nomuraauthor=Y.+Matsuzawaauthor=Y.+Kitamuraauthor=Y.+Kanakura&title=Ligand-independent+activation+of+c-kit+receptor+tyrosine+kinase+in+a+murine+mastocytoma+cell-line+p-815+generated+by+a+point+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DFuritsu%26aufirst%3DT.%26aulast%3DMorimoto%26aufirst%3DM.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DS.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26atitle%3DLigand-independent%2520activation%2520of%2520c-kit%2520receptor%2520tyrosine%2520kinase%2520in%2520a%2520murine%2520mastocytoma%2520cell-line%2520p-815%2520generated%2520by%2520a%2520point%2520mutation%26jtitle%3DBlood%26date%3D1994%26volume%3D83%26spage%3D2619%26epage%3D2626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Tsujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furitsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span> </span><span class="NLM_article-title">Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line rbl-2h3</span> <span class="citation_source-journal">Int. Arch. Allergy Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span><span class="refDoi"> DOI: 10.1159/000236870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1159%2F000236870" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2004&pages=377-385&author=T.+Tsujimuraauthor=T.+Furitsuauthor=M.+Morimotoauthor=Y.+Kanayamaauthor=S.+Nomuraauthor=Y.+Matsuzawaauthor=Y.+Kitamuraauthor=Y.+Kanakura&title=Substitution+of+an+aspartic+acid+results+in+constitutive+activation+of+c-kit+receptor+tyrosine+kinase+in+a+rat+tumor+mast+cell+line+rbl-2h3&doi=10.1159%2F000236870"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1159%2F000236870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000236870%26sid%3Dliteratum%253Aachs%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DFuritsu%26aufirst%3DT.%26aulast%3DMorimoto%26aufirst%3DM.%26aulast%3DKanayama%26aufirst%3DY.%26aulast%3DNomura%26aufirst%3DS.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26atitle%3DSubstitution%2520of%2520an%2520aspartic%2520acid%2520results%2520in%2520constitutive%2520activation%2520of%2520c-kit%2520receptor%2520tyrosine%2520kinase%2520in%2520a%2520rat%2520tumor%2520mast%2520cell%2520line%2520rbl-2h3%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2004%26volume%3D106%26spage%3D377%26epage%3D385%26doi%3D10.1159%2F000236870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Furitsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitayama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koshimizu, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugahara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterfield, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashman, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span> </span><span class="NLM_article-title">Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast-cell leukemia-cell line causing ligand-independent activation of c-kit product</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">1736</span><span class="NLM_x">–</span> <span class="NLM_lpage">1744</span><span class="refDoi"> DOI: 10.1172/JCI116761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1172%2FJCI116761" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1993&pages=1736-1744&author=T.+Furitsuauthor=T.+Tsujimuraauthor=T.+Tonoauthor=H.+Ikedaauthor=H.+Kitayamaauthor=U.+Koshimizuauthor=H.+Sugaharaauthor=J.+H.+Butterfieldauthor=L.+K.+Ashmanauthor=Y.+Kanayamaauthor=Y.+Matsuzawaauthor=Y.+Kitamuraauthor=Y.+Kanakura&title=Identification+of+mutations+in+the+coding+sequence+of+the+protooncogene+c-kit+in+a+human+mast-cell+leukemia-cell+line+causing+ligand-independent+activation+of+c-kit+product&doi=10.1172%2FJCI116761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1172%2FJCI116761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI116761%26sid%3Dliteratum%253Aachs%26aulast%3DFuritsu%26aufirst%3DT.%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DTono%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DKitayama%26aufirst%3DH.%26aulast%3DKoshimizu%26aufirst%3DU.%26aulast%3DSugahara%26aufirst%3DH.%26aulast%3DButterfield%26aufirst%3DJ.%2BH.%26aulast%3DAshman%26aufirst%3DL.%2BK.%26aulast%3DKanayama%26aufirst%3DY.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520mutations%2520in%2520the%2520coding%2520sequence%2520of%2520the%2520protooncogene%2520c-kit%2520in%2520a%2520human%2520mast-cell%2520leukemia-cell%2520line%2520causing%2520ligand-independent%2520activation%2520of%2520c-kit%2520product%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1993%26volume%3D92%26spage%3D1736%26epage%3D1744%26doi%3D10.1172%2FJCI116761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Linnekin, D.</span><span> </span><span class="NLM_article-title">Early signaling pathways activated by c-kit in hematopoietic cells</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1016/S1357-2725(99)00078-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS1357-2725%2899%2900078-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10582339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVWitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=1053-1074&author=D.+Linnekin&title=Early+signaling+pathways+activated+by+c-kit+in+hematopoietic+cells&doi=10.1016%2FS1357-2725%2899%2900078-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Early signaling pathways activated by c-Kit in hematopoietic cells</span></div><div class="casAuthors">Linnekin, D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1053-1074</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 171 refs.  C-Kit is a receptor tyrosine kinase that binds stem cell factor (SCF).  Structurally, c-Kit contains five Ig-like domains extracellularly and a catalytic domain divided into two regions by a 77 amino acid insert intracellularly.  Studies in white spotting and steel mice have shown that functional SCF and c-Kit are crit. in the survival and development of stem cells involved in hematopoiesis, pigmentation and reprodn.  Mutations in c-Kit are assocd. with a variety of human diseases.  Interaction of SCF with c-Kit rapidly induces receptor dimerization and increases in autophosphorylation activity.  Downstream of c-Kit, multiple signal transduction components are activated, including phosphatidylinositol-3-kinase, Src family members, the JAK/STAT pathway and the Ras-Raf-MAP kinase cascade.  Structure-function studies have begun to address the role of these signaling components in SCF-mediated responses.  This review will focus on the biochem. mechanism of action of SCF in hematopoietic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-8E1wr3VU-rVg90H21EOLACvtfcHk0ljllAKXGUdmWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVWitrc%253D&md5=f8fc51c696dbb65c6885bd55d0e0bde8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2899%2900078-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252899%252900078-3%26sid%3Dliteratum%253Aachs%26aulast%3DLinnekin%26aufirst%3DD.%26atitle%3DEarly%2520signaling%2520pathways%2520activated%2520by%2520c-kit%2520in%2520hematopoietic%2520cells%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D1999%26volume%3D31%26spage%3D1053%26epage%3D1074%26doi%3D10.1016%2FS1357-2725%2899%2900078-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Carvajal, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajewski, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutzky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolchok, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teitcher, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giobbie-Hurder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodi, F. S.</span><span> </span><span class="NLM_article-title">Phase ii study of nilotinib in melanoma harboring kit alterations following progression to prior kit inhibition</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2289</span><span class="NLM_x">–</span> <span class="NLM_lpage">2296</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F1078-0432.CCR-14-1630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25695690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2289-2296&author=R.+D.+Carvajalauthor=D.+P.+Lawrenceauthor=J.+S.+Weberauthor=T.+F.+Gajewskiauthor=R.+Gonzalezauthor=J.+Lutzkyauthor=S.+J.+O%E2%80%99Dayauthor=O.+Hamidauthor=J.+D.+Wolchokauthor=P.+B.+Chapmanauthor=R.+J.+Sullivanauthor=J.+B.+Teitcherauthor=N.+Ramaiyaauthor=A.+Giobbie-Hurderauthor=C.+R.+Antonescuauthor=M.+C.+Heinrichauthor=B.+C.+Bastianauthor=C.+L.+Corlessauthor=J.+A.+Fletcherauthor=F.+S.+Hodi&title=Phase+ii+study+of+nilotinib+in+melanoma+harboring+kit+alterations+following+progression+to+prior+kit+inhibition&doi=10.1158%2F1078-0432.CCR-14-1630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition</span></div><div class="casAuthors">Carvajal, Richard D.; Lawrence, Donald P.; Weber, Jeffrey S.; Gajewski, Thomas F.; Gonzalez, Rene; Lutzky, Jose; O'Day, Steven J.; Hamid, Omid; Wolchok, Jedd D.; Chapman, Paul B.; Sullivan, Ryan J.; Teitcher, Jerrold B.; Ramaiya, Nikhil; Giobbie-Hurder, Anita; Antonescu, Cristina R.; Heinrich, Michael C.; Bastian, Boris C.; Corless, Christopher L.; Fletcher, Jonathan A.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2289-2296</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases are unknown.  Exptl. Design: We conducted a phase II study of nilotinib 400 mg twice a day in two cohorts of patients with melanomas harboring KIT mutations or amplification: (A) those refractory or intolerant to a prior KIT inhibitor; and (B) those with brain metastases.  The primary endpoint was 4-mo disease control rate.  Secondary endpoints included response rate, time-to-progression (TTP), and overall survival (OS).  A Simon two-stage and a single-stage design was planned to assess for the primary endpoint in cohorts A and B, resp.  Results: Twenty patients were enrolled and 19 treated (11 in cohort A; 8 in cohort B).  Three patients on cohort A [27%; 95% confidence interval (CI), 8%-56%] and 1 on cohort B (12.5%; 90% CI, 0.6%-47%) achieved the primary endpoint.  Two partial responses were obsd. in cohort A (18.2%; 90% CI, 3%-47%); none were obsd. in cohort B. The median TTP and OS was 3.3 (90% CI, 2.1-3.9 mo) and 9.1 mo (90% CI, 4.3-14.2 mo), resp., in all treated patients.  Conclusions: Nilotinib may achieve disease control in patients with melanoma harboring KIT alterations and whose disease progressed after imatinib therapy.  The efficacy of this agent in KIT-altered melanoma with brain metastasis is limited.  Clin Cancer Res; 21(10); 2289-96. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0uI0vh_bEsLVg90H21EOLACvtfcHk0li30nOe08Ay2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOktbY%253D&md5=317cf98d4a3ea47bd52f7f4509cd61da</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1630%26sid%3Dliteratum%253Aachs%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DLawrence%26aufirst%3DD.%2BP.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DLutzky%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DTeitcher%26aufirst%3DJ.%2BB.%26aulast%3DRamaiya%26aufirst%3DN.%26aulast%3DGiobbie-Hurder%26aufirst%3DA.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DPhase%2520ii%2520study%2520of%2520nilotinib%2520in%2520melanoma%2520harboring%2520kit%2520alterations%2520following%2520progression%2520to%2520prior%2520kit%2520inhibition%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2289%26epage%3D2296%26doi%3D10.1158%2F1078-0432.CCR-14-1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Curtin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, B. C.</span><span> </span><span class="NLM_article-title">Somatic activation of kit in distinct subtypes of melanoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4340</span><span class="NLM_x">–</span> <span class="NLM_lpage">4246</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.2984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1200%2FJCO.2006.06.2984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=16908931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGju7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4340-4246&author=J.+A.+Curtinauthor=K.+Busamauthor=D.+Pinkelauthor=B.+C.+Bastian&title=Somatic+activation+of+kit+in+distinct+subtypes+of+melanoma&doi=10.1200%2FJCO.2006.06.2984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic activation of KIT in distinct subtypes of melanoma</span></div><div class="casAuthors">Curtin, John A.; Busam, Klaus; Pinkel, Daniel; Bastian, Boris C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4340-4346</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Melanomas on mucosal membranes, acral skin (soles, palms, and nail bed), and skin with chronic sun-induced damage have infrequent mutations in BRAF and NRAS, genes within the mitogen-activated protein (MAP) kinase pathway commonly mutated in melanomas on intermittently sun-exposed skin.  This raises the question of whether other aberrations are occurring in the MAP kinase cascade in the melanoma types with infrequent mutations of BRAF and NRAS.  We analyzed array comparative genomic hybridization data from 102 primary melanomas (38 from mucosa, 28 from acral skin, and 18 from skin with and 18 from skin without chronic sun-induced damage) for DNA copy no. aberrations specific to melanoma subtypes where mutations in BRAF and NRAS are infrequent.  A narrow amplification on 4q12 was found, and candidate genes within it were analyzed.  Oncogenic mutations in KIT were found in three of seven tumors with amplifications.  Examn. of all 102 primary melanomas found mutations and/or copy no. increases of KIT in 39% of mucosal, 36% of acral, and 28% of melanomas on chronically sun-damaged skin, but not in any (0%) melanomas on skin without chronic sun damage.  Seventy-nine percent of tumors with mutations and 53% of tumors with multiple copies of KIT demonstrated increased KIT protein levels.  KIT is an important oncogene in melanoma.  Because the majority of the KIT mutations we found in melanoma also occur in imatinib-responsive cancers of other types, imatinib may offer an immediate therapeutic benefit for a significant proportion of the global melanoma burden.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmjtnnmCP8IbVg90H21EOLACvtfcHk0li30nOe08Ay2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGju7bM&md5=daf0bb9b2dfabc78170cb5e596a402e2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2984%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DJ.%2BA.%26aulast%3DBusam%26aufirst%3DK.%26aulast%3DPinkel%26aufirst%3DD.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26atitle%3DSomatic%2520activation%2520of%2520kit%2520in%2520distinct%2520subtypes%2520of%2520melanoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4340%26epage%3D4246%26doi%3D10.1200%2FJCO.2006.06.2984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Ashman, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, R.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of c-kit in cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1517/13543784.2013.740010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1517%2F13543784.2013.740010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23127174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWqtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=103-115&author=L.+K.+Ashmanauthor=R.+Griffith&title=Therapeutic+targeting+of+c-kit+in+cancer&doi=10.1517%2F13543784.2013.740010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of c-KIT in cancer</span></div><div class="casAuthors">Ashman, Leonie K.; Griffith, Renate</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-115</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Mutated forms of the receptor tyrosine kinase c-KIT are "drivers" in several cancers and are attractive targets for therapy.  While benefits have been obtained from use of inhibitors of KIT kinase activity such as imatinib, esp. in gastrointestinal stromal tumors (GIST), primary resistance occurs with certain oncogenic mutations.  Furthermore, resistance frequently develops due to secondary mutations.  Approaches to addressing both of these issues as well as combination therapies to optimize use of KIT kinase inhibitors are discussed.Areas covered: This review covers the occurrence of oncogenic KIT mutations in different cancers and the mol. basis of their action.  The action of KIT kinase inhibitors, esp. imatinib, sunitinib, dasatinib and PKC412, on different primary and secondary mutants is discussed.  Outcomes of clin. trials in GIST, acute myeloid leukemia (AML), systemic mastocytosis and melanoma and their implications for future directions are considered.Expert opinion: Anal. of KIT mutations in individual patients is an essential prerequisite to the use of kinase inhibitors for therapy, and monitoring for development of secondary mutations that confer drug resistance is necessary.  However, it is unlikely that KIT inhibitors alone can lead to cure.  KIT mutations alone do not seem to be sufficient for transformation; thus identification and co-targeting of synergistic oncogenic pathways should lead to improved outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYeFNMHL4QSrVg90H21EOLACvtfcHk0li30nOe08Ay2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWqtbbI&md5=9e653c915071f0e90cf366bcb2b51be9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.740010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.740010%26sid%3Dliteratum%253Aachs%26aulast%3DAshman%26aufirst%3DL.%2BK.%26aulast%3DGriffith%26aufirst%3DR.%26atitle%3DTherapeutic%2520targeting%2520of%2520c-kit%2520in%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D103%26epage%3D115%26doi%3D10.1517%2F13543784.2013.740010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Abbaspour Babaei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamalidehghan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huri, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadipour, F.</span><span> </span><span class="NLM_article-title">Receptor tyrosine kinase (c-kit) inhibitors: A potential therapeutic target in cancer cells</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2459</span><span class="refDoi"> DOI: 10.2147/DDDT.S89114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.2147%2FDDDT.S89114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=27536065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=2443-2459&author=M.+Abbaspour+Babaeiauthor=B.+Kamalidehghanauthor=M.+Saleemauthor=H.+Z.+Huriauthor=F.+Ahmadipour&title=Receptor+tyrosine+kinase+%28c-kit%29+inhibitors%3A+A+potential+therapeutic+target+in+cancer+cells&doi=10.2147%2FDDDT.S89114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells</span></div><div class="casAuthors">Abbaspour Babaei Maryam; Ahmadipour Fatemeh; Kamalidehghan Behnam; Saleem Mohammad; Huri Hasniza Zaman</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2443-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">c-Kit, a receptor tyrosine kinase, is involved in intracellular signaling, and the mutated form of c-Kit plays a crucial role in occurrence of some cancers.  The function of c-Kit has led to the concept that inhibiting c-Kit kinase activity can be a target for cancer therapy.  The promising results of inhibition of c-Kit for treatment of cancers have been observed in some cancers such as gastrointestinal stromal tumor, acute myeloid leukemia, melanoma, and other tumors, and these results have encouraged attempts toward improvement of using c-Kit as a capable target for cancer therapy.  This paper presents the findings of previous studies regarding c-Kit as a receptor tyrosine kinase and an oncogene, as well as its gene targets and signaling pathways in normal and cancer cells.  The c-Kit gene location, protein structure, and the role of c-Kit in normal cell have been discussed.  Comprehending the molecular mechanism underlying c-Kit-mediated tumorogenesis is consequently essential and may lead to the identification of future novel drug targets.  The potential mechanisms by which c-Kit induces cellular transformation have been described.  This study aims to elucidate the function of c-Kit for future cancer therapy.  In addition, it has c-Kit inhibitor drug properties and their functions have been listed in tables and demonstrated in schematic pictures.  This review also has collected previous studies that targeted c-Kit as a novel strategy for cancer therapy.  This paper further emphasizes the advantages of this approach, as well as the limitations that must be addressed in the future.  Finally, although c-Kit is an attractive target for cancer therapy, based on the outcomes of treatment of patients with c-Kit inhibitors, it is unlikely that Kit inhibitors alone can lead to cure.  It seems that c-Kit mutations alone are not sufficient for tumorogenesis, but do play a crucial role in cancer occurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfTnK2L7idhRwLZxei1HN8fW6udTcc2ea448wWtOKGPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D&md5=c45d232471e049dc8d42a98fc5aa1d76</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S89114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S89114%26sid%3Dliteratum%253Aachs%26aulast%3DAbbaspour%2BBabaei%26aufirst%3DM.%26aulast%3DKamalidehghan%26aufirst%3DB.%26aulast%3DSaleem%26aufirst%3DM.%26aulast%3DHuri%26aufirst%3DH.%2BZ.%26aulast%3DAhmadipour%26aufirst%3DF.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520%2528c-kit%2529%2520inhibitors%253A%2520A%2520potential%2520therapeutic%2520target%2520in%2520cancer%2520cells%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D2443%26epage%3D2459%26doi%3D10.2147%2FDDDT.S89114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Poveda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sevilla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecumberri, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Beveridge, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estival, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicente, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubió, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Broto, J.</span><span> </span><span class="NLM_article-title">Seom clinical guideline for gastrointestinal sarcomas (gist) (2016)</span> <span class="citation_source-journal">Clin. Transl. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1221</span><span class="NLM_x">–</span> <span class="NLM_lpage">1228</span><span class="refDoi"> DOI: 10.1007/s12094-016-1579-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1007%2Fs12094-016-1579-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=27896638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWms7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1221-1228&author=A.+Povedaauthor=V.+Martinezauthor=C.+Serranoauthor=I.+Sevillaauthor=M.+J.+Lecumberriauthor=R.+D.+de+Beveridgeauthor=A.+Estivalauthor=D.+Vicenteauthor=J.+Rubi%C3%B3author=J.+Martin-Broto&title=Seom+clinical+guideline+for+gastrointestinal+sarcomas+%28gist%29+%282016%29&doi=10.1007%2Fs12094-016-1579-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)</span></div><div class="casAuthors">Poveda, A.; Martinez, V.; Serrano, C.; Sevilla, I.; Lecumberri, M. J.; de Beveridge, R. D.; Estival, A.; Vicente, D.; Rubio, J.; Martin-Broto, J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1221-1228</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, and this disease has served as a paradigmatic model for successful rational development of targeted therapies.  The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies.  The Spanish Society of Medical Oncol. (SEOM) guidelines provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients.  We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in ref. centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5KtCyjpxGOrVg90H21EOLACvtfcHk0liGHlBt0WWfjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWms7nJ&md5=d96fe59f5b0d990e0713991b199d195d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs12094-016-1579-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-016-1579-9%26sid%3Dliteratum%253Aachs%26aulast%3DPoveda%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DV.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DSevilla%26aufirst%3DI.%26aulast%3DLecumberri%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BBeveridge%26aufirst%3DR.%2BD.%26aulast%3DEstival%26aufirst%3DA.%26aulast%3DVicente%26aufirst%3DD.%26aulast%3DRubi%25C3%25B3%26aufirst%3DJ.%26aulast%3DMartin-Broto%26aufirst%3DJ.%26atitle%3DSeom%2520clinical%2520guideline%2520for%2520gastrointestinal%2520sarcomas%2520%2528gist%2529%2520%25282016%2529%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2016%26volume%3D18%26spage%3D1221%26epage%3D1228%26doi%3D10.1007%2Fs12094-016-1579-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">The GIST paradigm: Lessons for other kinase-driven cancers</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">252</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1002/path.2798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1002%2Fpath.2798" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2011&pages=252-262&author=C.+R.+Antonescu&title=The+GIST+paradigm%3A+Lessons+for+other+kinase-driven+cancers&doi=10.1002%2Fpath.2798"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpath.2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2798%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DThe%2520GIST%2520paradigm%253A%2520Lessons%2520for%2520other%2520kinase-driven%2520cancers%26jtitle%3DJ.%2520Pathol.%26date%3D2011%26volume%3D223%26spage%3D252%26epage%3D262%26doi%3D10.1002%2Fpath.2798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Søreide, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandvik, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Søreide, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giljaca, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jureckova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulusu, V. R.</span><span> </span><span class="NLM_article-title">Global epidemiology of gastrointestinal stromal tumours (gist): A systematic review of population-based cohort studies</span> <span class="citation_source-journal">Cancer Epidemiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1016/j.canep.2015.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.canep.2015.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=26618334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A280%3ADC%252BC28vmtFeisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=39-46&author=K.+S%C3%B8reideauthor=O.+M.+Sandvikauthor=J.+A.+S%C3%B8reideauthor=V.+Giljacaauthor=A.+Jureckovaauthor=V.+R.+Bulusu&title=Global+epidemiology+of+gastrointestinal+stromal+tumours+%28gist%29%3A+A+systematic+review+of+population-based+cohort+studies&doi=10.1016%2Fj.canep.2015.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies</span></div><div class="casAuthors">Soreide Kjetil; Sandvik Oddvar M; Soreide Jon Arne; Giljaca Vanja; Jureckova Andrea; Bulusu V Ramesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer epidemiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Gastrointestinal stromal tumours (GISTs) are rare, yet the most common mesenchymal tumour within the digestive tract.  Lack of diagnostic criteria and no specific code in the ICD system has prevented epidemiological evaluation except from overt malignant cases in the past.  A global estimate of incidence and disease patterns has thus not been available.  METHODS:  A systematic literature search of all available population-based studies on GIST published between January 2000 and December 2014 were reviewed.  Descriptive epidemiological data are presented.  RESULTS:  The search found 29 studies of more than 13,550 patients from 19 countries that reported sufficient data for regional or national population-based statistics.  Age at diagnosis ranged from 10 to 100 years, with median age being mid 60s across most studies.  Gender distribution was equal across studies.  On average, 18% of patients had an incidental diagnosis (range from 5% to 40%).  Anatomical location of primary tumour in 9747 GISTs demonstrated gastric location as the most frequent (55.6%) followed by small bowel (31.8%), colorectal (6.0%), other/various location (5.5%) and oesophagus (0.7%).  Most studies reported incidence at 10-15 per million per year.  Notably, lowest incidence was in China (Shanxi province) with 4.3 per million per year.  Highest incidence rates were reported also from China (Hong Kong and Shanghai areas), and in Taiwan and Norway (Northern part), with up to 19-22 per million per year.  CONCLUSIONS:  Epidemiology of GIST demonstrates some consistent features across geographical regions.  Whether the reported extreme differences in incidence reflect real variation in population risk warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQbNna3Ac64v_I8Jvzw4xCfW6udTcc2eYkwOzT707Zibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vmtFeisg%253D%253D&md5=9f67bfc194b674715c083ad06e3a1101</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.canep.2015.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canep.2015.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B8reide%26aufirst%3DK.%26aulast%3DSandvik%26aufirst%3DO.%2BM.%26aulast%3DS%25C3%25B8reide%26aufirst%3DJ.%2BA.%26aulast%3DGiljaca%26aufirst%3DV.%26aulast%3DJureckova%26aufirst%3DA.%26aulast%3DBulusu%26aufirst%3DV.%2BR.%26atitle%3DGlobal%2520epidemiology%2520of%2520gastrointestinal%2520stromal%2520tumours%2520%2528gist%2529%253A%2520A%2520systematic%2520review%2520of%2520population-based%2520cohort%2520studies%26jtitle%3DCancer%2520Epidemiol.%26date%3D2016%26volume%3D40%26spage%3D39%26epage%3D46%26doi%3D10.1016%2Fj.canep.2015.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhammad, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=T.+G.+Muhammadauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0ljK1935S6ysGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%26aufirst%3DT.%2BG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">PDGFRA activating mutations in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span><span class="refDoi"> DOI: 10.1126/science.1079666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1126%2Fscience.1079666" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=708-710&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=A.+Duensingauthor=L.+McGreeveyauthor=C.+J.+Chenauthor=N.+Josephauthor=S.+Singerauthor=D.+J.+Griffithauthor=A.+Haleyauthor=A.+Townauthor=G.+D.+Demetriauthor=C.+D.+Fletcherauthor=J.+A.+Fletcher&title=PDGFRA+activating+mutations+in+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.1079666"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079666%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DPDGFRA%2520activating%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D708%26epage%3D710%26doi%3D10.1126%2Fscience.1079666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Kit mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1567</span><span class="NLM_x">–</span> <span class="NLM_lpage">1572</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)61103-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0002-9440%2810%2961103-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=12000708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVKrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2002&pages=1567-1572&author=C.+L.+Corlessauthor=L.+McGreeveyauthor=A.+Haleyauthor=A.+Townauthor=M.+C.+Heinrich&title=Kit+mutations+are+common+in+incidental+gastrointestinal+stromal+tumors+one+centimeter+or+less+in+size&doi=10.1016%2FS0002-9440%2810%2961103-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size</span></div><div class="casAuthors">Corless, Christopher L.; McGreevey, Laura; Haley, Andrea; Town, Ajia; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1567-1572</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms of the gut wall that express the receptor Tyr kinase KIT.  Somatic mutations that result in constitutive activation of KIT kinase were identified in a no. of studies of GISTs, although the reported frequency of these mutations has varied over a wide range (20 to 92%).  Several reports have suggested that KIT gene mutations are more common in malignant GISTs than in benign lesions, and it was proposed that mutations in exon 11 of KIT are a neg. prognostic factor.  To maximize sensitivity for KIT mutations the authors have adapted denaturing high-pressure liq. chromatog. as a method for screening PCR amplimers of exons 9, 11, 13, and 17 from GIST genomic DNA.  This approach was used to assess the frequency of KIT mutations in 13 morphol. benign, incidentally discovered, GISTs identified at autopsy, endoscopy, or laparotomy for unrelated disease.  Representing the smallest pathol. recognizable GISTs, these lesions ranged in size from 4 to 10 mm in diam. and were all immunohistochem. pos. for KIT.  11 Of the 13 tumors had sequence-confirmed mutations in KIT, including 10 mutations in exon 11 (77%) and one mutation in exon 9 (7.7%).  The remaining 2 tumors were wild type for exons 9, 11, and 17; one of these was also analyzed for exon 13 and was wild type in this exon as well.  The mutations found in the incidental GISTs were identical to those that were documented in larger GISTs.  In addn., the overall frequency of mutations in the incidental tumors (85%) did not differ significantly from that the authors previously reported in a series of 72 advanced/metastatic GISTs (86%), strongly supporting the view that activating mutations in KIT are acquired very early in the development of most GISTs.  The findings suggest that KIT mutations per se are of little prognostic importance in GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0Z6pTmQr7LVg90H21EOLACvtfcHk0lj5cnzOR-pRMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVKrt7c%253D&md5=6bd426c9c39db050d7f6008384cd9fcb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2961103-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252961103-0%26sid%3Dliteratum%253Aachs%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DKit%2520mutations%2520are%2520common%2520in%2520incidental%2520gastrointestinal%2520stromal%2520tumors%2520one%2520centimeter%2520or%2520less%2520in%2520size%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2002%26volume%3D160%26spage%3D1567%26epage%3D1572%26doi%3D10.1016%2FS0002-9440%2810%2961103-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogendoorn, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1016/S0140-6736(04)17098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2804%2917098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.+Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-free+survival+in+gastrointestinal+stromal+tumours+with+high-dose+imatinib%3A+Randomised+trial&doi=10.1016%2FS0140-6736%2804%2917098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917098-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-free%2520survival%2520in%2520gastrointestinal%2520stromal%2520tumours%2520with%2520high-dose%2520imatinib%253A%2520Randomised%2520trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D1127%26epage%3D1134%26doi%3D10.1016%2FS0140-6736%2804%2917098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumours: Origin and molecular oncology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">865</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span><span class="refDoi"> DOI: 10.1038/nrc3143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Fnrc3143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=22089421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOisb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=865-878&author=C.+L.+Corlessauthor=C.+M.+Barnettauthor=M.+C.+Heinrich&title=Gastrointestinal+stromal+tumours%3A+Origin+and+molecular+oncology&doi=10.1038%2Fnrc3143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumours: origin and molecular oncology</span></div><div class="casAuthors">Corless, Christopher L.; Barnett, Christine M.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">865-878</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are a paradigm for the development of personalized treatment for cancer patients.  The nearly simultaneous discovery of a biomarker that is reflective of their origin and the presence of gain-of-function kinase mutations in these tumors set the stage for more accurate diagnosis and the development of kinase inhibitor therapy.  Subsequent studies of genotype and phenotype have led to a mol. classification of GIST and to treatment optimization on the basis of mol. subtype.  The study of drug-resistant tumors has advanced our understanding of kinase biol., enabling the development of novel kinase inhibitors.  Further improvements in GIST treatment may require targeting GIST stem cell populations and/or addnl. genomic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY7ze-9Y_FbVg90H21EOLACvtfcHk0lj5cnzOR-pRMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOisb3I&md5=345c2287f7cdf8775b2a05114ccf5563</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrc3143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3143%26sid%3Dliteratum%253Aachs%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBarnett%26aufirst%3DC.%2BM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DGastrointestinal%2520stromal%2520tumours%253A%2520Origin%2520and%2520molecular%2520oncology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D865%26epage%3D878%26doi%3D10.1038%2Fnrc3143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Jensen, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilfillan, A. M.</span><span> </span><span class="NLM_article-title">Pharmacological targeting of the kit growth factor receptor: A therapeutic consideration for mast cell disorders</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1572</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1038/bjp.2008.204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Fbjp.2008.204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=18500355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1572-82&author=B.+M.+Jensenauthor=C.+Akinauthor=A.+M.+Gilfillan&title=Pharmacological+targeting+of+the+kit+growth+factor+receptor%3A+A+therapeutic+consideration+for+mast+cell+disorders&doi=10.1038%2Fbjp.2008.204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders</span></div><div class="casAuthors">Jensen, B. M.; Akin, C.; Gilfillan, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1572-1582</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  KIT is a member of the tyrosine kinase family of growth factor receptors which is expressed on a variety of hematopoietic cells including mast cells.  Stem cell factor (SCF)-dependent activation of KIT is crit. for mast cell homeostasis and function.  However, when KIT is inappropriately activated, accumulation of mast cells in tissues results in mastocytosis.  Such dysregulated KIT activation is a manifestation of specific activating point mutations within KIT, with the human D816V mutation considered as a hallmark of human systemic mastocytosis.  A no. of other activating mutations in KIT have recently been identified and these mutations may also contribute to aberrant mast cell growth.  In addn. to its role in mast cell growth, differentiation and survival, localized concn. gradients of SCF may control the targeting of mast cells to specific tissues and, once resident within these tissues, mast cell activation by antigen may also be amplified by SCF.  Thus, KIT inhibitors may have potential application in multiple conditions linked to mast cells including systemic mastocytosis, anaphylaxis, and asthma.  In this review, we discuss the role of KIT in the context of mast cells in these disease states and how recent advances in the development of inhibitors of KIT activity and function may offer novel therapies for the treatment of these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohk3jlK_jsBLVg90H21EOLACvtfcHk0lhpmVScdGXDOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Grur8%253D&md5=15f0bd37c493278fbc58c2a2d33348f4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.204%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DB.%2BM.%26aulast%3DAkin%26aufirst%3DC.%26aulast%3DGilfillan%26aufirst%3DA.%2BM.%26atitle%3DPharmacological%2520targeting%2520of%2520the%2520kit%2520growth%2520factor%2520receptor%253A%2520A%2520therapeutic%2520consideration%2520for%2520mast%2520cell%2520disorders%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1572%26epage%3D82%26doi%3D10.1038%2Fbjp.2008.204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Gramza, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7510</span><span class="NLM_x">–</span> <span class="NLM_lpage">7518</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F1078-0432.CCR-09-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=20008851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGgurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=7510-7518&author=A.+W.+Gramzaauthor=C.+L.+Corlessauthor=M.+C.+Heinrich&title=Resistance+to+tyrosine+kinase+inhibitors+in+gastrointestinal+stromal+tumors&doi=10.1158%2F1078-0432.CCR-09-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Gramza, Ann W.; Corless, Christopher L.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7510-7518</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GIST) are the most common type of sarcoma in the gastrointestinal tract.  Surgery is the primary treatment modality, but many patients suffer disease recurrence or metastasis.  Fortunately, the management of advanced GIST has been revolutionized by the use of small mol. kinase inhibitors that target the underlying pathogenetic mutant kinases found in the vast majority of cases.  Approx. 85% of GISTs have oncogenic mutations in KIT, allowing for constitutive kinase activation that is responsible for cellular proliferation and survival.  About 5 to 7% of GISTs have activating mutations of the homologous platelet-derived growth factor receptor alpha (PDGFRA) kinase.  The progression-free and overall survival of patients with advanced disease is greatly improved by treatment with the kinase inhibitors imatinib and sunitinib.  However, the emergence of drug-resistant tumor clones limits the long-term benefit of these drugs in most patients.  Resistance to these kinase inhibitors is assocd. with distinctive clin. and mol. features, with the development of secondary mutations of the oncogenic kinase being the most common mechanism.  We review the mol. basis of GIST response and/or resistance to TKIs, and discuss strategies to prevent and/or overcome drug resistance.  These concepts are directly relevant to the development of targeted mol. therapy for other solid tumors. (Clin Cancer Res 2009;15(24):7510-8).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGTFj7EbnBtLVg90H21EOLACvtfcHk0lhpmVScdGXDOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGgurrO&md5=1c61da01fe3c61ff7f099b0defd50526</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0190%26sid%3Dliteratum%253Aachs%26aulast%3DGramza%26aufirst%3DA.%2BW.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DResistance%2520to%2520tyrosine%2520kinase%2520inhibitors%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D7510%26epage%3D7518%26doi%3D10.1158%2F1078-0432.CCR-09-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumour</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">382</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">983</span><span class="refDoi"> DOI: 10.1016/S0140-6736(13)60106-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2813%2960106-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23623056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFCmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2013&pages=973-983&author=H.+Joensuuauthor=P.+Hohenbergerauthor=C.+L.+Corless&title=Gastrointestinal+stromal+tumour&doi=10.1016%2FS0140-6736%2813%2960106-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu, Heikki; Hohenberger, Peter; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">9896</span>),
    <span class="NLM_cas:pages">973-983</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that arise in the gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in the abdomen.  They can occur at any age, the median age being 60-65 years, and typically cause bleeding, anemia, and pain.  GISTs have variable malignant potential, ranging from small lesions with a benign behavior to fatal sarcomas.  Most tumors stain pos. for the mast/stem cell growth factor receptor KIT and anoctamin 1 and harbor a kinase-activating mutation in either KIT or PDGFRA.  Tumors without such mutations could have alterations in genes of the succinate dehydrogenase complex or in BRAF, or rarely RAS family genes.  About 60% of patients are cured by surgery.  Adjuvant treatment with imatinib is recommended for patients with a substantial risk of recurrence, if the tumor has an imatinib-sensitive mutation.  Tyrosine kinase inhibitors substantially improve survival in advanced disease, but secondary drug resistance is common.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUnoEP2zf4WbVg90H21EOLACvtfcHk0lgeywfyJ29vhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFCmu74%253D&md5=11113c24bdb425aac4341372dea2e9bc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2960106-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252960106-3%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DGastrointestinal%2520stromal%2520tumour%26jtitle%3DLancet%26date%3D2013%26volume%3D382%26spage%3D973%26epage%3D983%26doi%3D10.1016%2FS0140-6736%2813%2960106-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Zimmermann, J.</span><span> </span><span class="NLM_article-title">Pyrimidin derivatives and process for their preparation</span>. EP0564409B1, 19.01.2000,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=J.+Zimmermann&title=Pyrimidin+derivatives+and+process+for+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26atitle%3DPyrimidin%2520derivatives%2520and%2520process%2520for%2520their%2520preparation%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Sun, C. L.; Wei, C. C.; Tang, P. C.; Koenig, M.; Zhou, Y.; Vojkovsky, T.; Nematalla, A. S.</span><span> </span><span class="NLM_article-title">Prodrugs of a 3-(pyrrolo-2-ylmethylidene)-2-indolinobne derivatives</span>. US 2003/0100555 A1, 29.05.2003,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=C.+L.+Sun&author=C.+C.+Wei&author=P.+C.+Tang&author=M.+Koenig&author=Y.+Zhou&author=T.+Vojkovsky&author=A.+S.+Nematalla&title=Prodrugs+of+a+3-%28pyrrolo-2-ylmethylidene%29-2-indolinobne+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%2BL.%26atitle%3DProdrugs%2520of%2520a%25203-%2528pyrrolo-2-ylmethylidene%2529-2-indolinobne%2520derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Boyer, S.; Dumas, J.; Phillips, B.; Scott, W. J.; Smith, R. A.; Chen, J.; Jones, B.; Wang, G.</span><span> </span><span class="NLM_article-title">2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders</span>. WO2004078746 A3, 01.03.2004,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=S.+Boyer&author=J.+Dumas&author=B.+Phillips&author=W.+J.+Scott&author=R.+A.+Smith&author=J.+Chen&author=B.+Jones&author=G.+Wang&title=2-Oxo-1%2C3%2C5-perhydrotriazapine+derivatives+useful+in+the+treatment+of+hyper-proliferative%2C+angiogenesis%2C+and+inflammatory+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DS.%26atitle%3D2-Oxo-1%252C3%252C5-perhydrotriazapine%2520derivatives%2520useful%2520in%2520the%2520treatment%2520of%2520hyper-proliferative%252C%2520angiogenesis%252C%2520and%2520inflammatory%2520disorders%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cioffi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno-Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Abl protein-tyrosine kinase inhibitor sti571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10991971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ygur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=139-145&author=E.+Buchdungerauthor=C.+L.+Cioffiauthor=N.+Lawauthor=D.+Stoverauthor=S.+Ohno-Jonesauthor=B.+J.+Drukerauthor=N.+B.+Lydon&title=Abl+protein-tyrosine+kinase+inhibitor+sti571+inhibits+in+vitro+signal+transduction+mediated+by+c-kit+and+platelet-derived+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors</span></div><div class="casAuthors">Buchdunger, Elisabeth; Cioffi, Catherine L.; Law, Norman; Stover, David; Ohno-Jones, Sayuri; Druker, Brian J.; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139-145</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">STI571 (formerly known as CGP 57148B) is a protein-tyrosine kinase inhibitor that is currently in clin. trials for the treatment of chronic myelogenous leukemia.  STI571 selectively inhibits the Abl and platelet-derived growth factor (PDGF) receptor tyrosine kinases in vitro and blocks cellular proliferation and tumor growth of Bcr-abl- or v-abl-expressing cells.  We have further investigated the profile of STI571 against related receptor tyrosine kinases.  STI571 was found to potently inhibit the kinase activity of the α- and β-PDGF receptors and the receptor for stem cell factor, but not the closely related c-Fms, Flt-3, Kdr, Flt-1, and Tek tyrosine kinases.  Addnl., no inhibition of c-Met or nonreceptor tyrosine kinases such as Src and Jak-2 has been obsd.  In cell-based assays, STI571 selectively inhibited PDGF and stem cell factor-mediated cellular signaling, including ligand-stimulated receptor autophosphorylation, inositol phosphate formation, and mitogen-activated protein kinase activation and proliferation.  These results expand the profile of STI571 and suggest that in addn. to chronic myelogenous leukemia, STI571 may have clin. potential in the treatment of diseases that involve abnormal activation of c-Kit or PDGF receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogymen0UOTarVg90H21EOLACvtfcHk0lgeywfyJ29vhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ygur4%253D&md5=b15a49df360ae0d00c34f7cc5d3b0fe8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DLaw%26aufirst%3DN.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DOhno-Jones%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DAbl%2520protein-tyrosine%2520kinase%2520inhibitor%2520sti571%2520inhibits%2520in%2520vitro%2520signal%2520transduction%2520mediated%2520by%2520c-kit%2520and%2520platelet-derived%2520growth%2520factor%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D139%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3z)-ylidenemethyl]-2,4- dimethyl-1h-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span><span class="refDoi"> DOI: 10.1021/jm0204183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.+Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1h-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase&doi=10.1021%2Fjm0204183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0liIT8HogRyAjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.%2BY.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1h-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119%26doi%3D10.1021%2Fjm0204183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierauch, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zopf, D.</span><span> </span><span class="NLM_article-title">Regorafenib (bay 73–4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1002/ijc.25864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1002%2Fijc.25864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=21170960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=245-255&author=S.+M.+Wilhelmauthor=J.+Dumasauthor=L.+Adnaneauthor=M.+Lynchauthor=C.+A.+Carterauthor=G.+Schutzauthor=K.+H.+Thierauchauthor=D.+Zopf&title=Regorafenib+%28bay+73%E2%80%934506%29%3A+A+new+oral+multikinase+inhibitor+of+angiogenic%2C+stromal+and+oncogenic+receptor+tyrosine+kinases+with+potent+preclinical+antitumor+activity&doi=10.1002%2Fijc.25864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity</span></div><div class="casAuthors">Wilhelm, Scott M.; Dumas, Jacques; Adnane, Lila; Lynch, Mark; Carter, Christopher A.; Schuetz, Gunnar; Thierauch, Karl-Heinz; Zopf, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-255</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Angiogenesis, a crit. driver of tumor development, is controlled by interconnected signaling pathways.  Vascular endothelial growth factor receptor (VEGFR) 2 and tyrosine kinase with Ig and epidermal growth factor homol. domain 2 play crucial roles in the biol. of normal and tumor vasculature.  Regorafenib (BAY 73-4506), a novel oral multikinase inhibitor, potently inhibits these endothelial cell kinases in biochem. and cellular kinase phosphorylation assays.  Furthermore, regorafenib inhibits addnl. angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF.  The antiangiogenic effect of regorafenib was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging.  Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts.  In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 h after the last dosing and correlated with tumor growth inhibition (TGI).  A significant redn. in tumor microvessel area was obsd. in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg.  Regorafenib exhibited potent dose-dependent TGI in various preclin. human xenograft models in mice, with tumor shrinkages obsd. in breast MDA-MB-231 and renal 786-O carcinoma models.  Pharmacodynamic analyses of the breast model revealed strong redn. in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2.  These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQpQXfCq04rVg90H21EOLACvtfcHk0liIT8HogRyAjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGlu7c%253D&md5=13eee29ef1f1f03fd1ed311ea613f566</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fijc.25864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25864%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DSchutz%26aufirst%3DG.%26aulast%3DThierauch%26aufirst%3DK.%2BH.%26aulast%3DZopf%26aufirst%3DD.%26atitle%3DRegorafenib%2520%2528bay%252073%25E2%2580%25934506%2529%253A%2520A%2520new%2520oral%2520multikinase%2520inhibitor%2520of%2520angiogenic%252C%2520stromal%2520and%2520oncogenic%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520preclinical%2520antitumor%2520activity%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D245%26epage%3D255%26doi%3D10.1002%2Fijc.25864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Carroll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno-Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing bcr-abl, tel-abl, and tel-pdgfr fusion proteins</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">4947</span><span class="NLM_x">–</span> <span class="NLM_lpage">4952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1997&pages=4947-4952&author=M.+Carrollauthor=S.+Ohno-Jonesauthor=S.+Tamuraauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=N.+B.+Lydonauthor=D.+G.+Gillilandauthor=B.+J.+Druker&title=CGP+57148%2C+a+tyrosine+kinase+inhibitor%2C+inhibits+the+growth+of+cells+expressing+bcr-abl%2C+tel-abl%2C+and+tel-pdgfr+fusion+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DOhno-Jones%26aufirst%3DS.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DCGP%252057148%252C%2520a%2520tyrosine%2520kinase%2520inhibitor%252C%2520inhibits%2520the%2520growth%2520of%2520cells%2520expressing%2520bcr-abl%252C%2520tel-abl%252C%2520and%2520tel-pdgfr%2520fusion%2520proteins%26jtitle%3DBlood%26date%3D1997%26volume%3D90%26spage%3D4947%26epage%3D4952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Pogorzelski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falkenhorst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1097/CCO.0000000000000303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1097%2FCCO.0000000000000303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=27163723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFGksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&pages=331-337&author=M.+Pogorzelskiauthor=J.+Falkenhorstauthor=S.+Bauer&title=Molecular+subtypes+of+gastrointestinal+stromal+tumor+requiring+specific+treatments&doi=10.1097%2FCCO.0000000000000303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments</span></div><div class="casAuthors">Pogorzelski, Michael; Falkenhorst, Johanna; Bauer, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-337</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: This article reviews and discusses the current literature on how mol. subtyping of gastrointestinal stromal tumor (GIST) impacts decision-making in clin. practice.  Recent findings: Genotyping has not yet been used for prognostication of localized GIST.  Recent findings indicate that mutations in platelet-derived growth factor receptor alpha (PDGFRA) and stem cell growth factor receptor (KIT) exon 11 duplication mutations are assocd. with a favorable prognosis.  Subgroup analyses of randomized trials provide first evidence on how genotyping predicts clin. benefit in the adjuvant setting.  In the palliative setting, genotyping should be performed for dose selection but may also be relevant in patients who are intolerant to imatinib.  For patients whose tumors harbor the notoriously resistant D842V PDGFRA mutations, novel inhibitors have entered clin. trials, which may end the therapeutic deadlock.  Several novel targets have been identified that are currently being investigated in GIST, including inhibitors against fibroblast growth factor receptor, hepatocyte growth factor receptor, mitogen-activated protein, and phosphoinositide 3-kinase.  Preliminary clin. data suggest that predictive markers will be needed to define sensitive mol. subgroups.  Summary: Genotyping should be an integral part of clin. management of GIST as it aids in prognostication, prediction of efficacy, and selection of drugs and dosing.  Genotyping reduces the risk of both unnecessary adjuvant treatment as well as undertreatment and overtreatment in the palliative setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsPtEF-K010LVg90H21EOLACvtfcHk0lhViR0CobK1BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFGksLw%253D&md5=81c18afbb38bb139809ffed76358885b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2FCCO.0000000000000303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0000000000000303%26sid%3Dliteratum%253Aachs%26aulast%3DPogorzelski%26aufirst%3DM.%26aulast%3DFalkenhorst%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DMolecular%2520subtypes%2520of%2520gastrointestinal%2520stromal%2520tumor%2520requiring%2520specific%2520treatments%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2016%26volume%3D28%26spage%3D331%26epage%3D337%26doi%3D10.1097%2FCCO.0000000000000303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owzar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borden, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bramwell, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertagnolli, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Correlation of kinase genotype and clinical outcome in the north American intergroup phase iii trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: Calgb 150105 study by cancer and leukemia group b and southwest oncology group</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5360</span><span class="NLM_x">–</span> <span class="NLM_lpage">5367</span><span class="refDoi"> DOI: 10.1200/JCO.2008.17.4284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1200%2FJCO.2008.17.4284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=18955451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5360-5367&author=M.+C.+Heinrichauthor=K.+Owzarauthor=C.+L.+Corlessauthor=D.+Hollisauthor=E.+C.+Bordenauthor=C.+D.+Fletcherauthor=C.+W.+Ryanauthor=M.+Von+Mehrenauthor=C.+D.+Blankeauthor=C.+Rankinauthor=R.+S.+Benjaminauthor=V.+H.+Bramwellauthor=G.+D.+Demetriauthor=M.+M.+Bertagnolliauthor=J.+A.+Fletcher&title=Correlation+of+kinase+genotype+and+clinical+outcome+in+the+north+American+intergroup+phase+iii+trial+of+imatinib+mesylate+for+treatment+of+advanced+gastrointestinal+stromal+tumor%3A+Calgb+150105+study+by+cancer+and+leukemia+group+b+and+southwest+oncology+group&doi=10.1200%2FJCO.2008.17.4284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of kinase genotype and clinical outcome in the north American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group</span></div><div class="casAuthors">Heinrich, Michael C.; Owzar, Kouros; Corless, Christopher L.; Hollis, Donna; Borden, Ernest C.; Fletcher, Christopher D. M.; Ryan, Christopher W.; von Mehren, Margaret; Blanke, Charles D.; Rankin, Cathryn; Benjamin, Robert S.; Bramwell, Vivien H.; Demetri, George D.; Bertagnolli, Monica M.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5360-5367</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Imatinib mesylate is std. treatment for patients who have advanced gastrointestinal stromal tumor (GIST), but not all patients benefit equally.  In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing.  We examd. the relationship between kinase genotype and treatment outcome for 428 patients enrolled on the North American phase III study SWOG S0033/CALGB 150105 and treated with either 400 mg or 800 mg daily doses of imatinib.  The presence of KIT exon 11-mutant genotype (n = 283) correlated with improved treatment outcome when compared with KIT exon 9-mutant (n = 32) and wild-type (WT; n = 67) genotypes for objective response (complete response [CR]/partial response [PR], 71.7% v 44.4% [P = .007]; and 44.6% [P = .0002], resp.); time to tumor progression (TTP; median 24.7 mo v 16.7 and 12.8 mo, resp.); and overall survival (OS; median 60.0 mo v 38.4 and 49.0 mo, resp.).  The survival outcomes for patients with exon 9-mutant, exon 11-mutant or WT GIST were not affected by imatinib dose.  However, there was evidence of improved response rates for patients with exon 9-mutant tumors treated with imatinib 800 mg vs. 400 mg (CR/PR, 67% v 17%; P = .02).  Patients who had CD117-neg. GIST had similar TTP but inferior OS compared with patients who had CD117-pos. disease, which suggests that patients who have CD117-neg. GIST may benefit from imatinib treatment.  In addn., we identified novel but rare mutations of the KIT extracellular domain (exons 8 and 9).  We confirmed the favorable impact of KIT exon 11 genotype when compared with KIT exon 9 and wild-type genotype for patients with advanced GIST who are treated with imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEsXG_BaegR7Vg90H21EOLACvtfcHk0lhViR0CobK1BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCmug%253D%253D&md5=e172b60b8246817b8dd79fa23794f2fc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.17.4284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.17.4284%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DOwzar%26aufirst%3DK.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DHollis%26aufirst%3DD.%26aulast%3DBorden%26aufirst%3DE.%2BC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3DVon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DRankin%26aufirst%3DC.%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DBramwell%26aufirst%3DV.%2BH.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBertagnolli%26aufirst%3DM.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DCorrelation%2520of%2520kinase%2520genotype%2520and%2520clinical%2520outcome%2520in%2520the%2520north%2520American%2520intergroup%2520phase%2520iii%2520trial%2520of%2520imatinib%2520mesylate%2520for%2520treatment%2520of%2520advanced%2520gastrointestinal%2520stromal%2520tumor%253A%2520Calgb%2520150105%2520study%2520by%2520cancer%2520and%2520leukemia%2520group%2520b%2520and%2520southwest%2520oncology%2520group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5360%26epage%3D5367%26doi%3D10.1200%2FJCO.2008.17.4284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyvraz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeijer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Kit mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1103</span><span class="refDoi"> DOI: 10.1016/j.ejca.2006.01.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.ejca.2006.01.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=1093-1103&author=M.+Debiec-Rychterauthor=R.+Sciotauthor=A.+Le+Cesneauthor=M.+Schlemmerauthor=P.+Hohenbergerauthor=A.+T.+van+Oosteromauthor=J.+Y.+Blayauthor=S.+Leyvrazauthor=M.+Stulauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=J.+Verweijauthor=M.+Van+Glabbekeauthor=A.+Hagemeijerauthor=I.+Judson&title=Kit+mutations+and+dose+selection+for+imatinib+in+patients+with+advanced+gastrointestinal+stromal+tumours&doi=10.1016%2Fj.ejca.2006.01.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.01.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.01.030%26sid%3Dliteratum%253Aachs%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSchlemmer%26aufirst%3DM.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DLeyvraz%26aufirst%3DS.%26aulast%3DStul%26aufirst%3DM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DKit%2520mutations%2520and%2520dose%2520selection%2520for%2520imatinib%2520in%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D1093%26epage%3D1103%26doi%3D10.1016%2Fj.ejca.2006.01.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4774</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.2265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1200%2FJCO.2006.06.2265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=16954519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4764-4774&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+Von+Mehrenauthor=C.+D.+Fletcherauthor=K.+Sandauauthor=K.+McDougallauthor=W.+B.+Ouauthor=C.+J.+Chenauthor=J.+A.+Fletcher&title=Molecular+correlates+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1200%2FJCO.2006.06.2265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Blanke, Charles D.; Demetri, George D.; Joensuu, Heikki; Roberts, Peter J.; Eisenberg, Burton L.; von Mehren, Margaret; Fletcher, Christopher D. M.; Sandau, Katrin; McDougall, Karen; Ou, Wen-bin; Chen, Chang-Jie; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4764-4774</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT or platelet-derived growth factor alpha (PDGFRA) kinases, which are targets for imatinib.  In clin. studies, 75% to 90% of patients with advanced GISTs experience clin. benefit from imatinib.  However, imatinib resistance is an increasing clin. problem.  Patients and Methods One hundred forty-seven patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clin. study of imatinib.  Specimens from pretreatment and/or imatinib-resistant tumors were analyzed to identify mol. correlates of imatinib resistance.  Secondary kinase mutations of KIT or PDGFRA that were identified in imatinib-resistant GISTs were biochem. profiled for imatinib sensitivity.  Results Mol. studies were performed using specimens from 10 patients with primary and 33 patients with secondary resistance.  Imatinib-resistant tumors had levels of activated KIT that were similar to or greater than those typically found in untreated GISTs.  Secondary kinase mutations were rare in GISTs with primary resistance but frequently found in GISTs with secondary resistance (10% v 67%, P = .002).  Evidence for clonal evolution and/or polyclonal secondary kinase mutations was seen in three (18.8%) of 16 patients.  Secondary kinase mutations were nonrandomly distributed and were assocd. with decreased imatinib sensitivity compared with typical KIT exon 11 mutations.  Using RNAi technol., we demonstrated that imatinib-resistant GIST cells remain dependent on KIT kinase activity for activation of crit. downstream signaling pathways.  Conclusion Different mol. mechanisms are responsible for primary and secondary imatinib resistance in GISTs.  These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw_n35sjCddLVg90H21EOLACvtfcHk0lhViR0CobK1BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN&md5=25f7b94dd02d55c2fb56cea499cb7ab8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2265%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3DVon%2BMehren%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSandau%26aufirst%3DK.%26aulast%3DMcDougall%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520correlates%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4764%26epage%3D4774%26doi%3D10.1200%2FJCO.2006.06.2265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolova, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Long-term results from a randomized phase ii trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing kit</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">620</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1200/JCO.2007.13.4403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1200%2FJCO.2007.13.4403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=18235121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1alsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=620-625&author=C.+D.+Blankeauthor=G.+D.+Demetriauthor=M.+Von+Mehrenauthor=M.+C.+Heinrichauthor=B.+Eisenbergauthor=J.+A.+Fletcherauthor=C.+L.+Corlessauthor=C.+D.+Fletcherauthor=P.+J.+Robertsauthor=D.+Heinzauthor=E.+Wehreauthor=Z.+Nikolovaauthor=H.+Joensuu&title=Long-term+results+from+a+randomized+phase+ii+trial+of+standard-+versus+higher-dose+imatinib+mesylate+for+patients+with+unresectable+or+metastatic+gastrointestinal+stromal+tumors+expressing+kit&doi=10.1200%2FJCO.2007.13.4403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT</span></div><div class="casAuthors">Blanke, Charles D.; Demetri, George D.; von Mehren, Margaret; Heinrich, Michael C.; Eisenberg, Burton; Fletcher, Jonathan A.; Corless, Christopher I.; Fletcher, Christopher D. M.; Roberts, Peter J.; Heinz, Daniela; Wehre, Elisabeth; Nikolova, Zariana; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">620-625</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown.  A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST detailed high response rates at both the 400 and the 600 mg/d dose levels.  We conducted a long-term anal. of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status.  Patients and Methods: Patients with advanced GIST were enrolled onto an open-label, multicenter trial and were randomly assigned (1:1) to receive imatinib 400 vs. 600 mg/d.  Data were prospectively collected on KIT mutational status, total tumor area, and other potential prognostic factors.  Patients were followed for a median of 63 mo.  Results: One hundred forty-seven patients were enrolled: 73 were in arm A (imatinib 400 mg/d), and 74 were in arm B (imatinib 600 mg/d).  Response rates, median progression-free survival, and median overall survival were essentially identical on both arms, and median survival was 57 mo for all patients.  Forty-one patients overall (28%) remained on the drug long-term.  Female sex, the presence of an exon 11 mutation, and normal albumin and neutrophil levels were independently assocd. with better survival.  Conclusion: Nearly 50% of patients with advanced GIST who were treated with imatinib mesylate survived for more than 5 years, regardless of a 400 or 600 mg/d starting dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyVblFUfMWELVg90H21EOLACvtfcHk0lgqUSpNp8BufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1alsL0%253D&md5=c46d47e909e201a380a236246a2af159</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.4403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.4403%26sid%3Dliteratum%253Aachs%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DVon%2BMehren%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinz%26aufirst%3DD.%26aulast%3DWehre%26aufirst%3DE.%26aulast%3DNikolova%26aufirst%3DZ.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DLong-term%2520results%2520from%2520a%2520randomized%2520phase%2520ii%2520trial%2520of%2520standard-%2520versus%2520higher-dose%2520imatinib%2520mesylate%2520for%2520patients%2520with%2520unresectable%2520or%2520metastatic%2520gastrointestinal%2520stromal%2520tumors%2520expressing%2520kit%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D620%26epage%3D625%26doi%3D10.1200%2FJCO.2007.13.4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1338</span><span class="refDoi"> DOI: 10.1016/S0140-6736(06)69446-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2806%2969446-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=17046465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOrtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1329-1338&author=G.+D.+Demetriauthor=A.+T.+van+Oosteromauthor=C.+R.+Garrettauthor=M.+E.+Blacksteinauthor=M.+H.+Shahauthor=J.+Verweijauthor=G.+McArthurauthor=I.+R.+Judsonauthor=M.+C.+Heinrichauthor=J.+A.+Morganauthor=J.+Desaiauthor=C.+D.+Fletcherauthor=S.+Georgeauthor=C.+L.+Belloauthor=X.+Huangauthor=C.+M.+Baumauthor=P.+G.+Casali&title=Efficacy+and+safety+of+sunitinib+in+patients+with+advanced+gastrointestinal+stromal+tumour+after+failure+of+imatinib%3A+A+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2806%2969446-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span></div><div class="casAuthors">Demetri, George D.; van Oosterom, Allan T.; Garrett, Christopher R.; Blackstein, Martin E.; Shah, Manisha H.; Verweij, Jaap; McArthur, Grant; Judson, Ian R.; Heinrich, Michael C.; Morgan, Jeffrey A.; Desai, Jayesh; Fletcher, Christopher D.; George, Suzanne; Bello, Carlo L.; Huang, Xin; Baum, Charles M.; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9544</span>),
    <span class="NLM_cas:pages">1329-1338</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">No effective therapeutic options for patients with unresectable imatinib-resistant gastrointestinal stromal tumor are available.  We did a randomized, double-blind, placebo-controlled, multicenter, international trial to assess tolerability and anticancer efficacy of sunitinib, a multitargeted tyrosine kinase inhibitor, in patients with advanced gastrointestinal stromal tumor who were resistant to or intolerant of previous treatment with imatinib.  Blinded sunitinib or placebo was given orally once daily at a 50-mg starting dose in 6-wk cycles with 4 wk on and 2 wk off treatment.  The primary endpoint was time to tumor progression.  Intention-to-treat, modified intention-to-treat, and per-protocol analyses were done.  This study is registered at ClinicalTrials.gov, no. NCT00075218.  Three hundred and twelve patients were randomized in a 2:1 ratio to receive sunitinib (n = 207) or placebo (n=105); the trial was unblinded early when a planned interim anal. showed significantly longer time to tumor progression with sunitinib.  Median time to tumor progression was 27.3 wk (95% CI 16.0-32.1) in patients receiving sunitinib and 6.4 wk (4.4-10.0) in those on placebo (hazard ratio 0.33; p < 0.0001).  Therapy was reasonably well tolerated; the most common treatment-related adverse events were fatigue, diarrhea, skin discoloration, and nausea.  We noted significant clin. benefit, including disease control and superior survival, with sunitinib compared with placebo in patients with advanced gastrointestinal stromal tumor after failure and discontinuation of imatinib.  Tolerability was acceptable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6YRQ18H894LVg90H21EOLACvtfcHk0lgqUSpNp8BufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOrtL%252FL&md5=b21e01faede44c98f645be945c2638c0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969446-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969446-4%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sunitinib%2520in%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumour%2520after%2520failure%2520of%2520imatinib%253A%2520A%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1329%26epage%3D1338%26doi%3D10.1016%2FS0140-6736%2806%2969446-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badalamenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (grid): An international, multicentre, randomised, placebo-controlled, phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1016/S0140-6736(12)61857-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2812%2961857-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23177515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=295-302&author=G.+D.+Demetriauthor=P.+Reichardtauthor=Y.+K.+Kangauthor=J.+Y.+Blayauthor=P.+Rutkowskiauthor=H.+Gelderblomauthor=P.+Hohenbergerauthor=M.+Leahyauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=G.+Badalamentiauthor=M.+Blacksteinauthor=A.+Le+Cesneauthor=P.+Sch%C3%B6ffskiauthor=R.+G.+Makiauthor=S.+Bauerauthor=B.+B.+Nguyenauthor=J.+Xuauthor=T.+Nishidaauthor=J.+Chungauthor=C.+Kappelerauthor=I.+Kussauthor=D.+Laurentauthor=P.+G.+Casali&title=Efficacy+and+safety+of+regorafenib+for+advanced+gastrointestinal+stromal+tumours+after+failure+of+imatinib+and+sunitinib+%28grid%29%3A+An+international%2C+multicentre%2C+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961857-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">Demetri, George D.; Reichardt, Peter; Kang, Yoon-Koo; Blay, Jean-Yves; Rutkowski, Piotr; Gelderblom, Hans; Hohenberger, Peter; Leahy, Michael; von Mehren, Margaret; Joensuu, Heikki; Badalamenti, Giuseppe; Blackstein, Martin; Le Cesne, Axel; Schoffski, Patrick; Maki, Robert G.; Bauer, Sebastian; Nguyen, Binh Bui; Xu, Jianming; Nishida, Toshirou; Chung, John; Kappeler, Christian; Kuss, Iris; Laurent, Dirk; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">9863</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Until now, only imatinib and sunitinib have proven clin. benefit in patients with gastrointestinal stromal tumors (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression.  We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.We did this phase 3 trial at 57 hospitals in 17 countries.  Patients with histol. confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratified by treatment line and geog. region) to receive either oral regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 wk of each 4 wk cycle.  The study sponsor, participants, and investigators were masked to treatment assignment.  The primary endpoint was progression-free survival (PFS).  At disease progression, patients assigned placebo could crossover to open-label regorafenib.  Analyses were by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT01271712.From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib (n=133) or matching placebo (n=66).  Data cutoff was Jan 26, 2012.  Median PFS per independent blinded central review was 4·8 mo (IQR 1·4-9·2) for regorafenib and 0·9 mo (0·9-1·8) for placebo (hazard ratio [HR] 0·27, 95% CI 0·19-0·39; p<0·0001).  After progression, 56 patients (85%) assigned placebo crossed over to regorafenib.  Drug-related adverse events were reported in 130 (98%) patients assigned regorafenib and 45 (68%) patients assigned placebo.  The most common regorafenib-related adverse events of grade 3 or higher were hypertension (31 of 132, 23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of 132, 5%).The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on std. treatments.  As far as we are aware, this is the first clin. trial to show benefit from a kinase inhibitor in this highly refractory population of patients.Bayer HealthCare Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2GIfYXBPyLVg90H21EOLACvtfcHk0ljyEH9V6LjzBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL&md5=f8ee42424a9b3bd7558b1a2f1461af33</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961857-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961857-1%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DM.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBadalamenti%26aufirst%3DG.%26aulast%3DBlackstein%26aufirst%3DM.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%2BB.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DKuss%26aufirst%3DI.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520regorafenib%2520for%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%2520%2528grid%2529%253A%2520An%2520international%252C%2520multicentre%252C%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D295%26epage%3D302%26doi%3D10.1016%2FS0140-6736%2812%2961857-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Garner, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vodala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Ponatinib inhibits polyclonal drug-resistant kit oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (gist) patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5745</span><span class="NLM_x">–</span> <span class="NLM_lpage">5755</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F1078-0432.CCR-14-1397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25239608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5745-5755&author=A.+P.+Garnerauthor=J.+M.+Gozgitauthor=R.+Anjumauthor=S.+Vodalaauthor=A.+Schrockauthor=T.+Zhouauthor=C.+Serranoauthor=G.+Eilersauthor=M.+Zhuauthor=J.+Ketzerauthor=S.+Wardwellauthor=Y.+Ningauthor=Y.+Songauthor=A.+Kohlmannauthor=F.+Wangauthor=T.+Clacksonauthor=M.+C.+Heinrichauthor=J.+A.+Fletcherauthor=S.+Bauerauthor=V.+M.+Rivera&title=Ponatinib+inhibits+polyclonal+drug-resistant+kit+oncoproteins+and+shows+therapeutic+potential+in+heavily+pretreated+gastrointestinal+stromal+tumor+%28gist%29+patients&doi=10.1158%2F1078-0432.CCR-14-1397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients</span></div><div class="casAuthors">Garner, Andrew P.; Gozgit, Joseph M.; Anjum, Rana; Vodala, Sadanand; Schrock, Alexa; Zhou, Tianjun; Serrano, Cesar; Eilers, Grant; Zhu, Meijun; Ketzer, Julia; Wardwell, Scott; Ning, Yaoyu; Song, Youngchul; Kohlmann, Anna; Wang, Frank; Clackson, Tim; Heinrich, Michael C.; Fletcher, Jonathan A.; Bauer, Sebastian; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5745-5755</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST).  Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic.  Here, we explore the KIT-inhibitory activity of ponatinib in preclin. models and describe initial characterization of its activity in patients with GIST.  Exptl. Design: The cellular and in vivo activities of ponatinib, imatinib, sunitinib, and regorafenib against mutant KIT were evaluated using an accelerated mutagenesis assay and a panel of engineered and GIST-derived cell lines.  The ponatinib-KIT costructure was also detd.  The clin. activity of ponatinib was examd. in three patients with GIST previously treated with all three FDA-approved agents.  Results: In engineered and GIST-derived cell lines, ponatinib potently inhibited KIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop.  Ponatinib also induced regression in engineered and GIST-derived tumor models contg. these secondary mutations.  In a mutagenesis screen, 40 nmol/L ponatinib was sufficient to suppress outgrowth of all secondary mutants except V654A, which was suppressed at 80 nmol/L.  This inhibitory profile could be rationalized on the basis of structural analyses.  Ponatinib (30 mg daily) displayed encouraging clin. activity in two of three patients with GIST.  Conclusion:Ponatinib possesses potent activity against most major clin. relevant KIT mutants and has demonstrated preliminary evidence of activity in patients with refractory GIST.  These data strongly support further evaluation of ponatinib in patients with GIST.  Clin Cancer Res; 20(22); 5745-55. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGG18CSl3XLVg90H21EOLACvtfcHk0ljyEH9V6LjzBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E&md5=7537e45f37546f9e0cb799bdf05ed847</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1397%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DVodala%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520inhibits%2520polyclonal%2520drug-resistant%2520kit%2520oncoproteins%2520and%2520shows%2520therapeutic%2520potential%2520in%2520heavily%2520pretreated%2520gastrointestinal%2520stromal%2520tumor%2520%2528gist%2529%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5745%26epage%3D5755%26doi%3D10.1158%2F1078-0432.CCR-14-1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Emerging agents for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors: Current status and future directions</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1323</span><span class="NLM_x">–</span> <span class="NLM_lpage">1334</span><span class="refDoi"> DOI: 10.1007/s40265-015-0440-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1007%2Fs40265-015-0440-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1323-1334&author=S.+Bauerauthor=H.+Joensuu&title=Emerging+agents+for+the+treatment+of+advanced%2C+imatinib-resistant+gastrointestinal+stromal+tumors%3A+Current+status+and+future+directions&doi=10.1007%2Fs40265-015-0440-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0440-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0440-8%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEmerging%2520agents%2520for%2520the%2520treatment%2520of%2520advanced%252C%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%253A%2520Current%2520status%2520and%2520future%2520directions%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1323%26epage%3D1334%26doi%3D10.1007%2Fs40265-015-0440-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badalamenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GRID study investigators</span><span> </span><span class="NLM_article-title">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (grid): An international, multicentre, randomised, placebo-controlled, phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1016/S0140-6736(12)61857-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS0140-6736%2812%2961857-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23177515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=295-302&author=G.+D.+Demetriauthor=P.+Reichardtauthor=Y.+K.+Kangauthor=J.+Y.+Blayauthor=P.+Rutkowskiauthor=H.+Gelderblomauthor=P.+Hohenbergerauthor=M.+Leahyauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=G.+Badalamentiauthor=M.+Blacksteinauthor=A.+Le+Cesneauthor=P.+Schoffskiauthor=R.+G.+Makiauthor=S.+Bauerauthor=B.+B.+Nguyenauthor=J.+Xuauthor=T.+Nishidaauthor=J.+Chungauthor=C.+Kappelerauthor=I.+Kussauthor=D.+Laurentauthor=P.+G.+Casaliauthor=GRID+study+investigators&title=Efficacy+and+safety+of+regorafenib+for+advanced+gastrointestinal+stromal+tumours+after+failure+of+imatinib+and+sunitinib+%28grid%29%3A+An+international%2C+multicentre%2C+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961857-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">Demetri, George D.; Reichardt, Peter; Kang, Yoon-Koo; Blay, Jean-Yves; Rutkowski, Piotr; Gelderblom, Hans; Hohenberger, Peter; Leahy, Michael; von Mehren, Margaret; Joensuu, Heikki; Badalamenti, Giuseppe; Blackstein, Martin; Le Cesne, Axel; Schoffski, Patrick; Maki, Robert G.; Bauer, Sebastian; Nguyen, Binh Bui; Xu, Jianming; Nishida, Toshirou; Chung, John; Kappeler, Christian; Kuss, Iris; Laurent, Dirk; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">9863</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Until now, only imatinib and sunitinib have proven clin. benefit in patients with gastrointestinal stromal tumors (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression.  We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.We did this phase 3 trial at 57 hospitals in 17 countries.  Patients with histol. confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratified by treatment line and geog. region) to receive either oral regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 wk of each 4 wk cycle.  The study sponsor, participants, and investigators were masked to treatment assignment.  The primary endpoint was progression-free survival (PFS).  At disease progression, patients assigned placebo could crossover to open-label regorafenib.  Analyses were by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT01271712.From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib (n=133) or matching placebo (n=66).  Data cutoff was Jan 26, 2012.  Median PFS per independent blinded central review was 4·8 mo (IQR 1·4-9·2) for regorafenib and 0·9 mo (0·9-1·8) for placebo (hazard ratio [HR] 0·27, 95% CI 0·19-0·39; p<0·0001).  After progression, 56 patients (85%) assigned placebo crossed over to regorafenib.  Drug-related adverse events were reported in 130 (98%) patients assigned regorafenib and 45 (68%) patients assigned placebo.  The most common regorafenib-related adverse events of grade 3 or higher were hypertension (31 of 132, 23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of 132, 5%).The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on std. treatments.  As far as we are aware, this is the first clin. trial to show benefit from a kinase inhibitor in this highly refractory population of patients.Bayer HealthCare Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2GIfYXBPyLVg90H21EOLACvtfcHk0li69KOiv9C0ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL&md5=f8ee42424a9b3bd7558b1a2f1461af33</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961857-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961857-1%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DM.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBadalamenti%26aufirst%3DG.%26aulast%3DBlackstein%26aufirst%3DM.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%2BB.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DKuss%26aufirst%3DI.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520regorafenib%2520for%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%2520%2528grid%2529%253A%2520An%2520international%252C%2520multicentre%252C%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D295%26epage%3D302%26doi%3D10.1016%2FS0140-6736%2812%2961857-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, L.</span><span> </span><span class="NLM_article-title">Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: A meta-analysis of recent clinical trials</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2061</span><span class="NLM_x">–</span> <span class="NLM_lpage">2067</span><span class="refDoi"> DOI: 10.2147/DDDT.S63840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.2147%2FDDDT.S63840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25378911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGitLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=2061-2067&author=L.+Wuauthor=Z.+Zhangauthor=H.+Yaoauthor=K.+Liuauthor=Y.+Wenauthor=L.+Xiong&title=Clinical+efficacy+of+second-generation+tyrosine+kinase+inhibitors+in+imatinib-resistant+gastrointestinal+stromal+tumors%3A+A+meta-analysis+of+recent+clinical+trials&doi=10.2147%2FDDDT.S63840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials</span></div><div class="casAuthors">Wu, Lile; Zhang, Zhongqiang; Yao, Hongliang; Liu, Kuijie; Wen, Yu; Xiong, Li</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2061-2067, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Primary and secondary resistance to imatinib, a selective receptor tyrosine kinase inhibitor (TKI), is a serious clin. problem in the control of advanced gastrointestinal stromal tumors (GIST).  Here we report on a meta-anal. we performed to evaluate the efficacy of second-generation TKIs in the treatment of patients with imatinib-resistant GIST.  Methods: Randomized controlled trials evaluating the clin. efficacy of second-generation TKIs were identified by searching PubMed and EMBASE from 2000 to Feb. 2014.  Outcomes subjected to anal. were progression-free survival and overall survival.  Statistical analyses were performed using Review Manager version 5.1.0 (Cochrane Collaboration, Oxford, UK).  Weighted hazard ratios (HR) with 95% confidence intervals (CIs) were calcd. for the outcomes.  Fixed-effects or random-effects models were used, depending on the degree of heterogeneity across the selected studies.  Results: Three randomized controlled trials were selected for meta-anal.  Among imatinib-resistant or imatinib-intolerant patients, 541 received second-generation TKIs (sunitinib, nilotinib, or regorafenib) and 267 controls received placebo or best supportive care.  Progression-free survival was significantly improved in the TKI-treated group (HR 0.38; 95% CI 0.24-0.59; P<0.0001).  No statistically significant difference was detected in overall survival between the treatment group and the control group (HR 0.85; 95% CI 0.71-1.03; P = 0.09).  In the subgroup of patients who were resistant or intolerant to both imatinib and sunitinib, TKI therapy (nilotinib or regorafenib) improved progression-free survival (HR 0.40; 95% CI 0.19-0.84; P = 0.02) but not overall survival (HR 0.83; 95% CI 0.63-1.08; P = 0.17).  Regorafenib was shown to be effective in terms of progression-free survival across different subpopulations of patients who were resistant to both imatinib and sunitinib.  Conclusion: Second-generation TKIs (sunitinib, nilotinib, and regorafenib) are effective in improving progression-free survival but not overall survival in patients with GIST who are resistant or intolerant to imatinib or to imatinib and sunitinib.  Regorafenib is promising as a third-line treatment option for patients with advanced GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbHHObRMJNKLVg90H21EOLACvtfcHk0li69KOiv9C0ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGitLnK&md5=b33a7d7375400e6a4fa8ccf1c20d7242</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S63840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S63840%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DXiong%26aufirst%3DL.%26atitle%3DClinical%2520efficacy%2520of%2520second-generation%2520tyrosine%2520kinase%2520inhibitors%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%253A%2520A%2520meta-analysis%2520of%2520recent%2520clinical%2520trials%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D2061%26epage%3D2067%26doi%3D10.2147%2FDDDT.S63840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitagawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span> </span><span class="NLM_article-title">The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines</span> <span class="citation_source-journal">Gastric Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1007/s10120-015-0526-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1007%2Fs10120-015-0526-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=3-14&author=T.+Nishidaauthor=J.+Y.+Blayauthor=S.+Hirotaauthor=Y.+Kitagawaauthor=Y.+K.+Kang&title=The+standard+diagnosis%2C+treatment%2C+and+follow-up+of+gastrointestinal+stromal+tumors+based+on+guidelines&doi=10.1007%2Fs10120-015-0526-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10120-015-0526-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10120-015-0526-8%26sid%3Dliteratum%253Aachs%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DKitagawa%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DY.%2BK.%26atitle%3DThe%2520standard%2520diagnosis%252C%2520treatment%252C%2520and%2520follow-up%2520of%2520gastrointestinal%2520stromal%2520tumors%2520based%2520on%2520guidelines%26jtitle%3DGastric%2520Cancer%26date%3D2016%26volume%3D19%26spage%3D3%26epage%3D14%26doi%3D10.1007%2Fs10120-015-0526-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Zhang, Y.; Hodous, B. L.; Kim, J. L.; Wilson, K. J.; Wilson, D.</span><span> </span><span class="NLM_article-title">Compositions useful for treating disorders related to kit</span>. WO2015/057873,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Zhang&author=B.+L.+Hodous&author=J.+L.+Kim&author=K.+J.+Wilson&author=D.+Wilson&title=Compositions+useful+for+treating+disorders+related+to+kit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DCompositions%2520useful%2520for%2520treating%2520disorders%2520related%2520to%2520kit%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Flynn, D. L.; Petillo, P. A.; Kaufman, M. D.</span><span> </span><span class="NLM_article-title">Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities</span>. US 8278331,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+L.+Flynn&author=P.+A.+Petillo&author=M.+D.+Kaufman&title=Cyclopropane+amides+and+analogs+exhibiting+anti-cancer+and+anti-proliferative+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DCyclopropane%2520amides%2520and%2520analogs%2520exhibiting%2520anti-cancer%2520and%2520anti-proliferative%2520activities%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span>Plx9486 ± plx3397; <span class="NLM_publisher-name">Plexxikon</span>: <span class="NLM_publisher-loc">San Antonio, TX</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.plexxikon.com/pipeline/plx9486-plx3397/" class="extLink">http://www.plexxikon.com/pipeline/plx9486-plx3397/</a> (accessed September 10, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Plx9486+%C2%B1+plx3397%3B+Plexxikon%3A+San+Antonio%2C+TX%2C+2017%3B+http%3A%2F%2Fwww.plexxikon.com%2Fpipeline%2Fplx9486-plx3397%2F+%28accessed+September+10%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DPlx9486%2520%25C2%25B1%2520plx3397%26pub%3DPlexxikon%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span> </span><span class="NLM_article-title">BLU-285, DCC-2618 show activity against gist</span>.  <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-NB2016-165</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F2159-8290.CD-NB2016-165" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BLU-285%2C+DCC-2618+show+activity+against+gist.+Cancer+Discovery+2017%2C+7%2C+121%E2%80%93122%2C+10.1158%2F2159-8290.CD-NB2016-165."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-NB2016-165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-NB2016-165%26sid%3Dliteratum%253Aachs%26atitle%3DBLU-285%252C%2520DCC-2618%2520show%2520activity%2520against%2520gist%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D121%26epage%3D122%26doi%3D10.1158%2F2159-8290.CD-NB2016-165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">Ap24534, a pan-bcr-abl inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span><span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=Ap24534%2C+a+pan-bcr-abl+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+t315i+mutant+and+overcomes+mutation-based+resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0liT1e315ZEbHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAp24534%252C%2520a%2520pan-bcr-abl%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520t315i%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-n-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (ap24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (bcr-abl) kinase including the t315i gatekeeper mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4701</span><span class="NLM_x">–</span> <span class="NLM_lpage">4719</span><span class="refDoi"> DOI: 10.1021/jm100395q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&author=W.+S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-n-%7B4-%5B%284-methylpiperazin-1-y+l%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28ap24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-abelson+%28bcr-abl%29+kinase+including+the+t315i+gatekeeper+mutant&doi=10.1021%2Fjm100395q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-[4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl]benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant</span></div><div class="casAuthors">Huang, Wei-Sheng; Metcalf, Chester A.; Sundaramoorthi, Raji; Wang, Yihan; Zou, Dong; Thomas, R. Mathew; Zhu, Xiaotian; Cai, Lisi; Wen, David; Liu, Shuangying; Romero, Jan; Qi, Jiwei; Chen, Ingrid; Banda, Geetha; Lentini, Scott P.; Das, Sasmita; Xu, Qihong; Keats, Jeff; Wang, Frank; Wardwell, Scott; Ning, Yaoyu; Snodgrass, Joseph T.; Broudy, Marc I.; Russian, Karin; Zhou, Tianjun; Commodore, Lois; Narasimhan, Narayana I.; Mohemmad, Qurish K.; Iuliucci, John; Rivera, Victor M.; Dalgarno, David C.; Sawyer, Tomi K.; Clackson, Tim; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4701-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents.  This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation.  A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of Ile315 side chain.  Extensive SAR studies led to the discovery of development candidate benzamide I (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC50s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines.  Daily oral administration of I significantly prolonged survival of mice injected i.v. with BCR-ABLT315I expressing Ba/F3 cells.  These data, coupled with a favorable ADME profile, support the potential of I to be an effective treatment for CML, including patients refractory to all currently approved therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoci2zVFUazgLVg90H21EOLACvtfcHk0lhGVvADOnuPUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D&md5=0dcd7b4ff31164b1d9883e897b7058ff</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-n-%257B4-%255B%25284-methylpiperazin-1-y%2520l%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528ap24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-abelson%2520%2528bcr-abl%2529%2520kinase%2520including%2520the%2520t315i%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4701%26epage%3D4719%26doi%3D10.1021%2Fjm100395q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bixby, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauro, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinn, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span> </span><span class="NLM_article-title">Ponatinib in refractory philadelphia chromosome-positive leukemias</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">2075</span><span class="NLM_x">–</span> <span class="NLM_lpage">2088</span><span class="refDoi"> DOI: 10.1056/NEJMoa1205127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1056%2FNEJMoa1205127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23190221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyltrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2075-2088&author=J.+E.+Cortesauthor=H.+Kantarjianauthor=N.+P.+Shahauthor=D.+Bixbyauthor=M.+J.+Mauroauthor=I.+Flinnauthor=T.+O%E2%80%99Hareauthor=S.+Huauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=T.+Clacksonauthor=C.+D.+Turnerauthor=F.+G.+Haluskaauthor=B.+J.+Drukerauthor=M.+W.+Deiningerauthor=M.+Talpaz&title=Ponatinib+in+refractory+philadelphia+chromosome-positive+leukemias&doi=10.1056%2FNEJMoa1205127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib in refractory Philadelphia chromosome-positive leukemias</span></div><div class="casAuthors">Cortes, Jorge E.; Kantarjian, Hagop; Shah, Neil P.; Bixby, Dale; Mauro, Michael J.; Flinn, Ian; O'Hare, Thomas; Hu, Simin; Narasimhan, Narayana I.; Rivera, Victor M.; Clackson, Tim; Turner, Christopher D.; Haluska, Frank G.; Druker, Brian J.; Deininger, Michael W. N.; Talpaz, Moshe</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2075-2088</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-pos. acute lymphoblastic leukemia (Ph-pos. ALL) is frequently caused by mutations in the BCR-ABL kinase domain.  Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T3151, which is uniformly resistant to tyrosine kinase inhibitors.  Methods: In this phase 1 dose-escalation study, we enrolled 81 patients with resistant hematol. cancers, including 60 with CML and 5 with Ph-pos. ALL.  Ponatinib was administered once daily at doses ranging from 2 to 60 mg.  Median follow-up was 56 wk (range, 2 to 140).  Results: Dose-limiting toxic effects included elevated lipase or amylase levels and pancreatitis.  Common adverse events were rash, myelosuppression, and constitutional symptoms.  Among Ph-pos. patients, 91% had received two or more approved tyrosine kinase inhibitors, and 51% had received all three approved tyrosine kinase inhibitors.  Of 43 patients with chronic-phase CML, 98% had a complete hematol. response, 72% had a major cytogenetic response, and 44% had a major mol. response.  Of 12 patients who had chronic-phase CML with the T315I mutation, 100% had a complete hematol. response and 92% had a major cytogenetic response.  Of 13 patients with chronic-phase CML without detectable mutations, 100% had a complete hematol. response and 62% had a major cytogenetic response.  Responses among patients with chronic-phase CML were durable.  Of 22 patients with accelerated-phase or blast-phase CML or Ph-pos. ALL, 36% had a major hematol. response and 32% had a major cytogenetic response.  Conclusion: Ponatinib was highly active in heavily pretreated patients with Ph-pos. leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrYE8Da39kZ7Vg90H21EOLACvtfcHk0lhGVvADOnuPUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyltrvJ&md5=8a563e3fc96860a13a16958c9e816834</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1205127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1205127%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DBixby%26aufirst%3DD.%26aulast%3DMauro%26aufirst%3DM.%2BJ.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DTurner%26aufirst%3DC.%2BD.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DTalpaz%26aufirst%3DM.%26atitle%3DPonatinib%2520in%2520refractory%2520philadelphia%2520chromosome-positive%2520leukemias%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2075%26epage%3D2088%26doi%3D10.1056%2FNEJMoa1205127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Dorer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knickerbocker, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span> </span><span class="NLM_article-title">Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.1016/j.leukres.2016.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.leukres.2016.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=27505637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSgsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=84-91&author=D.+J.+Dorerauthor=R.+K.+Knickerbockerauthor=M.+Baccaraniauthor=J.+E.+Cortesauthor=A.+Hochhausauthor=M.+Talpazauthor=F.+G.+Haluska&title=Impact+of+dose+intensity+of+ponatinib+on+selected+adverse+events%3A+Multivariate+analyses+from+a+pooled+population+of+clinical+trial+patients&doi=10.1016%2Fj.leukres.2016.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients</span></div><div class="casAuthors">Dorer, David J.; Knickerbocker, Ronald K.; Baccarani, Michele; Cortes, Jorge E.; Hochhaus, Andreas; Talpaz, Moshe; Haluska, Frank G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-91</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ponatinib is approved for adults with refractory chronic myeloid leukemia or Philadelphia chromosome-pos. acute lymphoblastic leukemia, including those with the T315I BCR-ABL1 mutation.  We pooled data from 3 clin. trials (N = 671) to det. the impact of ponatinib dose intensity on the following adverse events: arterial occlusive events (cardiovascular, cerebrovascular, and peripheral vascular events), venous thromboembolic events, cardiac failure, thrombocytopenia, neutropenia, hypertension, pancreatitis, increased lipase, increased alanine aminotransferase, increased aspartate aminotransferase, rash, arthralgia, and hypertriglyceridemia.  Multivariate analyses allowed adjustment for covariates potentially related to changes in dosing or an event.  Logistic regression anal. identified significant assocns. between dose intensity and most events after adjusting for covariates.  Pancreatitis, rash, and cardiac failure had the strongest assocns. with dose intensity (odds ratios >2).  Time-to-event analyses showed significant assocns. between dose intensity and risk of arterial occlusive events and each subcategory.  Further, these analyses suggested that a lag exists between a change in dose and the resulting change in event risk.  No significant assocn. between dose intensity and risk of venous thromboembolic events was evident.  Collectively, these findings suggest a potential causal relationship between ponatinib dose and certain adverse events and support prospective investigations of approaches to lower av. ponatinib dose intensity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vv1oh3lIkbVg90H21EOLACvtfcHk0lj0tuuPVqX-rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSgsLfP&md5=f68545645a3ade3680728652196ff35f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2016.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2016.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DDorer%26aufirst%3DD.%2BJ.%26aulast%3DKnickerbocker%26aufirst%3DR.%2BK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26atitle%3DImpact%2520of%2520dose%2520intensity%2520of%2520ponatinib%2520on%2520selected%2520adverse%2520events%253A%2520Multivariate%2520analyses%2520from%2520a%2520pooled%2520population%2520of%2520clinical%2520trial%2520patients%26jtitle%3DLeuk.%2520Res.%26date%3D2016%26volume%3D48%26spage%3D84%26epage%3D91%26doi%3D10.1016%2Fj.leukres.2016.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Jain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemmaraju, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daver, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gachimova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrajoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornblau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: A phase 2 study</span> <span class="citation_source-journal">Lancet Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e376</span><span class="NLM_x">–</span> <span class="NLM_lpage">e383</span><span class="refDoi"> DOI: 10.1016/S2352-3026(15)00127-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2FS2352-3026%2815%2900127-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=26436130" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=e376-e383&author=P.+Jainauthor=H.+Kantarjianauthor=E.+Jabbourauthor=G.+N.+Gonzalezauthor=G.+Borthakurauthor=N.+Pemmarajuauthor=N.+Daverauthor=E.+Gachimovaauthor=A.+Ferrajoliauthor=S.+Kornblauauthor=F.+Ravandiauthor=S.+O%E2%80%99Brienauthor=J.+Cortes&title=Ponatinib+as+first-line+treatment+for+patients+with+chronic+myeloid+leukaemia+in+chronic+phase%3A+A+phase+2+study&doi=10.1016%2FS2352-3026%2815%2900127-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2815%2900127-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252815%252900127-1%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DGonzalez%26aufirst%3DG.%2BN.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DGachimova%26aufirst%3DE.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DKornblau%26aufirst%3DS.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DPonatinib%2520as%2520first-line%2520treatment%2520for%2520patients%2520with%2520chronic%2520myeloid%2520leukaemia%2520in%2520chronic%2520phase%253A%2520A%2520phase%25202%2520study%26jtitle%3DLancet%2520Haematol.%26date%3D2015%26volume%3D2%26spage%3De376%26epage%3De383%26doi%3D10.1016%2FS2352-3026%2815%2900127-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span><span class="refDoi"> DOI: 10.1038/nsmb.1486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Fnsmb.1486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=18794843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1109-1118&author=M.+Azamauthor=M.+A.+Seeligerauthor=N.+S.+Grayauthor=J.+Kuriyanauthor=G.+Q.+Daley&title=Activation+of+tyrosine+kinases+by+mutation+of+the+gatekeeper+threonine&doi=10.1038%2Fnsmb.1486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span></div><div class="casAuthors">Azam, Mohammad; Seeliger, Markus A.; Gray, Nathanael S.; Kuriyan, John; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1109-1118</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinases targeted by small-mol. inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site.  Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-α and -β, and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells.  Structural anal. reveals that a network of hydrophobic interactions - the hydrophobic spine - characteristic of the active kinase conformation is stabilized by the gatekeeper substitution.  Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase.  Furthermore, a small-mol. inhibitor (compd. 14) that maximizes complementarity with the dismantled spine inhibits the gatekeeper mutation of BCR-ABL-T315I.  These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEoZTY5SkbALVg90H21EOLACvtfcHk0ljY4v2gRarw4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM&md5=4afc4e5a0850a4510ced3fa5fbda97fa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1486%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivation%2520of%2520tyrosine%2520kinases%2520by%2520mutation%2520of%2520the%2520gatekeeper%2520threonine%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D1109%26epage%3D1118%26doi%3D10.1038%2Fnsmb.1486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Barouch-Bentov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, K.</span><span> </span><span class="NLM_article-title">Mechanisms of drug resistance in kinases</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span><span class="refDoi"> DOI: 10.1517/13543784.2011.546344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1517%2F13543784.2011.546344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=21235428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVenur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=153-208&author=R.+Barouch-Bentovauthor=K.+Sauer&title=Mechanisms+of+drug+resistance+in+kinases&doi=10.1517%2F13543784.2011.546344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug resistance in kinases</span></div><div class="casAuthors">Barouch-Bentov, Rina; Sauer, Karsten</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-208</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Because of their important roles in disease and excellent "druggability", kinases have become the second largest drug target family.  The great success of the BCR-ABL inhibitor imatinib in treating chronic myelogenous leukemia illustrates the high potential of kinase inhibitor (KI) therapeutics, but also unveils a major limitation: the development of drug resistance.  This is a significant concern as KIs reach large patient populations for an expanding array of indications.  We provide an up-to-date understanding of the mechanisms through which KIs function and through which cells can become KI-resistant.  We review current and future approaches to overcome KI resistance, focusing on currently approved KIs and KIs in clin. trials.  We then discuss approaches to improve KI efficacy and overcome drug resistance and novel approaches to develop less drug resistance-prone KI therapeutics.  Although drug resistance is a concern for current KI therapeutics, recent progress in our understanding of the underlying mechanisms and promising technol. advances may overcome this limitation and provide powerful new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJUpdpkWU6bVg90H21EOLACvtfcHk0ljY4v2gRarw4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVenur8%253D&md5=cccffaca08cbcfb1e0d2c1d580c9e797</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.546344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.546344%26sid%3Dliteratum%253Aachs%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DSauer%26aufirst%3DK.%26atitle%3DMechanisms%2520of%2520drug%2520resistance%2520in%2520kinases%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D153%26epage%3D208%26doi%3D10.1517%2F13543784.2011.546344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Targeting gain of function and resistance mutations in abl and kit by hybrid compound design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5757</span><span class="NLM_x">–</span> <span class="NLM_lpage">5772</span><span class="refDoi"> DOI: 10.1021/jm4004076</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004076" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5757-5772&author=A.+Richtersauthor=J.+Ketzerauthor=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=R.+Schneiderauthor=J.+M.+Heuckmannauthor=S.+Heynckauthor=M.+L.+Sosauthor=A.+Guptaauthor=A.+Ungerauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+Bauerauthor=D.+Rauh&title=Targeting+gain+of+function+and+resistance+mutations+in+abl+and+kit+by+hybrid+compound+design&doi=10.1021%2Fjm4004076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm4004076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004076%26sid%3Dliteratum%253Aachs%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520gain%2520of%2520function%2520and%2520resistance%2520mutations%2520in%2520abl%2520and%2520kit%2520by%2520hybrid%2520compound%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5757%26epage%3D5772%26doi%3D10.1021%2Fjm4004076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Batista, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolbert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geballe, M. T.</span><span> </span><span class="NLM_article-title">SiteHopper - a unique tool for binding site comparison</span> <span class="citation_source-journal">J. Cheminf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="refDoi"> DOI: 10.1186/1758-2946-6-S1-P57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1186%2F1758-2946-6-S1-P57" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=57&author=J.+H.+Batistaauthor=P.+C.+D.+Hawkinsauthor=R.+Tolbertauthor=M.+T.+Geballe&title=SiteHopper+-+a+unique+tool+for+binding+site+comparison&doi=10.1186%2F1758-2946-6-S1-P57"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-6-S1-P57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-6-S1-P57%26sid%3Dliteratum%253Aachs%26aulast%3DBatista%26aufirst%3DJ.%2BH.%26aulast%3DHawkins%26aufirst%3DP.%2BC.%2BD.%26aulast%3DTolbert%26aufirst%3DR.%26aulast%3DGeballe%26aufirst%3DM.%2BT.%26atitle%3DSiteHopper%2520-%2520a%2520unique%2520tool%2520for%2520binding%2520site%2520comparison%26jtitle%3DJ.%2520Cheminf.%26date%3D2014%26volume%3D6%26spage%3D57%26doi%3D10.1186%2F1758-2946-6-S1-P57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Genheden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryde, U.</span><span> </span><span class="NLM_article-title">The mm/pbsa and mm/gbsa methods to estimate ligand-binding affinities</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span><span class="refDoi"> DOI: 10.1517/17460441.2015.1032936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1517%2F17460441.2015.1032936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25835573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=449-461&author=S.+Genhedenauthor=U.+Ryde&title=The+mm%2Fpbsa+and+mm%2Fgbsa+methods+to+estimate+ligand-binding+affinities&doi=10.1517%2F17460441.2015.1032936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities</span></div><div class="casAuthors">Genheden, Samuel; Ryde, Ulf</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">449-461</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The mol. mechanics energies combined with the Poisson-Boltzmann or generalized Born and surface area continuum solvation (MM/PBSA and MM/GBSA) methods are popular approaches to est. the free energy of the binding of small ligands to biol. macromols.  They are typically based on mol. dynamics simulations of the receptor-ligand complex and are therefore intermediate in both accuracy and computational effort between empirical scoring and strict alchem. perturbation methods.  They have been applied to a large no. of systems with varying success.  Areas covered: The authors review the use of MM/PBSA and MM/GBSA methods to calc. ligand-binding affinities, with an emphasis on calibration, testing and validation, as well as attempts to improve the methods, rather than on specific applications.  Expert opinion: MM/PBSA and MM/GBSA are attractive approaches owing to their modular nature and that they do not require calcns. on a training set.  They have been used successfully to reproduce and rationalize exptl. findings and to improve the results of virtual screening and docking.  However, they contain several crude and questionable approxns., for example, the lack of conformational entropy and information about the no. and free energy of water mols. in the binding site.  Moreover, there are many variants of the method and their performance varies strongly with the tested system.  Likewise, most attempts to ameliorate the methods with more accurate approaches, for example, quantum-mech. calcns., polarizable force fields or improved solvation have deteriorated the results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTBKte1pAZR7Vg90H21EOLACvtfcHk0livQLLN2hG9TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGktr8%253D&md5=b123b88809f275564f95a2271ebd159f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1032936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1032936%26sid%3Dliteratum%253Aachs%26aulast%3DGenheden%26aufirst%3DS.%26aulast%3DRyde%26aufirst%3DU.%26atitle%3DThe%2520mm%252Fpbsa%2520and%2520mm%252Fgbsa%2520methods%2520to%2520estimate%2520ligand-binding%2520affinities%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D449%26epage%3D461%26doi%3D10.1517%2F17460441.2015.1032936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuckmantel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Proteus in the world of proteins: Conformational changes in protein kinases</span> <span class="citation_source-journal">Arch. Pharm. (Weinheim, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span><span class="refDoi"> DOI: 10.1002/ardp.201000028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1002%2Fardp.201000028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=20336692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2010&pages=193-206&author=M.+Rabillerauthor=M.+Getlikauthor=S.+Kl%C3%BCterauthor=A.+Richtersauthor=S.+Tuckmantelauthor=J.+R.+Simardauthor=D.+Rauh&title=Proteus+in+the+world+of+proteins%3A+Conformational+changes+in+protein+kinases&doi=10.1002%2Fardp.201000028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Proteus in the world of proteins: Conformational changes in protein kinases</span></div><div class="casAuthors">Rabiller, Matthias; Getlik, Matthaeus; Klueter, Sabine; Richters, Andre; Tueckmantel, Sandra; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-206</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The 512 protein kinases encoded by the human genome are a prime example of Nature's ability to create diversity by introducing variations to a highly conserved theme.  The activity of each kinase domain is controlled by layers of regulatory mechanisms involving different combinations of post-translational modifications, intramol. contacts, and intermol. interactions.  Ultimately, they all achieve their effect by favoring particular conformations that promote or prevent the kinase domain from catalyzing protein phosphorylation.  The central role of kinases in various diseases has encouraged extensive investigations of their biol. function and 3-dimensional structures, yielding a more detailed understanding of the mechanisms that regulate protein kinase activity by conformational changes.  Here, the authors discuss these regulatory mechanisms and show how conformational changes can be exploited for the design of specific inhibitors that lock protein kinases in inactive conformations.  In addn., the authors highlight recent developments to monitor ligand-induced structural changes in protein kinases and for screening and identifying inhibitors that stabilize enzymically incompetent kinase conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRChkP9MKuIbVg90H21EOLACvtfcHk0livQLLN2hG9TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D&md5=0833f19b8565afc03c39bf5fb5a87175</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fardp.201000028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201000028%26sid%3Dliteratum%253Aachs%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DTuckmantel%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DProteus%2520in%2520the%2520world%2520of%2520proteins%253A%2520Conformational%2520changes%2520in%2520protein%2520kinases%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2010%26volume%3D343%26spage%3D193%26epage%3D206%26doi%3D10.1002%2Fardp.201000028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span> </span><span class="NLM_article-title">Protein kinases: Evolution of dynamic regulatory proteins</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1016/j.tibs.2010.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.tibs.2010.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=20971646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=65-77&author=S.+S.+Taylorauthor=A.+P.+Kornev&title=Protein+kinases%3A+Evolution+of+dynamic+regulatory+proteins&doi=10.1016%2Fj.tibs.2010.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases: evolution of dynamic regulatory proteins</span></div><div class="casAuthors">Taylor, Susan S.; Kornev, Alexandr P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic protein kinases have evolved as a family of highly dynamic mols. with a strictly organized internal architecture.  A single hydrophobic F-helix serves as a central scaffold for the assembly of the entire mol.  Two non-consecutive hydrophobic structures termed "spines" anchor all of the elements important for catalysis to the F-helix.  They make firm, but flexible, connections within the mol., providing a high level of internal dynamics of the protein kinase.  During the course of evolution, protein kinases developed a universal regulatory mechanism assocd. with a large activation segment that can be dynamically folded and unfolded in the course of cell functioning.  Protein kinases thus represent a unique, highly dynamic, and precisely regulated set of switches that control most biol. events in eukaryotic cells.  A comparison of 155 publicly available protein kinase structures of the human kinome, which includes 518 protein kinases divided into 7 major subfamilies, demonstrates a high level of structural plasticity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruzcRXGPlBN7Vg90H21EOLACvtfcHk0livQLLN2hG9TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOrtLg%253D&md5=f663148962d22944914e804e34fc947c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2010.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2010.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26atitle%3DProtein%2520kinases%253A%2520Evolution%2520of%2520dynamic%2520regulatory%2520proteins%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2011%26volume%3D36%26spage%3D65%26epage%3D77%26doi%3D10.1016%2Fj.tibs.2010.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haste, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, L. F.</span><span> </span><span class="NLM_article-title">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">17783</span><span class="NLM_x">–</span> <span class="NLM_lpage">17788</span><span class="refDoi"> DOI: 10.1073/pnas.0607656103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1073%2Fpnas.0607656103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=17095602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17783-17788&author=A.+P.+Kornevauthor=N.+M.+Hasteauthor=S.+S.+Taylorauthor=L.+F.+Ten+Eyck&title=Surface+comparison+of+active+and+inactive+protein+kinases+identifies+a+conserved+activation+mechanism&doi=10.1073%2Fpnas.0607656103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span></div><div class="casAuthors">Kornev, Alexandr P.; Haste, Nina M.; Taylor, Susan S.; Ten Eyck, Lynn F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">17783-17788</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The surface comparison of different serine-threonine and tyrosine kinases reveals a set of 30 residues whose spatial positions are highly conserved.  The comparison between active and inactive conformations identified the residues whose positions are the most sensitive to activation.  Based on these results, we propose a model of protein kinase activation.  This model explains how the presence of a phosphate group in the activation loop dets. the position of the catalytically important aspartate in the Asp-Phe-Gly (DFG) motif.  According to the model, the most important feature of the activation is a "spine" formation that is dynamically assembled in all active kinases.  The spine is comprised of four hydrophobic residues that we detected in a set of 23 eukaryotic and prokaryotic kinases.  It spans the mol. and plays a coordinating role in activated kinases.  The spine is disordered in the inactive kinases and can explain how stabilization of the whole mol. is achieved upon phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwv4ByA5owH7Vg90H21EOLACvtfcHk0livQLLN2hG9TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ&md5=f474acffd8b17d8352ac9f6fc9bbbf8f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607656103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607656103%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHaste%26aufirst%3DN.%2BM.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DTen%2BEyck%26aufirst%3DL.%2BF.%26atitle%3DSurface%2520comparison%2520of%2520active%2520and%2520inactive%2520protein%2520kinases%2520identifies%2520a%2520conserved%2520activation%2520mechanism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D17783%26epage%3D17788%26doi%3D10.1073%2Fpnas.0607656103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: The new wave of bcr-abl inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1038/nrd2324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Fnrd2324" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&author=A.+Quint%C3%A1s-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Flying+under+the+radar%3A+The+new+wave+of+bcr-abl+inhibitors&doi=10.1038%2Fnrd2324"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnrd2324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2324%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520The%2520new%2520wave%2520of%2520bcr-abl%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D834%26epage%3D848%26doi%3D10.1038%2Fnrd2324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of drug resistance in tyrosine kinases cabl and ckit</span> <span class="citation_source-journal">Crit. Rev. Biochem. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span><span class="refDoi"> DOI: 10.3109/10409238.2011.578612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.3109%2F10409238.2011.578612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=21539479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlyrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=295-309&author=J.+P.+DiNittoauthor=J.+C.+Wu&title=Molecular+mechanisms+of+drug+resistance+in+tyrosine+kinases+cabl+and+ckit&doi=10.3109%2F10409238.2011.578612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit</span></div><div class="casAuthors">DiNitto, Jonathan P.; Wu, Joe C.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The inhibition of protein kinases has gained general acceptance as an effective approach to treat a wide range of cancers.  However, in many cases, prolonged administration of kinase inhibitors often leads to acquired resistance, and the therapeutic effect is subsequently diminished.  The wealth of recent studies using biochem., kinetic, and structural approaches have revealed the mol. basis for the clin. obsd. resistance.  In this review, we highlight several of the most common mol. mechanisms that lead to acquired resistance to kinase inhibitors obsd. with the cAbl (cellular form of the Abelson leukemia virus tyrosine kinase) and the type III receptor tyrosine kinase cKit, including a newly identified mechanism resulting from accelerated kinase activation caused by mutations in the activation loop.  Strategies to overcome the loss of drug sensitivity that represents a challenge currently facing the field and the emerging approaches to circumvent resistance are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDF-2H4LKT5bVg90H21EOLACvtfcHk0lgZ7rTwT8s9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlyrsbw%253D&md5=28a337d17c0d117b731b8b1f7763df96</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.3109%2F10409238.2011.578612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10409238.2011.578612%26sid%3Dliteratum%253Aachs%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26atitle%3DMolecular%2520mechanisms%2520of%2520drug%2520resistance%2520in%2520tyrosine%2520kinases%2520cabl%2520and%2520ckit%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D46%26spage%3D295%26epage%3D309%26doi%3D10.3109%2F10409238.2011.578612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheibe, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">Structural basis for the autoinhibition and sti-571 inhibition of c-kit tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">31655</span><span class="NLM_x">–</span> <span class="NLM_lpage">31663</span><span class="refDoi"> DOI: 10.1074/jbc.M403319200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1074%2Fjbc.M403319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=15123710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31655-31663&author=C.+D.+Molauthor=D.+R.+Douganauthor=T.+R.+Schneiderauthor=R.+J.+Skeneauthor=M.+L.+Krausauthor=D.+N.+Scheibeauthor=G.+P.+Snellauthor=H.+Zouauthor=B.+C.+Sangauthor=K.+P.+Wilson&title=Structural+basis+for+the+autoinhibition+and+sti-571+inhibition+of+c-kit+tyrosine+kinase&doi=10.1074%2Fjbc.M403319200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase</span></div><div class="casAuthors">Mol, Clifford D.; Dougan, Douglas R.; Schneider, Thomas R.; Skene, Robert J.; Kraus, Michelle L.; Scheibe, Daniel N.; Snell, Gyorgy P.; Zou, Hua; Sang, Bi-Ching; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31655-31663</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers.  The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known.  We report the 1.9-Å resoln. crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase.  Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure.  A 1.6-Å crystal structure of c-Kit in complex with STI-571 (Imatinib or Gleevec) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state.  Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJsKx1IzXQbVg90H21EOLACvtfcHk0lgZ7rTwT8s9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D&md5=df6065a62b44e4c2e6b020da0f797ab4</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403319200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DScheibe%26aufirst%3DD.%2BN.%26aulast%3DSnell%26aufirst%3DG.%2BP.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520and%2520sti-571%2520inhibition%2520of%2520c-kit%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D31655%26epage%3D31663%26doi%3D10.1074%2Fjbc.M403319200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Lambert, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duhme-Klair, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramjee, M. K.</span><span> </span><span class="NLM_article-title">The background, discovery and clinical development of bcr-abl inhibitors</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">992</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span><span class="refDoi"> DOI: 10.1016/j.drudis.2013.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1016%2Fj.drudis.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=23769978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=992-1000&author=G.+K.+Lambertauthor=A.+K.+Duhme-Klairauthor=T.+Morganauthor=M.+K.+Ramjee&title=The+background%2C+discovery+and+clinical+development+of+bcr-abl+inhibitors&doi=10.1016%2Fj.drudis.2013.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The background, discovery and clinical development of BCR-ABL inhibitors</span></div><div class="casAuthors">Lambert, Gemma K.; Duhme-Klair, Anne-Kathrin; Morgan, Trevor; Ramjee, Manoj K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19-20</span>),
    <span class="NLM_cas:pages">992-1000</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The story of the inhibition of BCR-ABL as a treatment for chronic myelogenous leukemia serves to illustrate key aspects of the kinase drug discovery and development process.  Firstly, elucidation of the disease mechanism enabled identification of the mol. target(s) which catalyzed pharmaceutical research and resulted in Gleevec (Novartis) as the first FDA approved BCR-ABL inhibitor.  However, clin. success was soon tempered by the emergence of drug resistance through various mechanisms.  Using rational drug design, several hypotheses were devised to overcome resistance issues leading to the development of second generation inhibitors, providing clinicians and patients with greater therapeutic choice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2YF6Gz_LpYbVg90H21EOLACvtfcHk0lgZ7rTwT8s9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjtL%252FM&md5=e824d8f8d5957eb193bf004c7ec2b642</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DG.%2BK.%26aulast%3DDuhme-Klair%26aufirst%3DA.%2BK.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DRamjee%26aufirst%3DM.%2BK.%26atitle%3DThe%2520background%252C%2520discovery%2520and%2520clinical%2520development%2520of%2520bcr-abl%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D992%26epage%3D1000%26doi%3D10.1016%2Fj.drudis.2013.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Doroshow, J. H.</span><span> </span><span class="NLM_article-title">Overcoming resistance to targeted anticancer drugs</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">1852</span><span class="NLM_x">–</span> <span class="NLM_lpage">1853</span><span class="refDoi"> DOI: 10.1056/NEJMe1311325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1056%2FNEJMe1311325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=24180495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGhtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=1852-1853&author=J.+H.+Doroshow&title=Overcoming+resistance+to+targeted+anticancer+drugs&doi=10.1056%2FNEJMe1311325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming resistance to targeted anticancer drugs</span></div><div class="casAuthors">Doroshow, James H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1852-1853</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAG6F_vlJI97Vg90H21EOLACvtfcHk0liptTDOV328Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGhtb7P&md5=2b62cc5b32994f1480cb5d91ecc3df99</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1311325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1311325%26sid%3Dliteratum%253Aachs%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26atitle%3DOvercoming%2520resistance%2520to%2520targeted%2520anticancer%2520drugs%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D1852%26epage%3D1853%26doi%3D10.1056%2FNEJMe1311325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Rey, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Launay-Vacher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tournigand, C.</span><span> </span><span class="NLM_article-title">Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: An overview for pharmacists</span> <span class="citation_source-journal">Target Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span><span class="refDoi"> DOI: 10.1007/s11523-014-0333-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1007%2Fs11523-014-0333-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=25213039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A280%3ADC%252BC2M7gsVymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=199-213&author=J.+B.+Reyauthor=V.+Launay-Vacherauthor=C.+Tournigand&title=Regorafenib+as+a+single-agent+in+the+treatment+of+patients+with+gastrointestinal+tumors%3A+An+overview+for+pharmacists&doi=10.1007%2Fs11523-014-0333-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists</span></div><div class="casAuthors">Rey Jean-Baptiste; Launay-Vacher Vincent; Tournigand Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-213</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Regorafenib (BAY 73-4506, Stivarga® Bayer HealthCare Pharmaceutical Inc) is an oral multikinase inhibitor with a distinct and wide-ranging profile of tyrosine kinase inhibition, resulting in antiangiogenic and antiproliferative properties in tumors.  Single-agent regorafenib administered as a 160-mg daily dose for the first 21 days of a 28-day cycle is approved for use in patients with pretreated metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumor (GIST) progressing on imatinib and sunitinib, following publication of data from the phase III CORRECT and GRID studies respectively.  Regorafenib is currently under phase III investigation in patients with hepatocellular carcinoma and is in several phase II studies in patients with gastrointestinal (GI) tumors.  This review describes the clinical development of regorafenib in patients with GI cancers, and highlights the key issues important for the modern day clinical pharmacist who forms part of the multidisciplinary team ensuring safe and effective delivery of the drug to the patient.  This information is considered of particular importance to the clinical pharmacist for the future development of regorafenib in this treatment setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToN26KJumfTNXdcedVHT5tfW6udTcc2eZfu3Il1bhOt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7gsVymsg%253D%253D&md5=a832c4d640e4dae531c7f52c3dfb591c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs11523-014-0333-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-014-0333-x%26sid%3Dliteratum%253Aachs%26aulast%3DRey%26aufirst%3DJ.%2BB.%26aulast%3DLaunay-Vacher%26aufirst%3DV.%26aulast%3DTournigand%26aufirst%3DC.%26atitle%3DRegorafenib%2520as%2520a%2520single-agent%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520gastrointestinal%2520tumors%253A%2520An%2520overview%2520for%2520pharmacists%26jtitle%3DTarget%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D199%26epage%3D213%26doi%3D10.1007%2Fs11523-014-0333-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agaram, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Adamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">Sorafenib inhibits the imatinib-resistant kitt670i gatekeeper mutation in gastrointestinal stromal tumor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4874</span><span class="NLM_x">–</span> <span class="NLM_lpage">4881</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1158%2F1078-0432.CCR-07-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=17699867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4874-4881&author=T.+Guoauthor=N.+P.+Agaramauthor=G.+C.+Wongauthor=G.+Homauthor=D.+D%E2%80%99Adamoauthor=R.+G.+Makiauthor=G.+K.+Schwartzauthor=D.+Veachauthor=B.+D.+Clarksonauthor=S.+Singerauthor=R.+P.+DeMatteoauthor=P.+Besmerauthor=C.+R.+Antonescu&title=Sorafenib+inhibits+the+imatinib-resistant+kitt670i+gatekeeper+mutation+in+gastrointestinal+stromal+tumor&doi=10.1158%2F1078-0432.CCR-07-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor</span></div><div class="casAuthors">Guo, Tianhua; Agaram, Narasimhan P.; Wong, Grace C.; Hom, Glory; D'Adamo, David; Maki, Robert G.; Schwartz, Gary K.; Veach, Darren; Clarkson, Bayard D.; Singer, Samuel; DeMatteo, Ronald P.; Besmer, Peter; Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4874-4881</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain.  We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly obsd. imatinib-resistant KIT mutations (KITV654A, KITT670I, KITD820Y, and KITN822K) expressed in the Ba/F3 cellular system.  EXPTL. DESIGN: In vitro drug screening of stable Ba/F3 KIT mutants recapitulating the genotype of imatinib-resistant patients harboring primary and secondary KIT mutations was investigated.  Comparison was made to imatinib-sensitive Ba/F3 KIT mutant cells as well as Ba/F3 cells expressing only secondary KIT mutations.  The efficacy of drug treatment was evaluated by proliferation and apoptosis assays, in addn. to biochem. inhibition of KIT activation.  RESULTS: Sorafenib was potent against all imatinib-resistant Ba/F3 KIT double mutants tested, including the gatekeeper secondary mutation KITWK557-8del/T670I, which was resistant to other kinase inhibitors.  Although all three drugs tested decreased cell proliferation and inhibited KIT activation against exon 13 (KITV560del/V654A) and exon 17 (KITV559D/D820Y) double mutants, nilotinib did so at lower concns.  CONCLUSIONS: Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual mol. mechanisms of resistance.  The Ba/F3 KITWK557-8del/T670I cells were sensitive only to sorafenib inhibition, whereas nilotinib was more potent on imatinib-resistant KITV560del/V654A and KITV559D/D820Y mutant cells than dasatinib and sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqllTJoDeevKbVg90H21EOLACvtfcHk0liptTDOV328Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D&md5=f1643671ada85f1bcd05faa04cd88b52</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0484%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DAgaram%26aufirst%3DN.%2BP.%26aulast%3DWong%26aufirst%3DG.%2BC.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%2BD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DSorafenib%2520inhibits%2520the%2520imatinib-resistant%2520kitt670i%2520gatekeeper%2520mutation%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4874%26epage%3D4881%26doi%3D10.1158%2F1078-0432.CCR-07-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyonaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamasaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimaru, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuri, K.</span><span> </span><span class="NLM_article-title">Conventional and molecular cytogenetic characterization of a new human cell line, gist-t1, established from gastrointestinal stromal tumor</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1038/labinvest.3780461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=10.1038%2Flabinvest.3780461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=12004007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A280%3ADC%252BD383msVOjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2002&pages=663-665&author=T.+Taguchiauthor=H.+Sonobeauthor=S.+Toyonagaauthor=I.+Yamasakiauthor=T.+Shuinauthor=A.+Takanoauthor=K.+Arakiauthor=K.+Akimaruauthor=K.+Yuri&title=Conventional+and+molecular+cytogenetic+characterization+of+a+new+human+cell+line%2C+gist-t1%2C+established+from+gastrointestinal+stromal+tumor&doi=10.1038%2Flabinvest.3780461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor</span></div><div class="casAuthors">Taguchi Takahiro; Sonobe Hiroshi; Toyonaga Shin-ichi; Yamasaki Ichiro; Shuin Taro; Takano Atsushi; Araki Keijiro; Akimaru Kunihiro; Yuri Kazunari</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory investigation; a journal of technical methods and pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-5</span>
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfLoSxovx6e8RAV4D_Ins_fW6udTcc2eYAPjQX0ueCtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD383msVOjsg%253D%253D&md5=2a397ed59d4b02cde55eb3253dc2cb13</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.3780461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.3780461%26sid%3Dliteratum%253Aachs%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSonobe%26aufirst%3DH.%26aulast%3DToyonaga%26aufirst%3DS.%26aulast%3DYamasaki%26aufirst%3DI.%26aulast%3DShuin%26aufirst%3DT.%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DAraki%26aufirst%3DK.%26aulast%3DAkimaru%26aufirst%3DK.%26aulast%3DYuri%26aufirst%3DK.%26atitle%3DConventional%2520and%2520molecular%2520cytogenetic%2520characterization%2520of%2520a%2520new%2520human%2520cell%2520line%252C%2520gist-t1%252C%2520established%2520from%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DLab.%2520Invest.%26date%3D2002%26volume%3D82%26spage%3D663%26epage%3D665%26doi%3D10.1038%2Flabinvest.3780461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumbrink, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Indazole-based covalent inhibitors to target drug-resistant epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2361</span><span class="NLM_x">–</span> <span class="NLM_lpage">2372</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2361-2372&author=S.+Tomassiauthor=J.+Lategahnauthor=J.+Engelauthor=M.+Keulauthor=H.+L.+Tumbrinkauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=S.+Bauerauthor=D.+Rauh&title=Indazole-based+covalent+inhibitors+to+target+drug-resistant+epidermal+growth+factor+receptor&doi=10.1021%2Facs.jmedchem.6b01626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor</span></div><div class="casAuthors">Tomassi, Stefano; Lategahn, Jonas; Engel, Julian; Keul, Marina; Tumbrink, Hannah L.; Ketzer, Julia; Muehlenberg, Thomas; Baumann, Matthias; Schultz-Fademrecht, Carsten; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2361-2372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The specific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthrough in targeted cancer therapy and marks a drastic change in the treatment of non-small cell lung cancer (NSCLC).  The recurrent emergence of resistance to these targeted drugs requires the development of novel chem. entities that efficiently inhibit drug-resistant EGFR.  Herein, the authors report the optimization process for a hit compd. that has emerged from a phenotypic screen resulting in indazole-based compds.  These inhibitors are conformationally less flexible, target gatekeeper mutated drug resistant EGFR-L858R/T790M and covalently alkylate Cys 797.  Western blot anal., as well as characterization of the binding kinetics and kinase selectivity profiling, substantiates the authors' approach of targeting drug-resistant EGFR-L858R/T790M with inhibitors incorporating the indazole as hinge binder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwwmG17YkaV7Vg90H21EOLACvtfcHk0liViJb2c8vvqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D&md5=25e24252dc5a03ec5349359289ebd808</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01626%26sid%3Dliteratum%253Aachs%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DIndazole-based%2520covalent%2520inhibitors%2520to%2520target%2520drug-resistant%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2361%26epage%3D2372%26doi%3D10.1021%2Facs.jmedchem.6b01626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4u0i','PDB','4u0i'); return false;">PDB: 4u0i</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4bkj" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4bkj','PDB','4bkj'); return false;">PDB: 4bkj</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3g0e" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3g0e','PDB','3g0e'); return false;">PDB: 3g0e</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1t46" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1t46','PDB','1t46'); return false;">PDB: 1t46</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1t45" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1t45','PDB','1t45'); return false;">PDB: 1t45</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i26"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00841">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_20703"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00841">10.1021/acs.jmedchem.7b00841</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">RMSD profiles for the MD simulations of wild-type KIT, KIT<sup>T670I</sup>, and KIT<sup>V654A</sup> in the presence and absence of ponatinib; RMSF values of the active site of wild-type KIT, KIT<sup>T670I</sup>, and KIT<sup>V654A</sup>; angle between the axis of the α helix C and the unit cell vector x during a 300 ns MD simulation; kinome dendrogram derived from the SelectScreen; Analysis of the ponatinib binding site volume for the MD simulations in the absence of ponatinib; PCA results for the MD simulations in the absence of ponatinib; data of the SelectScreen; in vitro intrinsic clearance CL<sub>int</sub> in human and murine liver microsomes; relative compound degradation of <b>7f</b>, <b>10</b>, ponatinib, imatinib, and regorafenib; pharmacokinetic parameters of <b>7f</b>, <b>10</b>, ponatinib, imatinib, and regorafenib; results of the RMSD-based binding site clustering analyses; hydrogen bond occupancies for the MD simulations with ponatinib; free energies of binding as estimated by MM-PB(GB)SA calculations; binding site comparison results; detailed synthetic procedures for the preparation of inhibitors for KIT mutants (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_001.csv">jm7b00841_si_001.csv (4.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00841/suppl_file/jm7b00841_si_002.pdf">jm7b00841_si_002.pdf (2.7 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-21%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00841%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00841" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679961ea580e3dd7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
